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List of abbreviations 
 
AACC   American Association for Clinical Chemistry 
ALP   Alkaline Phosphatase 
ALT   Alanine Aminotransferase 
AMTM   All Manufacturer Trimmed Mean 
AST   Aspartate Aminotransferase 
CLSI   Clinical & Laboratory Standards Institute 
C-STFT  Committee for Standardization of Thyroid Function Tests 
CV   Coefficient of Variation 
DGKC   Deutsche Gesellschaft für Klinische Chemie 
EFLM   European Federation of Clinical Chemistry and Laboratory Medicine 
EQA   External Quality Assessment/Assurance 
FDA   Food and Drugs Administration 
FT4   Free Thyroxine 
FW   Forward 
GGT   Gamma-Glutamyltransferase 
GUM   Guide to the expression of Uncertainty in Measurement 
IFCC   International Federation for Clinical Chemistry and Laboratory Medicine 
ISE   Ion Selective Electrode 
ISO   International Organization for Standardization 
IQC   Internal Quality Control 
JCTLM  Joint Committee for Traceability in Laboratory Medicine 
LDH   Lactate Dehydrogenase 
LIS   Laboratory Information System 
MC   Master Comparison 
MM   Moving Median 
MU   Measurement Uncertainty 
NCEP   National Cholesterol Education Program 
PP   Pyridoxal Phosphate 
QC   Quality Control 
QI   Quality Indicator 
RE   Random Error 
RMP   Reference Measurement Procedure  
RMP-c AMTM  Reference Measurement Procedure-Corrected All Manufacturer 
Trimmed Mean 
RV   Reverse 
SD   Standard Deviation 
SE   Systematic Error 
SI   Système International d’ Unités 
SRE   Sample-Related Effect 
TE   Total Error 
TSH   Thyroid Stimulating Hormone 
VIM   Vocabulaire International de Métrologie/ 
International Vocabulary of Metrology 
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List of definitions 
 
Coefficient of variation (CV): 
A measure of dispersion defined as the ratio of the standard deviation to the mean (often 
expressed as a percentage). 
 
(Daily) patient medians: 
Median of results of patient samples, preferably outpatient samples, which are measured on 
a single day in a certain laboratory on a certain instrument. 
 
Hypo- and hyper-flagging rates:  
The daily number of results, expressed as percentage relative to the total number, that are 
automatically flagged when they are either lower (hypo) or higher (hyper) than the locally 
used decision limits or reference interval. 
 
Long-term median: 
A statistical measure that represents the median calculated from all daily patient medians 
(Percentiler) or daily flagging rates (Flagger) provided by the laboratory to which the graph 
applies. In the Percentiler and Flagger graphs this is indicated with the long-broken 
horizontal grey line. 
 
Moving average: 
A statistical measure which is commonly used with time series data in order to create charts 
that show whether a significant trend is visible by flattening out noise. To do so a series of 
averages is calculated of different subsets of the full dataset. 
 
Moving median: 
This measure is similar to the moving average but instead of a series of averages, a series of 
medians is calculated, which is less sensitive towards outliers. In the Percentiler these 
moving medians are calculated for daily patient medians, in the Flagger for daily hypo-and 
hyper-flagging rates (each time grouped per 5, 8 or 16 days). 
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Robust CV: 
The robust CV is calculated as 100 * (median absolute difference x 1.4826)/(median). The 
robust CV is less sensitive towards outliers, because it uses the median absolute difference 
as measure of the variability of quantitative data. This median absolute difference is 
calculated by taking the median of the absolute differences of each measurement in the 
dataset with the median of that dataset.  
 
Sy/x (standard error of estimate): 
A statistical measure for the accuracy of predictions made with a regression line. The value 
either represents the within-run imprecision (when a laboratory is compared with its peer) or 
the combined imprecision and sample-related effects (when a laboratory is compared with a 
trueness based target). 
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Highlights 
In healthcare, just like in any other discipline, a measurement is not an absolute concept, but 
it delivers an estimate of the “true” value. This is due to the fact that a measurement is 
always accompanied by a certain amount of error, which consists of a one-sided systematic 
error and a two-sided random error. These two types of error, which by definition have 
different origins, make up for the total error of the measurement. Making a measurement 
error on an in vitro diagnostic (IVD) instrument is unfortunately inevitable. Therefore, in order 
to avoid inaccurate patient management, the total error should always be minimized and not 
exceed a certain quality specification. A clinical laboratory can apply internal quality control 
(IQC) and external quality assessment (EQA) tools to control the analytical quality it 
manages when it measures patient samples. 
 
This chapter describes: 
 The concept “error”: the different error components and error models. 
 Quality specifications – what is a significant error? 
 Established quality management tools in the clinical laboratory: IQC and EQA 
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1. Analytical Quality (Assessment) – Measurement introduces error 
Introducing significant (analytical) errors in a clinical laboratory environment can have a 
harmful effect on patient care and health economics. These errors can, for example, lead to 
falsely interpreting analytical runs and misclassification of patient results (1). A report from 
the Institute of Medicine from the United States (US) indicates that medical errors are costing 
the US healthcare system $17 billion each year (2). Although In Vitro Diagnostics (IVD) only 
contribute to a small part of these errors, performing measurements on an IVD instrument 
will always introduce a certain amount of error, that could lead to results which are not 
necessarily stable or comparable over time and location. Table 1 shows an educational 
example of a patient who is being monitored for his/her alanine aminotransferase (ALT) 
values on different platforms.  
Table 1 Educational example of ALT measurements (fictional case). 
Date 
Measuring 
system 
ALT 
(U/L) Patient/Physician communication 
Jan 2010 Cobas S1 20 Patient monitors his/her ALT out of curiosity, even though the values are considered healthy 
April 2010 Cobas S1 25 Patient asks about difference, physician explains biological variation 
July 2010 Cobas S1 26 Patient is happy, values are normal and stable 
Oct 2010 Cobas S2 30 Patient gets nervous, physician says short-term 
elevations are normal; patient requires retest 
Oct 2010 Cobas S2 (new lot) 35 
Patient stays nervous, physician repeats that short-
term elevations are normal 
Jan 2011 Cobas S2 34 Patient is happy, values are normal and stable 
July 2011 Architect 45 Patient is near crisis, new physician explains report and 
new reference intervals; patient requires retest 
July 2011 Architect 46 Patient satisfied about health, but dissatisfied about physician, extends retest period 
Jan 2012 Architect 44 Patient calmed down 
Oct 2012 Vitros 60 Patient in “panic” (new town, new physician); physician 
repeats above stories; patient requests retest 
Oct 2012 Vitros 59 Patient dissatisfied, but accepts 
Oct 2013 AU 31 Patient starts to amuse him/herself 
Oct 2014 Cobas  27 Patient becomes interested in the topic 
Oct 2014 Patient stops None Patient writes a thesis 
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The patient had been tested before for ALT by his general practitioner (GP) because 
of certain clinical symptoms. Although testing was negative, the patient was so concerned 
about his health status that he urged his GP to continue the monitoring of his ALT values. 
Over time the measured ALT value changes significantly due to a combination of biological 
variation and a number of quality-related problems. The Westgard biodatabase (3) indicates 
that the typical within-subject biological variation for ALT equals 19.40%. Assuming the 
numbers from that source are correct, the differences shown in Table 1 can’t simply be 
explained by biological variation. And, although the mentioned values in Table 1 are fictional, 
they still represent realistic numbers, which is reflected in Figure 1. This dotplot shows the 
outcome when a single sample is measured for ALT in 126 different laboratories (data from 
our Master Comparison survey). It shows huge measurement variation for ALT and indicates 
that a twofold difference between laboratories is not impossible. Note, here abstraction is 
made from the aforementioned biological variation. 
 
Figure 1. Dotplot showing the distribution of measurements for a single-donation sample 
(126 laboratories using different IVD systems). Measurement values extend from 14 to 36 
U/L, with an average value of 22 U/L. 
This dotplot is actually a nice demonstration which indicates that a measurement is 
not an absolute concept – as some patients may believe – but an estimate of the true value. 
The correctness of that estimate depends on the size of the error which is made during the 
patient management process. Errors can occur at three different stages: the pre-analytical, 
analytical and post-analytical phase (4). The pre- and post-analytical phases consist of every 
aspect in patient management besides the clinical laboratory. In short, the pre-analytical 
phase includes the collection of patient samples and its transportation, whilst the post-
13 
 
analytical phase includes the interpretation and utilization of laboratory information (5). This 
thesis, however, will mostly focus on the analytical phase, which consists of the core 
laboratory work under control of the laboratory staff. Errors introduced in this phase relate to 
the reliability of the applied instrumentation. 
The different error components 
As already mentioned, a measurement is always accompanied by a certain amount of error. 
The total error (TE) can be described as a combination of random error (RE) or (im)precision, 
systematic error (SE) or bias, and in some cases also interferences (see Figure 2). The 
International Vocabulary of Metrology (VIM) defines measurement accuracy (which relates to 
the TE) as: “The closeness of agreement between a measured quantity value and a true 
quantity value of a measurand”. Measurement accuracy consists of both measurement 
trueness (which relates to the SE) and measurement precision (which relates to the RE). 
Trueness is defined as: “closeness of agreement between the average of an infinite number 
of replicate measured quantity values and a reference quantity value”, and precision as: 
“closeness of agreement between indications or measured quantity values obtained by 
replicate measurements on the same or similar objects under specified conditions” (6). 
The total imprecision or RE consists of a combination of imprecision and sample-
related effects (SRE’s). The imprecision is a measure for the degree of variation of a result in 
a set of replicate measurements (7). It is an inevitable characteristic of every measurement, 
where results lie on both sides of a mean value. It is usually expressed as a standard 
deviation (SD) or coefficient of variation (CV). One usually makes a distinction between 
within-run imprecision and between-run imprecision of a method, which can quite easily be 
assessed with available guidelines such as the EP05-A3 protocol (8,9). When the RE of a 
method is estimated with the Sy/x value after linear regression analysis, SRE’s can increase 
the RE due to the inherent variation of the measured samples (Sy/x = the standard deviation 
of the residuals). This additional RE or lack of fit error causes the data to not strictly fit the 
estimated regression line (10). In contrast to the measurement imprecision, retesting and 
increasing the number of replicates will not significantly lower the error caused by SRE’s. 
 A bias or SE is defined as: “the mean that would result from an infinite number of 
measurements carried out under repeatability conditions minus a true value of the 
measurand” (7). As shown in Figure 2, this bias can be introduced at several levels of the 
measurement process (manufacturer, laboratory, module of the instrument, lot, and 
calibration). Again, several guidelines (e.g. the EP09-A3 protocol) are available to assess the 
size of the bias (11). Interference, finally, is defined as: “a SE in the measure of signal 
caused by the presence of concomitants in a sample” (7,12). The interference can be 
assessed with the EP07-A3 protocol (13). 
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Figure 2. Overview of total error components influencing the test result. 
Trueness – Establishing a traceability chain 
In the hypothetical case that a SE is non-existent, the mean that would result from an infinite 
number of measurements carried out under repeatability conditions equals the “true value”. 
In order to realize the trueness of a routine measurement method or IVD instrument, one 
needs to establish its traceability to a higher order “reference” using appropriate materials 
(14,15). The International Organization for Standardization (ISO) introduced the traceability 
concept as a means to link the result of patient samples to a commonly accepted reference, 
in order to make them comparable over time and location, and across systems (16). In the 
ideal case, all routine methods are traceable – also called standardized – to a trueness-
based higher order primary reference material and/or reference measurement procedure 
(RMP), both realizing the Système International d’ Unités (SI). 
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The traceability chain itself starts with the definition of the measurand and the unit of 
expression for measurement results (preferably SI), and consist of an unbroken chain of 
calibrations (depicted in Figure 3). Each material from this chain (blue frames in Figure 3) is 
used to calibrate a lower-order measurement procedure (red frames in Figure 3). The 
calibrated measurement procedure is, in turn, used to assign a value to the lower calibrator. 
Given that all elements from the chain are present, calibration starts with a primary reference 
material used by reference laboratories to calibrate the highest order RMP, and goes all the 
way down, via the instrument manufacturers, to the routine clinical laboratory. Meanwhile, 
the inevitable uncertainty of the measurement increases after each calibration step, to reach 
the highest uncertainty at the level of the clinical laboratory. 
 
Figure 3. Metrological traceability chain. The traceability chain consist of an unbroken chain 
of calibrations. Each material (blue frames) is used to calibrate a lower-order measurement 
procedure (red frames). The calibrated measurement procedure is, in turn, used to assign a 
value to the lower calibrator. 
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Two problems can arise related to the concept traceability. Either the chain is 
incomplete, or an artificial bias is introduced by one of the applied calibrating materials. To 
account for the former issue different concepts of the traceability chain have been 
established (see Vesper et al; 14). A returning problem is the unavailability of a higher-order 
reference material and/or method. This means that SI-traceability or standardization of 
routine measurements is not possible, but this doesn’t mean that equivalent results across 
different methods cannot be obtained. The routine methods can still be harmonized to a 
lower-order reference material or to a surrogate target (17). One of this surrogate targets can, 
for example, be an “All Method/Manufacturer Trimmed Mean” or AMTM (18). Lack of both 
standardization and harmonization will lead to a lack of comparability between different 
methods available on the market. 
A second problem arises when a bias is introduced due to a matrix effect. This 
problem is referred to as “non-commutability” (19,20). This is typically due to the fact that the 
measurand (or quantity which is intended to be measured) is contained in a different matrix 
for the calibrator/reference material compared to patient samples. When both of these 
samples (reference materials and patient samples) are measured with two or more analytical 
methods, the reference materials can only be considered as commutable when they have 
interassay properties comparable to the properties of the patient samples (21). Non-
commutable reference materials should never be used for calibration purposes as they will 
hamper the traceability chain and jeopardize a trueness-based value. 
Apart from establishing a traceability chain, one should also select measurement 
principles which are as insensitive as possible to interferences to be specific, and select 
stable, high quality instrumentation (i.e. without system drifts or shifts) in order to minimize 
the SE and guarantee trueness. 
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The different error models  
As explained in the VIM vocabulary, RE and SE (or precision and trueness) are by definition 
different. They are combined in different ways to calculate the TE (22,23). The following 
models exist: 
1. The variance model treats the two types of error as two similar entities and 
combines them by error propagation (24). 
σ 	= σ	
 + |bias|	
2. In the measurement uncertainty model (MU model) described by the Guide to the 
expression of Uncertainty in Measurement (GUM), the error around the estimated 
quantity is expressed as uncertainty. The GUM states that all known components 
of error should be evaluated and if possible corrected for. For example, known 
bias components should be eliminated by applying correction factors. The 
uncertainty of that correction is added to all other forms of uncertainty by error 
propagation. Unknown bias components are transformed into variances assuming 
a rectangular distribution with the same probability for any value of the presumed 
interval (25). This model is mostly used in the Quality Control (QC) environment of 
IVD manufacturers and reference laboratories. 
3. Thirdly, the TE or linear model (also referred to as the Westgard model) combines 
bias and imprecision via a linear relationship (26). This model is mostly used in 
the QC environment of clinical laboratories. 
TE = |bias| + z.σ	
 
(with z = 1.65 for one-tailed probability or 1.96 for two-tailed probability)	
4. Finally, the combined model includes the biological variation component in the 
equation and is, therefore, a useful model to be applied when inferring quality 
goals (discussed in part 2 of the introduction). This model is more complex, and 
discussing it is beyond the scope of this introduction. Further information can be 
found in the publication of Gowans et al (27). 
The TE and MU model are most frequently used in a QC environment. Nonetheless, 
there is some debate on the correct use of these different types of models (28-31). Westgard 
promotes a clear separation between the TE and MU model. He proposes to use the TE 
model in the QC environment of a clinical laboratory, because it allows to use one error 
budget (indicated with TE limits or a total allowable error) which laboratories can spend for 
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both bias and imprecision without having to differentiate between both type of errors. On the 
other hand he proposes to use the MU model for quality management by manufacturers, 
reference laboratories and metrological institutes to assure the traceability and comparability 
of results across clinical laboratories (28). Oosterhuis et al find this clear separation too 
simplistic. They propose to improve the TE model by implementing uncertainty component 
estimations to take into account all sources of variation when handling patient samples, i.e. 
not only analytical variation, but also variation within and between reagent lots and 
calibrations, within and between biological variation, pre-analytical variation, etc. The idea 
behind this concept is to include all sources of variation to get an idea on the total MU when 
comparing patient samples with either a previous result, with a population reference interval 
or with a clinical decision point. The MU model would, thereby, ease the identification of 
patient samples which are significantly different from another result for the same quantity 
(29,30). Currently, however, the TE model is most frequently used at the level of the clinical 
laboratory, because removing all known bias components – as suggested by the MU model – 
remains a cumbersome to impossible task for the clinical laboratory. 
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2. Quality specifications – What values are acceptable for bias and 
imprecision? 
One problem which frequently arises in the investigation of laboratory error is how to define 
what actually constitutes significant error. Introduction of measurement error is unavoidable, 
therefore the question remains how large this error can be without compromising medical 
decisions? Or expressed in an alternative manner: what quality is sufficient for patient care? 
To answer this question, one has to rely on quality specifications which define a reasonable 
budget to make measurement errors (32). This leads to the next question: what values for 
quality specifications should be used? Inferring these values unequivocally is not that simple 
because different strategies have been proposed to calculate specifications or limits. A first 
landmark on how to deal with these different strategies was proposed at the 1999 Stockholm 
conference organized by the European Federation of Clinical Chemistry and Laboratory 
Medicine (EFLM). This conference derived a Consensus Statement on analytical 
performance specifications, which has set a clear hierarchy on the strategies which can be 
applied to calculate the specifications (33,34). This hierarchy is addressed in Table 2 and 
shows five hierarchal levels. 
Table 2. The hierarchy of strategies/models to set analytical quality specifications as decided 
on the 1999 Stockholm conference (33). 
1. Evaluation of the effect of analytical performance on clinical outcomes in specific 
clinical situations. 
2. Evaluation of the effect of analytical performance on clinical decisions in general. 
a. Data based on the components of biological variation. 
b. Data based on analysis of clinicians' opinions. 
3. Published professional recommendations. 
a. From national and international expert bodies. 
b. From expert local groups or individuals. 
4. Performance goals set by: 
a. Regulatory bodies 
b. Organizers of External Quality Assessment (EQA) schemes 
5. Goals based on the current state of the art. 
a. As demonstrated by data from EQA or Proficiency Testing Schemes. 
b. As found in current publications on methodology 
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At the first strategic conference of the EFLM on “Defining analytical performance 
goals 15 years after the Stockholm conference on quality specifications in laboratory 
medicine” held in Milan on November 2014, the consensus agreement on quality 
specifications was revisited (35). This revision mostly led to a simplification of the hierarchy 
from five to three models: 
1. The first model is based on the effect of clinical performance on clinical outcomes. 
These types of specifications are called outcome-based quality limits and they are 
calculated using either direct or indirect outcome studies. Direct outcome studies 
are extremely valuable because they reflect the clinical needs of patients, but they 
are also difficult to perform because clinical tests are only indirectly linked to the 
clinical outcome of that test (36). That explains why there are only a limited 
number of examples available on these types outcome studies (e.g. 37-40). 
Indirect outcome studies either rely on simulations to model the probability of 
clinical outcome (41), or on clinicians’ and/or experts’ opinion, e.g. by providing 
questionnaires to clinicians (42). 
2. The second model is based on the biological variation of the measurand. This 
approach attempts to minimize the ratio of analytical to biological variation (43). 
Two of the most frequently used concepts for desirable performance 
specifications have been described by Harris (44) and Gowans (27). Harris et al 
discussed that, in order for the analytical variation to add maximally 12% to the 
total test variability, the analytical variation should be smaller than 50% of the 
within-subject biological variation (CVA ≤ 0.5CVI). Gowans at her turn showed that, 
in order for laboratories with a homogeneous population to use the same 
reference interval, the bias should be lower than 25% of the error propagation of 
the within- and between biological variation (bias ≤ 0.25(CVI2 + CVG2)). Other 
models based on biological variation exist, but discussing these is beyond the 
scope of this introduction. 
The advantage for models based on biological variation is that they are simple 
to use and they can be applied to most measurands for which within-subject and 
between-subject biological variation data have been established. There are, 
however, several limitations to this approach: (i) sometimes the biological 
variation is quite narrow leading to limits which are too stringent, (ii) when the 
biological variation is too broad, the limits will be too generous, (iii) different 
studies provide different outcomes on biological variation, and (iv), this model 
doesn't consider the necessity for different requirements in different concentration 
ranges.  
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3. The third and last model is based on state-of-the-art performance. These 
specifications show what is currently achievable at the highest level of analytical 
performance. These limits are usually assessed with empirical methods, for 
example by performing an EQA survey. Different studies, however, usually don’t 
provide a consensus on the goal-setting.  
Depending on the applied empirical model/concept, these limits can either 
represent what is currently achievable by the best instrument and/or assay on the 
market or represent a certain quality which most laboratories can achieve. 
Laboratories which are not able to meet this level of quality are expected to verify 
and, if needed, change their practice. State-of-the-art performance limits can, in 
addition, be compared with the limits from other models to identify the technology 
which should be improved in order to meet the requirements to suffice for clinical 
needs.  
Although in theory one should always choose the highest possible model in the hierarchy, 
certain models will be more suitable for certain measurands than for others. That’s why there 
is currently still no clarity on which model to be used for which test. Therefore, a task force 
has been created by the EFLM to allocate different tests to different models (45). 
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3. How to address problems with analytical quality in the clinical 
laboratory 
Typically, the individual patient’s health status is monitored in a specific laboratory which 
uses a module of an IVD instrument with a particular assay. This means that a measurement 
result for the individual patient will comprise the full test variation or measurement error 
extending from the manufacturer over laboratories to system sites. This also means that a 
whole range of quality-related problems can occur upon measurement of a patient’s sample 
in a clinical laboratory including interference errors, pre-analytical variation, bias-related 
issues, stability problems, lot- and calibration variation... The list of potential errors is quite 
extensive and measurement errors which are too large will lead to the inability to reliably 
examine a patient’s health status or monitor the patient over time and across sites. Luckily, 
tools to map these problems are available in the quality monitoring discipline. 
 First of all, there is the ISO 15189 accreditation standard which specifies 
requirements for the competence and quality of clinical laboratories (46,47). The goal of this 
international standard for common use is to enhance the credibility of accredited clinical 
laboratories, and to provide a minimum standard of quality testing. To achieve this 
international standard, laboratory quality management typically relies on IQC and EQA (or 
proficiency testing) tools. These are not only used to identify (the cause of) erroneous results, 
but also provide a means to correct for errors (4). IQC in the clinical laboratory – just like any 
other analytical laboratory – involves a continuous evaluation of the laboratory’s own 
analytical methods to monitor day-to-day precision and accuracy of a given assay. The 
theory behind IQC is that the laboratory runs QC samples in parallel with routine patient 
samples. The results for the QC samples are plotted in a control chart to verify whether the 
measurement procedure performs stable within given specifications. If the QC results fall 
outside the specifications, corrective action might be necessary (48). EQA, on the other hand 
tries to ensure interoperable/comparable results by comparing a laboratory to its peer, i.e. a 
group of laboratories using instruments with similar technology, or to a trueness-based 
reference system. These surveys are usually overseen by a third party and imply sending a 
(small) set of samples to all survey participants. These are expected to handle and measure 
the EQA samples in the same manner as the patient samples. The results of the measured 
samples are returned to the third party, which then processes the results from all survey 
participants and provides feedback on the quality of each laboratory (49). 
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As shown in the introduction, quality assurance in the clinical laboratory is essential to 
guarantee appropriate interpretation of clinical IVD test results. Laboratories strive to ensure 
that correct results are obtained for the samples they analyze to prevent negative impact on 
the patient’s health. To accomplish this, QC systems, such as IQC and EQA, are 
implemented by the clinical laboratory community. These are not only used to identify (the 
cause of) erroneous results, but also to provide a means to correct for the observed errors. 
Both IQC and EQA have a prominent position in quality assurance, however, these tools 
have limitations. Among others, the artificial nature of QC materials (e.g. pooled, stripped, 
dialyzed, delipidated, fortified, lyophilized…) can hamper correct interpretation of analytical 
errors, because the materials don’t necessarily reflect the reality of performance of IVD tests 
on patient samples. As mentioned in the introduction (on page 16), these problems are 
referred to as (non-)commutability issues. Therefore, IQC and EQA can sometimes fail to 
identify or falsely suggest significant analytical variation/error at the patient level. In addition, 
because of the aforementioned potential non-commutability, comparison of QC data can only 
be reliably done at the peer group level, which makes it more difficult to compare quality 
across assays. Therefore, this thesis introduces a number of alternative quality management 
tools which can be used together with the established QC system to aid in providing global 
evidence about field performance of IVD tests. 
The tools described here are intended to monitor the analytical quality of clinical IVD 
tests by using patient results instead of QC materials, simply because “only good samples 
can make good assays” (1). Therefore, they essentially avoid problems related to non-
commutability. The studies and surveys performed with these tools are further designed to 
establish a bottom-up approach to quality assessment which facilitates collaboration between 
laboratories and IVD manufacturers. The aim is to offer involved parties evidence on quality 
of performance on patient samples, better data access, and a communication platform. To do 
so, this thesis project is divided in two big parts. The first part involves stability monitoring 
(chapter 1, 2 and 3), whilst the second focuses on the comparability status of the different 
IVD tests on the market (chapter 4). 
Chapter 1 focuses on the traditional stability assessment by means of IQC. It 
discusses what type of stability information can be extracted when QC materials are 
evaluated on either a daily or a monthly basis. To this end, a number of datasets are 
processed to distinguish between shifts caused by container- and/or lot-effects and 
calibration aberrations. Chapter 2 and chapter 3 illustrate two quality management tools, 
called the Percentiler and the Flagger, which can be used for mid- to long-term quality 
monitoring. With these applications one can perform continuous stability performance for 22 
common analytes by calculating their daily (out)patient medians (for the Percentiler) and 
hypo-, and hyper-flagging rate (for the Flagger), which both have to be sent to the project’s 
29 
 
database. These two web applications allow data visualization based on graphical 
presentation of the moving medians in time and summary statistics. Thereby, they provide 
evidence about stability of performance and help to elucidate the reasons for assay variation. 
For example, allocating assay instabilities to either manufacturer-related problems such as 
lot inconsistencies or laboratory-related problems such as recalibration issues or poor pre-
analytics. In addition these chapters describe how these tools can help with the 
establishment of realistic quality specifications (based on state-of-the-art performance of the 
assays currently on the market), and how they provide a means for comparison across 
manufacturers. Furthermore, by comparing an assay’s stability in the Percentiler with the 
stability in the Flagger, these tools strive to translate the effect of instabilities on “surrogate” 
medical decisions (with the latter being the hypo- and hyper-flagging rates). In chapter 4, the 
subject is changed to trueness and comparability assessment of several IVD instruments by 
means of the Master Comparison surveys. These studies are designed to provide the 
participating laboratories with a panel of 20 commutable single donation serum samples to 
examine for eight different analytes. Thereby, these surveys are created to provide correct 
information on the comparability and standardization status of assays and laboratories, and 
to set benchmarks for the intrinsic quality of commercial assays and for laboratory 
performance. In addition, these studies intend to add information about the reasons for assay 
bias (laboratory or manufacturer performance). Next, chapter 5 describes the 
communication platform, called the Empower project. It is the overarching concept which 
encompasses, amongst others, the Percentiler, the Flagger and the Master Comparison 
surveys. Overall, the Empower project intends to promote the quality, stability, and 
comparability of global IVD testing by “bottom-up” cooperation of laboratories and 
manufacturers. Chapter 6, finally, elaborates on some statistical tools described in the 
guidelines from the Clinical & Laboratory Standards Institute (CLSI). This part of the thesis 
stresses the need for the correct use of statistics for the verification of reference intervals in 
the clinical laboratory and for commutability assessment of reference materials used by 
manufacturers to calibrate their assay.  
Note, this thesis is a continuation on the work of Dr. Hedwig Stepman (Analytical 
quality and its effect on medical decisions of laboratory tests for the management of chronic 
kidney disease, 2). Whilst her work focused on pilot experiments of different aspects of the 
Empower project, this thesis builds upon those bricks to guide the Empower project from a 
pilot to an operational scale. This was accomplished by recruiting laboratories for real-time 
participation to the project. It is also a joint cooperation with the thesis of Linde De Grande. 
While her project focuses more on the application of the Percentiler and Flagger in the 
standardization and/or harmonization of thyroid hormone measurements, this thesis 
emphasizes on clinical chemistry analytes.  
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1 Chapter I Internal Quality Control 
monitoring 
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Highlights 
Internal Quality Control (IQC) plays a key role in ensuring reliable results for patient samples 
analyzed in the clinical laboratory. It is based on the analysis of materials which act as 
surrogate for patient samples, and is intended for monitoring of the day-to-day precision and 
accuracy of a laboratory. Different control materials can be used and measured on a daily 
basis, however, data interpretation can be done at different frequencies. Here, we discuss 
interpretation of IQC data either on a daily or a monthly basis. We describe what type of 
information can be extracted from these stability studies. 
 
Highlights of the research: 
 Daily IQC results are ideal to focus on short term (in)stability effects, however, they 
can also be used to address mid- to long-term effects. 
 Monthly IQC results can only address long-term effects. 
 IQC data can make it possible to distinguish between shifts caused by container- 
and/or lot-effects and calibration aberrations. 
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1. Introduction 
IQC is the most important and most appropriate tool in a clinical laboratory to monitor the 
day-to-day precision and accuracy of the applied assays (1). The major objective of (I)QC is 
to identify measurements where significant errors occurred as well as the reason of those 
errors, and to stop the process before it exceeds a critical limit of deterioration (2). It thus 
intends to contribute to the quality of clinical data by guaranteeing reliable laboratory results 
so that an appropriate clinical interpretation can be made. 
 To perform IQC in the best possible manner, the laboratory should use IQC materials 
which fulfill a number of requirements. The applied quality materials should have clinically 
relevant concentrations of the analyte (preferably at decision limits), and they should be 
treated in the same manner as the patient samples so that every key step in the process is 
covered. In addition, they should resemble patient samples as closely as possible, so that 
any error observed for the QC materials also applies to the patient samples. However, in 
practice, this can be difficult to achieve due to non-commutability issues and potential 
instability of the QC material (3,4).  
The commercially available IQC materials can be bought from two different sources. 
In some cases manufacturers provide control materials for their own assays. These types of 
QC materials are often manufactured from the same material as the calibrator (3). However, 
the approved CLSI guidelines for statistical QC state that QC materials should be different 
from the calibrator materials to ensure that the QC procedure provides an independent 
assessment of the measurement procedure’s performance in its entirety, including the 
procedure for calibration of the measurement (5). It is, therefore, recommended to apply 
control materials from a third party (such as Bio-Rad or Randox), because they deliver 
independent assessment of the assays. 
In this chapter we interpret a dataset obtained from IQC materials from both sources 
(manufacturer and third party control). Some of the data were already gathered in the past, 
but the first analysis was done currently. Unprocessed IQC data which were measured on a 
daily basis were provided by Roche Belgium (6), in consent with the laboratories which 
owned the results. Bio-Rad Laboratories (7) provided a second dataset, but this only 
contained the monthly mean of IQC samples which were also measured on a daily basis. 
The focus in this chapter lies on the stability observations one can make on the basis of IQC 
data which are evaluated on a daily (Roche) and on a monthly basis (Bio-Rad). In addition, 
for the dataset provided by Roche, we try to distinguish between effects caused by 
mathematical calibration and effects caused by using a new reagent container. 
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2. Stability assessment based on daily IQC results 
A large dataset was received from Roche laboratories (6) comprising data from IQC material 
which were measured on a daily basis in 43 different laboratories and covering four analytes: 
calcium, sodium, inorganic phosphor, and albumin. The measurements were done on a 
Roche Cobas 6000 system and covered a period of 21 months or 639 days starting at 
01/01/2011 and ending at 30/09/2012. For some periods there were fewer data available. 
Therefore, only data from 23/05/11 until 22/05/12 were processed. In addition, data were split 
up according to the concentration level of the IQC sample (level “391” or “392”). Data 
analysis was performed with the different levels apart. In case an IQC sample was measured 
more than once on a single day, the daily average was calculated. 
In order to interpret the stability and quality of the IQC measurements, data were 
visualized with Excel using a moving median grouped per 2, 5, 10, or 15 days. Data analysis 
started with the 20 labs which had the most values for both concentration levels, but none of 
them provided data on all of the 639 days of the investigated timeline. Laboratories which 
provided less than 1000 values for both levels together were excluded from further analysis. 
In addition, it was necessary to do a mathematical normalization of the two QC material lots 
which were used for calcium and inorganic phosphor. If not, this resulted in a moving median 
which was obviously going up or down due to the different concentration of the QC material. 
The result was a number of graphs presenting each the stability of the IQC measurements of 
one laboratory in time. Furthermore, by calculating the daily median for all laboratories using 
the same assay, we could also plot and interpret the stability of the entire Roche Cobas peer 
group and compare each laboratory with its peer. Around the moving median of the peer 
group we plotted QC limits which take into account both the biological variation of the studied 
analytes, and the current capabilities of the applied Roche Cobas assays (calcium: ±0.05 
mmol/L; sodium: ±1 mmol/L; inorganic phosphor: ±0.04 mmol/L; albumin: ±1 g/L). We 
interpreted the quality of the IQC measurements versus the chosen analyte-specific QC 
limits, but it should be noted that a consensus on these does not exist (8). 
Depending on the applied value for the moving median, the Excel graphs can either 
be used to detect short term quality problems (n = 2, 5) or they can be applied for mid-to-long 
term monitoring and interpretation of the analytical quality (n = 10, 15). In Figure 1 an 
example can be seen for lab 0611-06 for calcium level “391” demonstrating the difference 
when applying a moving median grouped per 2, 5, 10, or 15 days. The IQC data from this 
laboratory (indicated in orange) shows both good comparability to its peer group (indicated in 
red) and sufficient stability within the applied QC limits (indicated in black; around the peer 
group median). 
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Figure 1. Calcium IQC data for one laboratory 0611-06. Orange lines represent the moving 
median (MM; n = 2, 5, 10 or 15 days) for the individual laboratory. The red lines correspond 
with the moving median of the Roche Cobas peer group, the black lines with the limits (±0.05 
mmol/L for calcium). 
Described on the next four pages are four examples for each analyte, but only data 
on the “391” level are discussed (Figures 2-5). A complete overview of all data can be found 
in the annex (Supplemental Figure 1-4). Note, only moving medians for n = 10 are shown. 
This is a good approach to identify general effects, but one can miss short term 
stability/quality problems. For the latter, a moving median of 2 or 5 should be used or the 
data should be plotted with a scatterplot instead of using a moving median. 
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Albumin (see Figure 2) 
• 0807-03: a calibration aberration which occurred in fall 2011 led to an upwards shift 
borderline to significant outside of the defined QC limits. 
• 0969-21: long-term stability of the laboratory is interrupted by a downwards drift 
(starting from 2012), leading to a (borderline) negative bias. 
• 0952-15: the laboratory starts with a number of low values for the IQC material, but 
improves and has generally good stability at the end of the timeframe. 
• 0616-06: laboratory with a good stability. Only two shifts possibly occurred over the 
complete timeframe, but these didn’t lead to a significant bias compared to the peer 
group. 
  
  
Figure 2. Albumin IQC data from Roche for four laboratories. Colored lines (not red) 
represent the moving median (n = 10) of the individual laboratory. The peer group moving 
median is shown with a red line, the applied QC limits (± 1 g/L) are shown in black lines. 
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Calcium (see Figure 3) 
• 1098-13: high variation of the measurements of the IQC material. The calcium assay 
of the laboratory shows a sawtooth pattern, indicating a drift caused by an unstable 
assay, which is followed by a recalibration. At the end of the timeframe a positive bias 
arises. 
• 0969-21: a long term negative bias from mid to the end of 2011. Comparability to the 
peer target improves in 2012, but the data still suffer from a high variation. 
• 0625-01: a very clear shift occurs near the end of 2011 moving the data from a bias 
which is borderline positive to a borderline negative bias. 
• 0765-05: a long term borderline negative bias within the QC limits. 
  
  
Figure 3. Calcium IQC data from Roche for four laboratories. Colored lines (not red) 
represent the moving median (n = 10) of the individual laboratory. The peer group moving 
median is shown with a red line, the applied QC limits (± 0.05 mmol/L) are shown in black 
lines. 
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Inorganic phosphor (see Figure 4) 
• 1098-13: insignificant negative bias, within the specification limits. Pearls on a string 
effect caused by rounding of the result. 
• 0954-25: data was mostly stable with the exception of a very clear calibration 
aberration around March 2012. 
• 0811-20: two positive shifts (September – December 2011 and February – April 2012) 
led to a significant long term positive bias. Each time this effect was cancelled by a 
downward shift restoring values which are comparable with the peer group median. 
• 1006-08: a laboratory with a very good stability and comparability to the peer group. 
  
  
Figure 4. Inorganic phosphor IQC data from Roche for four laboratories. Colored lines (not 
red) represent the moving median (n = 10) of the individual laboratory. The peer group 
moving median is shown with a red line, the applied QC limits (± 0.04 mmol/L) are shown in 
black lines. 
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Sodium (see Figure 5) 
• 0611-06: occurrence of a high variation due to a significant number of calibration 
aberrations, and a small positive bias. 
• 0969-21: a significant long term positive bias exists. It is remediated from 2012 on. 
• 0750-09: a significant long term negative bias occurs which persists over the 
complete timeframe. 
• 0952-15: a laboratory with a very good stability and comparability to the peer group. 
  
  
Figure 5. Sodium IQC data from Roche for four laboratories. Colored lines (not red) 
represent the moving median (n = 10) of the individual laboratory. The peer group moving 
median is shown with a red line, the applied QC limits (± 1 mmol/L) are shown in black lines. 
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3. Container and calibration effects 
Roche IQC data for albumin, calcium, and inorganic phosphor, also included the reagent 
container identification number of each measurement performed. With this information one 
can distinguish between analytical shifts which are caused by a new reagent container or by 
mathematical calibration. In theory one can also distinguish shifts which are caused by a new 
lot, but the lot numbers were not supplied with the data. Each measurement result per day 
was plotted in a scatterplot. Different reagent container ID’s were visualized with a different 
symbol. For each analyte, a dataset of two laboratories is shown. Figures 6-7 show that 
some containers are subject to a higher drift than others, caused by a higher instability. 
When a shift occurs during the use of a single container, this can be allocated to a calibration 
effect. An example can be seen in Figure 7 for calcium (middle row, left column, blue 
diamonds). When a new container is taken into service, a shift can either be caused by the 
new container itself or by a combination of a new lot and new container. An example can be 
seen in Figure 7 for inorganic phosphor (bottom row, left column, transition from yellow 
circles to red squares). 
 
Figure 6. Container and calibration effects for albumin (one laboratory). Different container 
ID’s are visualized with a different symbol. 
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Figure 7. Container and calibration effects for albumin, calcium and inorganic phosphor (two 
laboratories each). Different container ID’s are visualized with a different symbol. 
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4. Stability assessment based on monthly IQC results 
A second large dataset was received from Bio-Rad Laboratories Inc (7) comprising IQC data 
from 430 different laboratories and covering the same four analytes: calcium, sodium, 
inorganic phosphor, and albumin. The IQC measurements were performed daily by the 
laboratories but only the monthly mean was provided by Bio-Rad. The dataset covered 
measurements on seven different devices (Abbott Architect, Beckman DxC, Ortho Vitros, 
Roche Cobas, Roche Integra, Siemens Advia, and Siemens Dimension Vista), and a period 
of about 20 months going from October 2010 until June 2012. In order to interpret the 
stability and quality of the IQC measurements, data were visualized with Excel using a 
scatterplot of the monthly means. Shown and interpreted in this section are data for 
laboratories using the Roche Integra device. The same QC limits as before, i.e., that take 
into account biological variation and the current capabilities of the assays, were applied in 
the graphical representation (calcium: ±0.05 mmol/L; sodium: ±1 mmol/L; inorganic phosphor: 
±0.04 mmol/L; albumin: ±1 g/L). Again, these QC limits are plotted around the Roche Integra 
peer group median values. 
With the graphs, we described four example laboratories for each analyte. The other 
data were added in the annex (Supplemental Figure 5-8). Note, because only monthly 
means were reported these data can only be used to visualize long term effects. Short term 
and even mid-to-long term effects can’t be addressed. 
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Albumin (see Figure 8) 
• 155555: laboratory with a very good stability and comparability to the peer group. 
Only at the end of the timeframe a potential problem occurred. 
• 210311: a borderline to significant negative bias compared to the peer target. 
• 916217: the laboratory started with a good stability but a shift in mid-2011 caused a 
significant positive bias. 
• 916229: this laboratory shows the same trend as number 916217 and other 
laboratories (data not shown). This might indicate that a new lot was deployed by 
these IQC participants. Because the majority of laboratories didn’t show this trend, 
the peer median is not influenced by the potential new lot. 
 
 
  
Figure 8. Albumin IQC data from Bio-Rad for four laboratories. Colored lines (not red) 
represent the data of the individual laboratory. The peer group data are shown with a red 
line, the applied QC limits (± 1 g/L) in black lines. 
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Calcium (see Figure 9) 
• 382382: laboratory with a good stability and comparability to the peer group 
• 346892: a significant long term positive bias occurs over the complete timeframe. 
• 172131: a borderline to significant long term negative bias occurs over the complete 
timeframe. 
• 390916: a borderline to significant long term positive bias occurs over the complete 
timeframe. 
  
  
Figure 9. Calcium IQC data from Bio-Rad for four laboratories. Colored lines (not red) 
represent the data of the individual laboratory. The peer group data are shown with a red 
line, the applied QC limits (± 0.05 mmol/L) in black lines. 
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Inorganic phosphor (see Figure 10) 
• 916197: laboratory with a good stability and comparability to the peer group 
• 916205: analogous to number 916197, a laboratory with a good stability and 
comparability to the peer group. 
• 346892: laboratory with a good stability but with a long term borderline positive bias 
compared to the peer group. 
• 172131: compared to the other laboratories, a high variation occurs. However, almost 
all measurement values remain within the quality specifications. 
  
  
Figure 10. Inorganic phosphor IQC data from Bio-Rad for four laboratories. Colored lines 
(not red) represent the data of the individual laboratory. The peer group data are shown with 
a red line, the applied QC limits (± 0.04 mmol/L) in black lines. 
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Sodium (see Figure 11) 
• 382382: the laboratory started with a good stability but a shift in mid-2011 caused a 
significant positive bias. 
• 916197: this laboratory shows the same trend as number 382382 and other 
laboratories (data shown in the annex; Supplemental Figure 8). This might indicate 
that a new lot was deployed by these IQC participants. Because the majority of 
laboratories didn’t show this trend, the peer median is not influenced by the potential 
new lot. 
• 908214: a rather high variation, but most measurements remain within the quality 
limits. 
• 195994: laboratory with a good stability but with a long term borderline negative bias 
compared to the peer group. 
  
 
 
Figure 11. Sodium IQC data from Bio-Rad for four laboratories. Colored lines (not red) 
represent the data of the individual laboratory. The peer group data are shown with a red 
line, the applied QC limits (± 1 mmol/L) in black lines. 
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5. Conclusion on the use of IQC data 
IQC data can provide key insight into a laboratory’s performance as the process contributes 
to a better understanding of analytical error. When performed correctly it allows for early 
recognition of measurement and technical problems and rapid introduction of counteracting 
measures (1). Depending on the frequency at which the QC material is evaluated (e.g. daily 
values grouped per 2, 5, 10, or 15 days or grouped per month), it allows for both short-term 
and mid- to long-term quality monitoring. However, when the QC material is rarely evaluated 
(e.g. when using the monthly mean) it loses its ability for early recognition of measurement 
problems. Therefore, the discussed examples of the Bio-Rad IQC can only be used to get a 
broad idea about the long-term performance of assays/instruments, whilst IQC data which is 
interpreted on a daily basis can be used to track effects of unstable assays, (re)calibrations, 
and the introduction of different lots and/or different reagent containers. 
Although data based on QC materials serve as the first line of defense against 
unreliable patient results, it should not be ignored that, in some cases, trends (shifts or drifts) 
in measurements of patient samples can be missed by QC materials. For example, 
commutability problems make them inappropriate to verify consistency of patient sample 
results when reagent lots are changed. Data from Miller et al indicate that there is no reliable 
relationship between the bias for QC results and the bias for patient results caused by two 
different reagent lots (4). In addition, these commutability effects make it inappropriate to 
compare IQC data of laboratories from different peer groups. However, when laboratories 
use the same instruments and assays, QC materials can still be used to compare the stability 
and comparability of laboratories with their peer group. 
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Annex to chapter 1 
Roche IQC results for several laboratories on albumin: 
   
   
  
 
Supplemental Figure 1. Albumin IQC data from Roche for several laboratories. Colored lines 
(not red) represent the moving median (n = 10) of the individual laboratory. The peer group 
moving median is shown with a red line, the applied limits (± 1 g/L) in black lines. 
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Roche IQC results for several laboratories on calcium: 
 
  
 
  
 
  
 
  
Supplemental Figure 2. Calcium IQC data from Roche for several laboratories. Colored lines 
(not red) represent the moving median (n = 10) of the individual laboratory. The peer group 
moving median is shown with a red line, the applied limits (± 0.05 mmol/L) in black lines. 
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Roche IQC results for several laboratories on inorganic phosphor: 
 
  
 
  
 
  
 
 
 
Supplemental Figure 3. Inorganic phoshor IQC data from Roche for several laboratories. 
Colored lines (not red) represent the moving median (n = 10) of the individual laboratory. The 
peer group moving median is shown with a red line, the applied limits (± 0.04 mmol/L) in black 
lines. 
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Roche IQC results for several laboratories on sodium: 
   
   
   
   
   
Supplemental Figure 4. Sodium IQC data from Roche for several laboratories. Colored lines 
(not red) represent the moving median (n = 10) of the individual laboratory. The peer group 
moving median is shown with a red line, the applied limits (± 1 mmol/L) in black lines. 
53 
 
Biorad IQC results for several laboratories on albumin: 
   
   
   
   
   
Supplemental Figure 5. Albumin IQC data from Biorad for several laboratories. Colored lines 
(not red) represent the data of the individual laboratory. The peer group data are shown with a 
red line, the applied QC limits (± 1 g/L) in black lines. 
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Biorad IQC results for several laboratories on calcium: 
   
  
 
  
 
 
 
 
 
 
 
Supplemental Figure 6. Calcium IQC data from Biorad for several laboratories. Colored lines 
(not red) represent the data of the individual laboratory. The peer group data are shown with a 
red line, the applied QC limits (± 0.05 mmol/L) in black lines. 
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Biorad IQC results for several laboratories on inorganic phosphor: 
   
 
  
  
 
 
 
 
 
  
Supplemental Figure 7. Inorganic phosphor IQC data from Biorad. Colored lines (not red) 
represent the data of the individual laboratory. The peer group data are shown with a red line, 
the applied QC limits (± 0.04 mmol/L) in black lines. 
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Biorad IQC results for several laboratories on sodium: 
   
 
  
  
 
   
  
 
Supplemental Figure 8. Sodium IQC data from Biorad for several laboratories. Colored lines 
(not red) represent the data of the individual laboratory. The peer group data are shown with a 
red line, the applied QC limits (± 1 mmol/L) in black lines. 
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2 Chapter II The Percentiler 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter is based upon: 
• Goossens K, Van Uytfanghe K, Twomey P, Thienpont L, and Participating 
laboratories. Monitoring laboratory data across manufacturers and laboratories – A 
prerequisite to make “Big Data” work. Clin Chim Acta 2015;445:12-18. 
• De Grande LAC, Goossens K, Van Uytfanghe K, Das B, MacKenzie F, Patru M, 
Thienpont LM, for the IFCC Committee for Standardization of Thyroid Function 
Tests (C-STFT). Monitoring the stability of the standardization status of FT4 and 
TSH assays by use of daily outpatient medians and flagging frequencies. Clin Chim 
Acta 2016; doi: 10.1016/j.cca.2016.04.032. [Epub ahead of print] 
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Highlights 
Most real-time laboratory quality monitoring is based on the analysis of QC materials. 
Although this is the most suitable tool for the first line of defense against measurement errors, 
it can miss some analytical variation in results from patient samples due to commutability 
issues of the samples. Therefore, as a surplus to the established IQC in detecting analytical 
errors, we will now discuss the developed Percentiler tool, which has the potential to 
visualize the analytical variation of performance on patient samples directly. 
 
Highlights of the research: 
 An automatic web application for monitoring patient medians (“The Percentiler”) was 
built. 
 The Percentiler does not require additional measurement, as is the case in traditional 
EQA, and makes use of perfectly “commutable” samples.  
 The Percentiler data provide global evidence about test stability. 
 Both individual laboratories and manufacturers can use the Percentiler to assess their 
problem analytes. 
 The Percentiler is capable of showing what stability can be achieved by current state-
of-the-art performance. 
 The Percentiler can guide on which quality specifications, derived from state-of-the-
art performance, to use. 
 The Percentiler is capable of providing reliable peer group overviews to assess the 
relative comparability of the different assays on the market. 
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1. Introduction 
As mentioned at the end of the previous chapter, most real-time laboratory quality monitoring 
is based on the analysis of materials which act as surrogate for a patient specimen (1). IQC, 
however, should not be used as a stand-alone tool to identify analytical errors. A second tool 
can be built on the direct use of results for patient sample analysis. This can be achieved by 
using procedures to detect absurd patient results and delta checks. While these use 
individual patient data, data can also be grouped as is done with the “average of normals” 
procedure (2,3). This concept was already introduced by Hoffman et al in 1965. Its use has 
been investigated in several settings, however, the basic concept was always the same: the 
average of patient results is calculated (e.g. daily or monthly), plotted in time, and compared 
with control limits (4-7). In the following chapters we will discuss two new applications which 
also make use of grouped patient data for the assessment of mid- to long-term quality 
monitoring: the Percentiler (chapter 2) makes use of daily patient medians and the Flagger 
(chapter 3) uses daily hypo- and hyper-flagging rates. These tools have the potential of 
directly showing the effect of analytical quality on results for patient sample analysis. 
 Before the Percentiler was created, a pilot study was conducted to verify whether it 
was possible to perform stability monitoring by plotting daily patient medians. When the 
patient medians for sodium from two laboratories were plotted, Stepman et al could easily 
follow the stability of the assays, and observe periods with a good stability versus periods 
where analytical shifts occurred (8,9). After this pilot study, the first foundation for the 
Percentiler project was laid in the thesis work of Dr. H. Stepman (10). The current study 
extended Stepman’s work to 22 analytes and as much participants as possible. 
The Percentiler is a freely available online web tool. The underlying database is fed 
with instrument-specific, daily patient medians. The latter are calculated and transferred by a 
laboratory from their middleware or Laboratory Information Software (LIS) to our database. 
This is done by e-mail. Subsequently, the data are automatically read by software into a 
MySQL database. In the pilot phase the project focuses on 20 clinical chemistry analytes, i.e., 
albumin (ALB); alkaline phosphatase (ALP); alanine aminotransferease (ALT); aspartate 
aminotransferase (AST); total-bilirubin (BIL); calcium (CA); total-cholesterol (CHOL); chloride 
(Cl); C-reactive protein (CRP); gamma-glutamyl transferase (GGT); glucose (GLU); 
potassium (K); creatinine (CRE); lactate dehydrogenase (LDH); magnesium (Mg); sodium 
(Na); inorganic phosphor (PHOS); total-protein (PROT); urea or bound urea nitrogen (BUN); 
and uric acid (UAC). In a later stage, free thyroxine (FT4) and thyroid-stimulating hormone 
(TSH) were added to the database, in the context of a project for 
standardization/harmonization of thyroid function tests. 
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2. Percentiler functionality 
Patient medians are collected in a MySQL database and data are graphically and statistically 
interpreted via an online quality tool called “The Percentiler”. This site, which was created by 
IT engineer Bruno Neckebroek, is accessible to both the UGent project team and the 
individual participants. The latter group is only capable of interpreting their own data via the 
Quality and Samples tab; only the project team has the possibility to access all data and to 
create accounts for new laboratories. 
Login 
The Percentiler is accessible online on: https://www.thepercentiler.be/. Usernames (not case 
sensitive) and passwords (case sensitive) are available for individual labs, for groups (e.g. 
organizations with multiple sites), and for the entire database (see Figure 1). After sending 
data for eight weeks, the participant receives its login information, which gives access to the 
user interface for the graphical interpretation of his/her data. Those who do not yet 
participate can make use of a demo-account (username: DEMOLAB; Password: demo1234). 
Note that for the demonstration laboratory data of only one year are used. User guides are 
available in Dutch, English and French so that interested laboratories and new participants 
can get acquainted with the tool. 
Figure 1. The Percentiler login screen. 
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The “Quality” tab 
 
Figure 2. Demonstration of “The Percentiler”, enabling a laboratory to track its moving 
medians per instrument over time (Quality tab). The chart shows for the selected lab i) the 
moving median of the selected devices over the selected period (full colored lines); ii) the 
long-term median (horizontal long-broken grey line; represents the median calculated from 
all daily patient medians provided by the laboratory to which the graph applies) and the 
limits for the respective analyte (short-broken grey lines; the area in-between is shaded); 
iii) the Peer Group moving median (black broken line). 
This window shows the stability information from a selected laboratory in a graphical and 
tabular output. The lab can be chosen in the “Lab” box. Only the project team has access to 
the data of all laboratories, while participants are restricted to view only their own data. In the 
“Device model” box one can choose either “your device” or “All device models”. in the 
“Device” box, one can choose between the different devices of the chosen lab. In the default 
condition all devices of the lab are shown. In addition, it is possible to include or exclude 
weekend data, and to choose the data range via “Start date”, “Stop date” or via the buttons 
3M (months), 6M, 1Y (year), and All. Finally, one needs to select n for the moving median 
(default: 5) and the analyte with the respective buttons. Once selections are done, the chart 
appears and the table is filled. The chart (example in Figure 2) shows for the selected lab i) 
the moving median of the selected devices over the selected period (full colored lines); ii) the 
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long-term median (long-broken grey line; represents the median calculated from all daily 
medians from results from patients provided by the laboratory to which the graph applies) 
and the limits for the respective analyte (short-broken grey lines; the area in-between is 
shaded and called the stability zone); and iii) the peer group moving median (black broken 
line). It is possible to print and download the chart by pressing the respective buttons. 
The table from the Quality tab (example in Figure 3) shows two parts: the upper part 
refers to the data of the complete period (static when the range is changed), the lower part 
refers to data of the selected range (dynamic when the range is changed). 
 The “Value” column lists: 
•  “Your” median = the long-term median from 
the selected laboratory/instrument. This 
corresponds to the horizontal long-broken 
grey line in the Percentiler graph. 
• “Peer/All” median = the long-term median 
from either the peer group data or all data. 
• Target = a fixed “reference” value which is 
taken from literature or trueness-based 
reference intervals (see pages 69-70). 
 
 The “Bias (%)” column indicates: 
• “Your” bias = bias of the selected 
laboratory/instrument compared to the peer 
group. 
• “Peer/All” bias = bias of the peer/all data 
compared to the target. 
• Percentiler limit expressed as a percentage 
of the target (e.g. 9.5% = 2 U:L of 21 U/L). 
 
 The “Robust CV (%)”, calculated as 100 * (median absolute difference x 
1.4826)/(median), lists the lab’s robust CV (“Your”), and the robust CV of its Peer/All. 
The robust CV relates to the regular CV as the median relates to the mean. When 
data is perfectly normally distributed the median will equal the mean, and the robust CV will 
equal the regular CV. When data isn’t normally distributed the robust CV is less sensitive 
towards outliers, because it uses the median absolute difference as robust measure of the 
variability of quantitative data. This median absolute difference is calculated by taking the 
Figure 3. Demonstration of 
“The Percentiler” (Quality tab) 
– Table with summary 
statistics (bias, robust CV) 
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median of the absolute differences of each measurement in the dataset with the median of 
that dataset.  
The “Samples” tab 
This window shows all entries in the database of the chosen laboratory (example see Figure 
4). Note, however, that data are mapped to the “Percentiler” analyte names and units (not 
necessarily identical to the names and units given by the participants). One can filter the data 
(for example, according to analyte, to select in the “Analyte” box, always followed by pressing 
the “Filter” button) and sort () (e.g. according to date, value, etc.). This tab also contains 
an Excel exporting feature, where one can download the data, either completely or filtered. 
The project team uses this tool to make monthly overviews of the data per analyte and per 
peer group. These overviews can be used to visualize potential changes in peer group 
medians (which is discussed on pages 81-82). 
Figure 4. Demonstration of “The Percentiler” (Samples tab). The table shows nine 
attributes for the selected lab: lab identification number; date; median value; analyte; 
device identification; vendor or manufacturer; laboratory name; and lab ID code. 
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The “Labs” tab and data transmission 
Via the “Labs” tab the project team can map new participants. Each laboratory is given a 
unique identifier and code, usually chosen by the participants themselves. Each data format 
provided by the laboratory (date, device representation, analyte coding, and unit coding) is 
mapped according to the Percentiler format. 
The data of each participant should be in a “table” consisting of a data-related number 
of rows with ten fields (note, fields 8 to 10 are only necessary for mapping in the Flagger, see 
chapter 3). The order of the fields can vary. 
1. Laboratory ID: chosen by the laboratory or already assigned by the laboratory 
2. Date 
3. Instrument ID: as already assigned by the laboratory 
4. Patient code: three letters (e.g. OUT) or as already assigned by the laboratory 
5. Analyte name: as already assigned by the laboratory 
6. Unit: as already assigned by the laboratory 
7. Value of the median (decimal separator = point or comma) 
8. Number of results used for calculating the median 
9. % flagged hypo 
10. % flagged hyper 
Data can be transmitted as: i) e-mail embedded table; ii) e-mail attached EXCEL-file; or iii) e-
mail attached text-file. Data are sent to a database-specific email address (percentile@stt-
consulting.com) and is automatically read into a MySQL database. Examples of data 
transition are shown in Figure 5. 
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e-mail embedded Table (without n and flagging frequencies!) 
From: *** 
Sent: Saturday, 28 september 2013 06:31 
To: percentile@stt-consulting.com 
Content: Empower Percentile Project 
 
Time produced : 27-09-2013 00:00 - 27-09-2013 23:59 
 
ABCDEF;27/09/2013;C16000-5;POL;NA;mmol/L;140.9 
ABCDEF;27/09/2013;C16000-6;POL;NA;mmol/L;139.4 
ABCDEF;27/09/2013;C16000-5;POL;CL;mmol/L;104.6 
ABCDEF;27/09/2013;C16000-6;POL;CL;mmol/L;103.8 
ABCDEF;27/09/2013;C16000-5;POL;CA;mmol/L;2.44 
ABCDEF;27/09/2013;C16000-6;POL;CA;mmol/L;2.42 
ABCDEF;27/09/2013;C16000-5;POL;P;mmol/L;1.09 
ABCDEF;27/09/2013;C16000-6;POL;P;mmol/L;1.03 
ABCDEF;27/09/2013;C16000-5;POL;MG;mmol/L;0.85 
ABCDEF;27/09/2013;C16000-6;POL;MG;mmol/L;0.84 
ABCDEF;27/09/2013;C16000-1;POL;UREUM;mg/dl;30.5 
ABCDEF;27/09/2013;C16000-2;POL;UREUM;mg/dl;33.3 
Text attachment to e-mail 
From: *** 
Sent: Saturday, 28 september 2013 06:31 
To: percentile@stt-consulting.com 
Content: Empower Percentile Project 
 
Time produced : 27-09-2013 00:00 - 27-09-2013 23:59 
 
Filename: Empower Percentile.txt 
ABCDEF;27/09/2013;80_AU5822;POL;ALB;g/dl;3.0;69;5;2 
ABCDEF;27/09/2013;80_AU5822;POL;CA;mmol/l;2.125;90;10;12 
EXCEL attachment to e-mail (without n and flagging frequencies!) 
From: *** 
Sent: Wednesday, 13 november 2013 06:18 
To: percentile@stt-consulting.com 
Content: Empower Percentile Project 
 
Time produced : 12-11-2013 00:00 - 12-11-2013 23:59 
 
Filename: Empower Percentile.xlsx (or xls) 
ABCDEF 12/11/2013 VITROS5.1FS E Alb g/L 42.2 
ABCDEF 12/11/2013 VITROS5.1FS E APase U/L  91.5 
ABCDEF 12/11/2013 VITROS5.1FS E Ca mmol/L  2.355 
 
Figure 5. Examples of data transition to the MySQL database of the Percentiler. 
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The “Devices” tab 
In the “Devices” tab the project team can define new device vendors (or manufacturers), 
device models (or peer groups), and device types. In the device model category, it is 
possible to define a new peer group and set a starting date for showing the peer target on 
the chart. When a new device is mapped for a participant, it is catalogued with the correct 
vendor, model, and type, thereby allowing comparison of its data to the correct peer group. 
The “Analytes” and “Units” tab 
In the “Analytes” tab the project team can define new analytes. Each analyte is given an ID, a 
unit, a fixed target value and an allowable range for stability. Units are chosen according to 
the international system (SI) of units. When a laboratory reports non-SI units these are 
converted to the SI target by providing a factor. In the “Units” tab every unit which is used for 
reporting is defined. 
The “Mails” tab 
When a laboratory sends its data, this is registered in the “Mails” tab. The table in this sheet 
shows: the e-mail sender, date and time of receipt, e-mail subject, the number of median 
values reported, and when relevant an error message. For example, when a laboratory 
reports data for a new device which is not yet mapped in the Percentiler, an error message 
mentions the reporting of an unknown device. 
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3. Data stratification for outpatients 
Preferably, laboratories should only send daily medians on their outpatients, i.e., patients 
who are not hospitalized overnight but who visit a hospital, clinic, or associated facility for 
diagnosis or treatment. Clinical laboratories, particularly hospital laboratories, however, 
receive samples from many different sites: 
• The hospital itself (inpatients, i.e. patients who stay for one or more nights in a 
hospital for treatment, often specified by ward) 
• Special treatment units (diabetic centers; dialysis centers; wellness centers; nursing 
homes) 
• General practitioners/specialists who send samples from chronically diseased 
patients 
• Samples from “New” patients sent by General Practitioners 
• Samples from patients who have a general health check (also sent by General 
Practitioners) 
The middleware/LIS should be able to code these different “sender-sites” by type (the 
actually coded types will depend on the situation in the laboratory). “Outpatients” may then 
be defined by the laboratory in principally two different ways: 
• “Total minus” (total minus inpatients, minus dialysis, for example) 
• “Add-on”: samples from general practitioners + chronically diseased + wellness + 
others. 
The driver should support the “Total-minus” solution; this allows the laboratory a step-wise 
stratification of their patient population. In addition, the middleware/LIS should be able to 
code the results by measuring instrument; for example, when there are two Cobas c701 
instruments on a “Cobas 8000 analyzer” those should be given two different identifiers (for 
example: Cobas c701 A, Cobas c701 B). 
Comparison of outpatient/all patient monitoring 
Table 1 shows the differences between all patient and outpatient medians in typical hospital 
laboratories and the CV-ratio (not the robust CV) of those two groups. The patient medians 
and CV-values from both outpatients and all patients were calculated from the same dataset 
comprising two months of measurements from one instrument from a single medium sized 
laboratory. Note, although data were extracted for a single hospital laboratory, they were 
confirmed with data from other laboratories. There is a considerable difference in the median 
of outpatients and all patients for most of the analytes. Note, however, only outpatients will 
give medians which can be compared with “target” medians from reference interval 
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information, because the latter information is based on the distribution of a “healthy” 
population. 
The CV-ratios All-/Out-patients are typically <1, meaning that monitoring all patients 
would result in better stability. We decided, however, to continue with outpatient monitoring 
because only outpatients may give comparable values between different laboratories, 
allowing the assessment of laboratory/peer group bias. The somewhat higher variability can 
be compensated by a slightly higher “n” for the moving medians. In cases where an 
exceptionally high population variation was observed for a laboratory, we proposed them to 
define two Percentiler accounts. Data from outpatients could still be used for comparison with 
target medians, whilst the second account with all data was more suited for stability 
monitoring. 
Table 1. Comparison between outpatient and all patient data. 
  
%-Diff (Out/All)* CV Ratio (All/Out) 
Albumin 14.2 1.76 
ALP -7.0 0.69 
ALT -4.6 0.79 
AST -4.5 0.83 
Total Bilirubin -7.3 0.68 
Calcium 3.0 1.18 
Total cholesterol 1.6 0.90 
Chloride 0.2 0.76 
Creatinine 1.9 0.74 
CRP -93.2 1.27 
GGT -23.6 0.89 
Glucose -5.2 0.87 
Potassium 2.8 0.58 
LDH -5.0 0.83 
Magnesium 1.6 0.61 
Sodium 0.4 0.89 
Inorganic phosphorus 0.7 0.65 
Total protein 7.0 1.13 
Urea 3.4 0.65 
Uric acid 4.4 0.78 
*%-Diff = Outpatient median - All patient median
(Outpatient median + All patient median)
× 100 
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4. Limits and targets 
Stability limits 
The Percentiler bias limits (or specifications), indicated with the horizontal, grey broken lines 
in the graphs, are guided by the systematic error goals based on biological variation 
(“desirable” values from the Westgard website; 11). However, we took the current capability 
of diagnostic assays into account (i.e. state-of-the-art performance) and expanded these 
goals for analytes with narrow biological variation, such as sodium, chloride, calcium, etc. In 
contrast, we restricted the upper limit to ~10% for analytes with very high biological variation 
(e.g. CRP). The values for each limit are mentioned in Table 2 of Article 1. They are 
assigned semi-arbitrarily for each analyte (by spending a lot of time interpreting the 
Percentiler data) so most of the participating laboratories belonging to the best performing 
peer group are able of achieving the set limits. The actually chosen numbers were “tailored” 
to the SI-units. For albumin and total-protein, for example, we chose 1 g/L; the respective 
percentages were then calculated at the median concentration, resulting in “non-integer” 
numbers: 2.4% for albumin, 1.4% for total-protein. 
 Note, the Percentiler limits are dynamic, meaning they are adapted according to 
changes in state-of-the-art performance and changes in the biological variation data in the 
Westgard Biodatabase. Therefore, some Percentiler figures in this thesis might still show a 
grey stability zone flanked by limits representing former numbers. Whenever the limits are 
functional to the provided explanation, however, the values and figures for the limits are 
adapted to the most recent numbers. 
Target values 
Target values are structured according to hierarchy: long-term laboratory median, peer group 
moving median, and a “reference” target. The latter, however, is difficult to define. The Nordic 
Reference Interval Project (NORIP) database is the only source we know which claims 
“trueness-based” reference intervals (12). The reliability of that source is high for analytes 
such as sodium and calcium. The information for some enzymes has to be used critically (for 
example, there have been changes in the procedures recommended by the International 
Federation of Clinical Chemistry and Laboratory Medicine or IFCC). 
We also compiled reference interval information from manufacturers’ data sheets. For 
example, for albumin we compiled the following reference intervals: Abbott Architect: [35-50 
g/L]; Beckman AU: [35-52 g/L]; Beckman DxC: [35-50 g/L]; Ortho Vitros: [35-50 g/L]; Roche 
Cobas: [35-52 g/L]; Roche Integra: [35-52 g/L]; Siemens Advia: [32-48 g/L]; and Siemens 
Vista: [35-52 g/L]. The mean of each interval was calculated and converted to a median 
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value using the mean-median relationship from the NORIP database. For albumin those 
median values were: 42.3; 43.3; 42.3; 42.3; 43.3; 43.3; 39.8; and 43.3 g/L respectively. The 
median value of those assay medians was calculated (i.e., 42.8 g/L for albumin) and cross 
compared with the NORIP data. This comparison may help to define some preliminary 
“reference” targets for several analytes (see Table 2). Current analytes with “reference” 
targets could be albumin, ALT, AST, calcium, glucose, magnesium, sodium, phosphate, urea, 
uric acid. 
Table 2. Compiled reference interval information from 
manufacturers’ data sheets. The median value from the 
reference intervals is compared with the NORIP data. 
   
Median Diff 
  
Unit NORIP Assays (%) 
Albumin g/L 41.5 42.8 3.1 
ALP U/L 63.0 73.2 16.2 
ALT U/L 21.0 21.5 2.3 
AST U/L 23.0 22.6 -1.9 
Total Bilirubin µmol/L 10.0 8.6 -13.8 
Calcium mmol/L 2.34 2.33 -0.3 
Total cholesterol mmol/L 5.20 - - 
Chloride mmol/L - 102.5 - 
CRP mg/L - - - 
GGT U/L 22.0 17.5 -20.6 
Glucose mmol/L 4.87 4.80 -1.5 
Potassium mmol/L 4.05 4.25 4.9 
Creatinine µmol/L 70.7 77.0 8.9 
LDH U/L 152 176 15.6 
Magnesium mmol/L 0.83 0.86 3.6 
Sodium mmol/L 141.1 140.6 -0.4 
Inorganic phosphorus mmol/L 1.13 1.12 -0.9 
Total protein g/L 69.8 73.2 4.9 
Urea mmol/L 4.89 4.96 1.4 
Uric acid µmol/L 282 272 -3.5 
  
71 
 
5. Comparison with IQC 
Table 3. Comparison of typical CV-values for IQC-monitoring and percentile 
monitoring. 
  
IQC - CV (%) Percentile - CV (%)  CV-ratio 
Albumin 0.9 2.0 2.3 
ALP 1.1 5.4 4.8 
ALT 2.8 5.8 2.1 
AST 1.9 4.7 2.4 
Total Bilirubin 2.2 12.1 5.6 
Calcium 1.0 1.2 1.2 
Total cholesterol 1.5 5.4 3.6 
Chloride 0.4 0.6 1.2 
CRP 2.6 23.5 8.9 
GGT 1.8 11.1 6.2 
Glucose 0.6 2.8 4.4 
Potassium 0.4 1.4 3.7 
Creatinine 1.6 4.7 3.0 
LDH 1.3 4.9 3.8 
Magnesium 0.9 2.6 3.1 
Sodium 0.3 0.4 1.4 
Inorganic phosphorus 1.0 3.7 3.8 
Total protein 0.9 1.9 2.1 
Urea 1.2 4.8 4.0 
Uric acid 0.5 5.3 10.5 
Table 3 compares typical CV-values for IQC-monitoring and percentile monitoring (daily 
medians) for UZ Gent. These CV -values (not the robust CV-values) were calculated from a 
single dataset comprising 40 days of measurements from one instrument using a single 
reagent lot. The CV’s for patient data are, generally, greater than for IQC data (ratios >1). 
Exceptions are the “high-volume” analytes with narrow biological variation (calcium, chloride 
and sodium). Therefore, daily QC decisions will have to rely on IQC data in most laboratories. 
However, applying moving medians with “tailored” n, will reduce the variability by √n. This 
makes percentile monitoring applicable for mid-to long-term monitoring of analytical 
variability. The actual number of daily medians required for reliable monitoring will depend on 
the number of outpatient results generated by a laboratory, in combination with the 
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population variation of a certain analyte (again, analytes with low biological variation allow 
lower “n” to be used).  
By way of illustration, we compared daily patient medians with IQC results from that 
same dataset. Figure 6 shows the moving averages grouped per four days (not the moving 
medians in this case!) for daily patient medians in blue and daily IQC results in black for four 
analytes. Note, IQC values were normalized towards the patient medians. Analytes with CV’s 
for patient data which are similar to IQC, tend to follow the same pattern for both types of 
data (e.g. calcium and chloride). Analytes with higher CV’s based on patient data can only be 
used for mid- to long-term monitoring of the patient medians (e.g. glucose and uric acid). An 
overview of all analytes can be found in the annex (pages 104-106). 
  
  
Figure 6. Comparison of moving averages (n = 4 days) for daily IQC values (black) and 
daily patient medians (blue) for four analytes (calcium, chloride, glucose and uric acid). 
Moving averages were calculated from a single dataset comprising 40 days of 
measurements from one instrument using a single reagent lot. 
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6. Percentiler applications 
Mid- to long-term stability assessment 
A) Big private laboratories versus small hospital laboratories 
All sorts of clinical laboratories can participate to the Percentiler. The size of these 
laboratories will, however, influence how they need to interpret the graphical output from the 
Percentiler and what type of information they can extract from it. Laboratories of all sizes 
participate ranging from small (~200 beds) and big hospital laboratories (~2000 beds) to 
high-throughput private laboratories. For smaller hospital laboratories, with greater intrinsic 
median variation, a higher number of days (n = 8 or 16) has to be chosen for the moving 
median, especially for analytes with big population variation such as CRP, GGT, albumin, 
and uric acid. Consequently, the effect of that population variation is partially suppressed, but 
the consequence is that longer observation times are needed to uncover analytical 
instabilities and that some shorter-term information is lost (see Figure 7). High-throughput 
laboratories will be able to work with a moving median grouped per 5 days and they might 
even be capable of observing small analytical effects which are smaller than the Percentiler 
limits. 
A
 
B
 
Figure 7. Higher population variation in hospital/low-throughput laboratories can be partly 
compensated for by increased “n” for calculation of the moving median. (A) n = 5 days. (B) n 
= 16 days. 
Laboratories with high population variation, however, might also run in danger of 
overinterpreting the Percentiler graphs. Interpreting the stability for total-cholesterol, in Figure 
7, when the moving median is grouped per 16 days (right graph), might suggest the 
occurrence of high instability. These observations are not or barely confirmed when the 
moving median is grouped per 5 days (left graph). Interpretation of the Percentiler data when 
the population variation is high should always be handled with caution. Therefore, 
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laboratories with high population variation are advised to verify their stability on a moving 
median of n = 5 (or n = 8), when they are interpreting their long-term stability at n = 16. 
B) Stability issues in the laboratory or in the entire peer group 
The Percentiler provides a real-time monitoring tool for test stability across laboratories and 
manufacturers. The individual laboratory can use it as a direct, real-time quality indicator for 
its analyses of patient samples, not confounded by commutability issues. Together with data 
from IQC, the project helps the laboratory to build evidence about mid- to long-term stability 
of assays/performance. A number of examples where laboratories can observe significant 
analytical variation are shown in Figure 8. 
A
 
B
 
C
 
D
 
Figure 8. Selected time course examples from The Percentiler (stability limits in gray). (A) 
Long-term drift for a magnesium assay caused by several upwards lot shifts (B) Difference 
between instruments for an ALT assay: one system lower for long period. (C) Sawtooth 
pattern for a total-protein assay: instrument instability causes the instrument to drift which is, 
after a while, corrected by a recalibration (shift). (D) Several long-term drifts and shifts 
leading to non-comparability between four different chloride assays. 
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Of course the single laboratory can’t distinguish whether stability issues are related to 
its own performance or that of the manufacturer’s instrument. To know whether a problem is 
restricted to a specific laboratory, occurring in an entire peer group, or in the entire 
Percentiler database, one needs access to the entire database. That’s why the project team 
informs participants (both laboratories and manufacturers) about problems occurring in 
several labs belonging to the same peer group, by means of peer group specific reports. In 
addition, manufacturers are, thereby, provided with real-time data about field performance of 
their instruments and application issues in particular laboratories. Figure 9 shows a returning 
problem for the total-bilirubin assay in a single peer group. These types of observations point 
to the need for an improvement of the assay for an entire peer group. 
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B
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Figure 9. Selected time course examples from The Percentiler (stability limits in gray). 
Stability issues for the total-bilirubin assay in several laboratories belonging to the same 
peer group. 
Assessing stability with the Percentiler mostly involves investigation of the graphs to 
detect significant analytical shifts and drifts. Visual inspection of all graphs, however, is a 
laborious work, and therefore it would be interesting to interpret stability in a more automated 
manner. One possibility would be to use the (robust) CV, mentioned in the descriptive table 
of the Percentiler application. Similar to using the CV as a measure for (in)stability with IQC, 
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the robust CV from the Percentiler might be a good indicator to compare the stability 
between different periods for a single laboratory/instrument. The potential of using the robust 
CV for that matter, however, hasn’t been thoroughly investigated. One might assume that 
this approach can work well for laboratories that have low population variation and a stable 
population (stratification) throughout the year. On the other hand, there is no guarantee that 
an increase in the robust CV might always be regarded as a deterioration of the stability for 
an instrument (especially for small sized labs). One would always need to exclude whether a 
population effect might cause the increase in the robust CV. In other words, investigating 
how the Percentiler data can be used to assess stability in an automated manner is still open 
for improvement. 
C) Case study – instability of ALT assays jeopardizes patient management 
The value of the Percentiler was considered in an ALT case study. Literature indicates the 
relevance of mild elevations of transaminases (ALT and AST) in nonalcoholic fatty liver 
disease (metabolic syndrome), which becomes more and more prevalent as obesity rates 
increase (13). Although the actual ALT and AST values may differ from laboratory to 
laboratory, serum levels are usually considered normal if they are less than 40 U/L for AST 
and less than 50 U/L for ALT. However, some experts have suggested lowering the upper 
limit of normal because of the increasing prevalence of obesity and associated nonalcoholic 
fatty liver disease, which may not be detected using the traditional, higher normal values (14). 
A case study (female developing metabolic syndrome) was considered with the following 
ALT values (U/L): 17, at the start of yearly check-up; 44, diagnosed as development of 
metabolic syndrome; 28, after six months of treatment; 18, after long-term treatment. This 
case study showed that, for correct monitoring of disease development and treatment, stable 
and comparable assays are needed. However, in the Percentiler application, significant lot-
to-lot changes are sometimes observed for these assays (for example: ALT 35 to 22 U/L, in 
several steps; Figure 10A), which shows that these can jeopardize patient management. 
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Figure 10. Selected time course examples from the Percentiler application indicating the 
instability of some ALT and AST assays. 
D) Preanalytics 
A typical observation when blood samples are stored or transported for a longer time, is the 
occurrence of a temperature-dependent pattern for certain analytes, e.g., potassium and 
LDH. At lower temperatures the erythrocyte/plasma potassium gradient can no longer be 
kept stable if the blood is not centrifuged on time (the responsible enzymes need a certain 
temperature for activity). As a result, the values of the patient potassium medians are 
elevated during the winter (15). For LDH the reverse pattern is observed, with the highest 
values in the summer. The latter can be explained by increased hemolysis of red blood cells 
at higher temperatures (16). These patterns are most often observed in private laboratories, 
when the clinical laboratory is at a different location than where the blood is drawn and not 
centrifuged (see examples in Figure 11). 
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B 
 
Figure 11. Selected time course examples from the Percentiler application indicating 
preanalytical variation for (A) potassium and (B) LDH. For both analytes a sinusoidal pattern 
occurs which repeats every year. 
E) Seasonal variation 
In some cases seasonal variation of the patient medians can be observed in the Percentiler 
for certain analytes. For example, several laboratories showed a seasonal variation in the 
moving medians for TSH (Figure 12), which is also reported in literature (17,18). However, in 
order to fully exploit the Percentiler to visualize seasonal variation, preferably data from big-
sized laboratories with proven stable analytical performance and low population variation 
should be used. A more extensive discussion on the seasonal variation in the Percentiler can 
be found in an article from De Grande et al (19). 
A 
 
B 
 
Figure 12. Selected time course examples from the Percentiler application showing 
seasonal variation in the moving medians for TSH. 
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Bias assessment 
A) Bias assessment between different instruments from a single laboratory 
The Percentiler not only provides a real-time monitoring tool for test stability, it can also be 
used for bias assessment. First of all, laboratories can verify whether their in-house 
instruments are comparable. If the long-term patient medians for their instruments differ, this 
can have two possible reasons. Either they measure a different population on their different 
instruments (= population effect) or the instruments are calibrated differently (= real analytical 
bias). 
A 
 
B  
 
Figure 13. Examples of bias observations between different instruments in a single 
laboratory. 
B) Bias assessment versus the peer group 
By comparing the long-term median values of their own instruments (colored lines) with the 
peer median (black dotted line), laboratories can also use the Percentiler to check for 
possible bias issues between their own data and the peer group. These bias observations 
can have four possible reasons. Either a real analytical bias is present or the difference is 
caused by a mathematical factor, a population effect or by the use of a different method 
principle. In the latter case a laboratory might observe a bias because they use a less 
common method, e.g. creatinine Jaffé versus enzymatic. Not only the measurement method, 
but also the selected measurement matrix can cause a bias observation in the Percentiler 
(for example, plasma versus serum). Participants who send data on the measurement of 
plasma will usually observe a bias for potassium, inorganic phosphor, LDH and total-protein, 
because most participants send data on serum samples. In addition, some regions, e.g. The 
Netherlands and Scandinavian countries, have the habit of applying a factor to their 
measurement data, which will also result in a bias compared to the peer group. A number of 
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examples, with bias-related issues not allocated to a real analytical bias, can be found in 
Figure 14. 
A
 
B 
 
Figure 14. Examples of bias observations due to population effects and the use of different 
method principals. (A) Bias for creatinine to the Roche Cobas peer group due to a 
combination of a population effect and the use of a different method. Note, for creatinine two 
method principals exist, i.e. Jaffé or enzymatic, which give significantly different results. (B) 
Bias for albumine to the Roche Cobas peer group due to the use of a different method. This 
specific laboratory uses a immunoturbidimetric method to measure albumin, whilst most 
Percentiler participants use the bromcresol green (BCG) method. 
To differentiate between a real analytical bias and a population effect, one cannot 
solely rely on Percentiler data. Laboratories can first cross-check the Percentiler observation 
with IQC data. In a second stage they can cross-check whether the same population is 
measured as for most Percentiler instruments (random sample assignment), or whether the 
laboratory preferentially measures, for example, inpatients. If one or several instruments 
would predominantly measure inpatients, one would expect, amongst others, a low albumin 
median, a low median for total-protein, and lower sodium values. In addition, the final proof 
can be made by measuring 20 left-over samples on two instruments, i.e., one instrument with 
and another without a bias versus the peer group. If the observed Percentiler bias is 
confirmed in this sample exchange experiment, one has proven the existence of an analytical 
bias. Two examples can be found in Figure 15. Note, for analytes with a narrow biological 
variation and a clear reference or peer target, such as electrolytes, it is easier to detect 
potential bias issues. 
Mind, laboratories which use instruments belonging to a small peer group (< 20 
instruments) can only compare their data with the median from all data, and not with the peer 
group. In that case an observed difference can also be caused by a lack of comparability 
between the different peer groups. 
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Figure 15. Examples of analytical bias observations. (A) Long-term bias compared to the 
peer for a sodium assay due to lot changes. The instrument measured at 143 mmol/L for a 
long time – which is a borderline significant bias compared to the long-term Vitros peer 
median of 141 mmol/L – and it even went up to 145 mmol/L (significant bias). (B) Long-term 
bias for a chloride assay compared to the Cobas peer. Due to electrode change this 
laboratory measured chloride medians around 105 mmol/L, whilst the Cobas peer is located 
at ~101 mmol/L. 
C) Comparability assessment between peer groups 
A final comparability assessment can only be performed by the project team (not by the 
individual laboratory). By extracting the median values grouped for one month from all 
Percentiler instruments we are able to assess the relative comparability status of the peer 
groups. This is done by presenting the monthly instrument medians in box- and whisker plots 
(peer specific). The box represents instruments within the 25th to 75th percentile; the whiskers 
extend to the minimum and maximum results. Therefore, these plots give a clear indication 
on the distribution of the instrument data per peer group, and it allows to compare those 
same peer groups. In addition, by creating box- and whisker plots for two time periods we are 
able to assess the robustness of the data. Figure 16 shows the data for GGT and chloride 
from March 2014 and July 2015. In general the observed patterns of the plots changed little 
over the course of the year for all analytes, at least for the peer groups which are sufficiently 
substantiated. In contrast, significant changes occurred for the small peer groups (n < 10), 
whilst other changes were restricted within the set bias specifications. 
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Figure 16. Box- and Whisker plots with the indication of peer group medians for (A) GGT 
and (B) chloride. The box represents instruments within the 25th to 75th percentile; the 
whiskers extend to the minimum and maximum results. The blue or grey bar in the box 
represents the monthly peer group median. Data from March 2014 are indicated in grey and 
set in the background; data from July 2015 are indicated in blue. To give an idea about the 
size of the dispersion, bias limits from the Percentiler are indicated with a grey shaded zone. 
These are constructed around the median value of the July 2015 data. 
Normally, the comparability status of the different assays available on the market can 
only be reliably assessed with an EQA study making use of commutable samples. However, 
we tested whether comparability information from the Percentiler is reliable. To this end we 
compared the Percentiler peer group medians with the average of 20 samples from 
apparently healthy volunteers measured in our Master Comparison survey (see Chapter 4). 
Data in Figure 17 are presented as plots with indication of the Percentiler medians in blue, 
and Master Comparison 2014 sample averages in red (for each peer group). Note, the 
sample averages for the Master Comparison study were normalized to the patient medians. 
This was necessary because stratification for outpatients may not completely exclude the 
influence of diseased persons (mostly those having chronic diseases such as diabetes or 
kidney disease can significantly influence certain analytes, such as creatinine, glucose, uric 
acid, etc.). 
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As obvious from Figure 17, the relative comparability between the peer groups was 
very similar in the Percentiler and Master Comparison data, for most analytes and peer 
groups. Observed differences could be explained by the occurrence of small peer groups in 
either the Percentiler or the Master Comparison survey. This supports the potential of the 
Percentiler to study relative assay biases at median concentrations. However, the need for 
adaptation of the Master Comparison data to the Percentiler data may indicate that 
assessment of “absolute” bias is more challenging, in particular, for the enzymes. The latter 
(assessment of “absolute” bias) may require a more stringent outpatient stratification or a 
selection of laboratories which mainly serve the general population. 
A
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Figure 17. Plots with indication of the Percentiler medians in blue (from May 2014), and 
Master Comparison 2014 sample averages in red (for each manufacturer/peer group); for 
(A) GGT and (B) chloride. The sample averages for the Master Comparison study were 
normalized to the patient medians. 
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Link with the Committee for Standardization of Thyroid Function Tests 
In a later stage, FT4 and TSH were added to the Percentiler and Flagger database. This was 
done in the framework of the Committee for Standardization of Thyroid Function Tests (C-
STFT), which aimed at using the Percentiler for monitoring the stability of the assays which 
participate in their standardization efforts. Indeed, clinicians diagnose and follow thyroid 
dysfunction based on TSH and FT4 testing. However, the current lack of comparability 
between assays limits the optimal use of these laboratory data. The IFCC gave a mandate to 
the C-STFT to resolve this limitation by standardization of FT4 and harmonization of TSH. 
However, before implementation of the technical recalibration, they were furthered by the 
Food and Drugs Administration (FDA) to develop a tool to assess the sustainability of the 
new calibration basis. C-STFT began to use the Percentiler and the Flagger, with the 
intention to assess their utility for this purpose. Current data suggest the suitability of both 
applications to document the sustainability of the calibration basis in the post-standardization 
phase. For more information we refer to a publication from the doctoral work from Linde De 
Grande (20). 
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7. Conclusion on the Percentiler 
The Percentiler has added value compared to the limitations of traditional QC. First, there are 
little additional costs involved (no measurement of additional samples). Second, the 
materials used for the Percentiler are “as commutable as they possibly can be”, i.e. patient 
samples. And, third, the Percentiler is an online, continuous quality monitoring tool, in 
contrast to the low frequency surveys typical for EQA. It provides the mid- to long-term 
analytical stability assessment against realistic specifications guided by biological variation; if 
this was not feasible, state-of-the-art performance limits were adopted. Observations from 
the Percentiler graphs show that test variability due to confirmed calibration and lot changes 
is still a significant problem for both laboratories and manufacturers. 
Naturally, the Percentiler also has limitations. First, patient data have of course a 
much higher variation then single-concentration IQC samples. Therefore, the Percentiler’s 
utility is the better the higher test volumes are achieved and the more carefully stratification 
for outpatient results is done. The latter might be difficult to achieve because different 
hospital have different lab policies concerning (out)patient stratification and the LIS market is 
highly fragmented. Second, patient percentile monitoring is typically restricted to the median 
of the results because monitoring at “outer percentiles” (e.g., at 2.5%- or 97.5%-percentile) 
results in much higher variation. 
Concluding, patient percentile monitoring for mid-to-long-term quality management is 
particularly attractive for laboratories as well as manufacturers, because it has the potential 
to build a continuous, global evidence base on IVD test stability (and relative comparability). 
It gives evidence about stability of performance and the reasons for assay variation 
(manufacturer, lot-to-lot, calibration, instrument). In addition, it helps with the establishment 
of realistic quality specifications derived from state-of-the-art performance, and it provides a 
basis for comparison across manufacturers. 
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Introduction 
Laboratory data has the potential for 
substantially aiding the development, 
implementation, and management of 
public healthcare policies. It can create 
public awareness of the importance of 
maintaining a healthy lifestyle as well as 
reacting early to signals of health 
problems. As such, it can indirectly 
contribute to reduce the burden of 
healthcare expenses. The drive to focus 
on improved exploitation of laboratory data 
typically comes from financial pressures, 
such as the steady increase in health-care 
expenses in the US during the last 20 
years. Such expenses now represent 17.6% 
of the gross domestic product and nearly 
$600 billion more than the expected 
benchmark for a nation of the size and 
wealth of the US (1). An additional impetus 
to transform the laboratory landscape 
comes from the information technology (IT) 
revolution, offering, among others, the 
opportunity to create reliable and 
accessible “Big Data” (2, 3). Nevertheless, 
the “big bang” for the active role of IT in 
healthcare policy came in the US from 
legislation “The Health Information 
Technology for Economic and Clinical 
Health (HITECH) Act” (4) and the push by 
the government to adopt electronic health 
records (EHRs) (5-8). The research firm 
Frost & Sullivan predicts that use of 
advanced health data analytics solutions 
in hospitals will increase to 50% adoption 
by 2016 (9). This may create enormous 
business opportunities, for example, the 
Washington Post reported the inclusion of 
"as much as $36.5 billion in spending to 
create a nationwide network of electronic 
health records" (10). However, big 
spending should be justified by big savings. 
Indeed, according to a report from 
McKinsey & Company, the largest 
managed care organization in the US 
(Kaiser Permanente), reported that their 
“Big Data” strategy has saved the 
organization $1 billion in reduced office 
visits and lab testing (1). 
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 If data is the new gold, then access 
to data is going to be key to insights (2), 
but key is also the expertise of the 
laboratory to ensure the reliability of the 
data as well as its safe and efficient use. 
While promises are sky-high, EHR is not 
without risks, especially in the start-up 
phase. In this regard “The November 2011 
Institute of Medicine report, Health IT and 
Patient Safety: Building Safer Systems for 
Better Care” noted that the lack of 
empirical data on the nature and 
prevalence of EHR system-related 
adverse patient events makes it 
challenging to determine the extent of the 
associated risks to patient safety (11). If 
one takes this note seriously, the question 
is how to minimize risks? Can a small non-
US based group play a role in this highly 
innovative, competitive, multi-billion dollar 
environment? We believe yes, because 
we are convinced that efforts to take care 
of the quality of the input data will improve 
the quality of the output. The utility of the 
EHR is often overlooked as a result of 
laboratory diagnostics sometimes giving 
significantly different results for the same 
patient sample, even for the simple, high-
volume clinical chemistry tests (12-14).  
 In an attempt to illustrate this 
limitation and more importantly to do 
something about it, we describe “The 
Percentiler” project, which is part of our 
overarching “Empower” project introduced 
elsewhere (15). In essence, it provides 
quasi real-time access to patient medians 
across laboratories and manufacturers. 
This data can serve as a “clearinghouse” 
for potential future EHR applications, such 
as the retrieval of laboratory data for 
epidemiological or toxicological research 
on national or global scale, long-term 
follow-up of chronic diseases, or linking 
laboratory data to mortality risk (16, 17). 
Materials and methods 
Participants and participation process 
Participating laboratories are globally 
distributed. They range from medium-sized 
to big hospital laboratories, but also 
include private laboratories (for the current 
list of participants, see www.stt-
consulting.com, Empower tab). When a 
laboratory declares its intention to join, we 
provide it with the information about the IT 
requirements for sending data, together 
with a request for a test e-mail. One of our 
project team controls the test-mail, maps 
the data and verifies error-free 
transmission into our database. If 
successful, we continue this verification for 
a while before giving the definitive 
Percentiler e-mail address. Subsequently, 
data transfer either occurs automatically 
and on a daily basis (depending on the 
Laboratory Information System (LIS)) or is 
done in manual batches. After sending 
data for 6 to 8 weeks, the participating 
laboratory receives its login information, 
which gives access to the graphical 
presentation of its data via a user interface. 
Data is assessed by peer group: typically 
10 or more laboratories using the same 
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test system. Participation is free of charge. 
Furthermore, all LIS solutions for 
automatic median calculation and data 
transfer are provided at no or minimal cost 
and without running costs. 
Data 
We collect instrument-specific daily 
medians calculated from outpatient results 
of 20 commonly measured analytes in 
serum or plasma: albumin, alanine 
aminotransferase (ALT), alkaline 
phosphatase (ALP), aspartate 
aminotransferase (AST), calcium, chloride, 
C-reactive protein (CRP), creatinine, γ-
glutamyl transferase (GGT), glucose, 
inorganic phosphorus (phosphate), lactate 
dehydrogenase (LDH), magnesium, 
potassium, sodium, total-bilirubin, total-
cholesterol, total-protein, urea, and uric 
acid (urate). 
Data coding and transfer to a database 
Data coding comprises 7 attributes each 
separated by “semicolon”: laboratory 
identification (Lab ID); date (e.g., 
02/01/2014); instrument identification (Instr 
ID); code for outpatients (e.g., OUT); test 
name (e.g., CA for calcium); test unit (e.g., 
mmol/L); median (e.g., 2.35). The 
laboratories can retrieve these attributes 
directly from the LIS and adopt the used 
mnemonics. The only requirement is for 
the laboratories to organize the data in a 
table according to the format below: 
Lab ID; 02/01/2014; Instr ID; OUT; 
CA;mmol/L; 2.35 
Lab ID; 02/01/2014; Instr ID; OUT; NA; 
mmol/L; 141 
Lab ID; 02/01/2014; Instr ID; OUT; CL; 
mmol/L; 102.5 
Data must be sent electronically to our 
project-specific e-mail address either as i) 
an e-mail embedded table, ii) an e-mail 
attached EXCEL-file; or iii) an e-mail 
attached text-file. Retrieval of data and 
electronic exporting is done either 
automatically (by features available in a 
specific LIS), or manually. Automatic 
solutions send the data daily, while 
manual solutions operate in a batch 
fashion with the data manually extracted 
weekly or monthly and manually sent by e-
mail. 
Database 
The software for data downloading from 
the e-mail, transfer into a MySQL 
database, and the development of “The 
Percentiler” application and user interface 
was programmed by Bruno Neckebroek 
(Zwijnaarde, Belgium). Data from the 
individual laboratories are “mapped” by the 
STT/UGent project team to common 
analyte names, units, and instrument 
names and other technical details. 
Data analysis/User interface 
The database is fully accessible to the 
STT/UGent project team, who investigate 
laboratory and peer group data for bias 
and trends. Critical observations are 
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communicated in the first instance to the 
laboratories concerned. They are also 
shared with instrument vendors, and 
regularly, with the whole group of 
participants. It is important to note that the 
identity of the laboratory is not disclosed to 
a third party under any circumstances. The 
user interface (accessed via a specific 
login at https://thepercentiler.be) only 
gives the laboratories access to their own 
data (login with username and password). 
Investigation of data is possible on-line. 
However, if detailed off-line analysis is 
preferred, the data can be downloaded 
into Excel. Other functionality in the user 
interface allows a downloadable chart of 
the moving median in time (laboratory and 
peer), and a table with summary statistics 
(bias, robust CV) for each analyte. The 
selection possibilities include i) n for 
calculation of the moving median (n = 5, 8, 
16); ii) time window; iii) inclusion/exclusion 
of weekends. When participants report 
medians for two or more instruments, an 
instrument-specific color code is used in 
the charts. The assessment of the stability 
of laboratory testing is done against 
desirable bias limits from biological 
variation, at least for the analytes for which 
state-of-the-art performance allows this. 
However, the maximum bias limit is set to 
~10%. The limits are visualized in the 
charts by a gray zone, and violations >1 
week are considered significant. For more 
detailed information, the reader is referred 
to the demo version of “The Percentiler” 
(https://thepercentiler.be, login: demolab, 
password: demo1234).  
Partners 
The Royal Belgian Society of Clinical 
Chemistry scientifically supports the 
project. The assistance from several LIS 
vendors in providing solutions for 
automatic data calculation, retrieval, and 
electronic sending greatly contributed to 
the practical realization of the project. 
Further support is received from the 
Belgian representatives of the main in vitro 
diagnostic manufacturers (see www.stt-
consulting.com, Empower tab, for LIS and 
manufacturer information). 
Results 
Participation and reporting 
Currently (December 2014), 124 
laboratories participate with ~250 
instruments, distributed over the following 
peer groups: Advia (n = 8); Architect (19); 
AU (13); Cobas (153); Integra (3); Modular 
(11); Synchron (11); Vista (6); Vitros (26). 
Participation is global (see Fig. 1), 
however, most of the current participants 
come from Belgium. 
As of December 2014, several 
reports have been produced that address i) 
the general features of the project, ii) peer 
group observations; iii) synergisms 
between “The Percentiler” and our 
dedicated EQA surveys, the so-called 
“Master Comparisons (MCs)”. These 
reports are accessible at www.stt-
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consulting.com (under the Empower-Tab). 
Exemplary observations are presented 
below. 
Test comparability 
Table 1 presents the peer group data for 
the 5 most prominent instrument types 
(Architect, AU, Cobas, Synchron, and 
Vitros). It also shows the %-differences 
between the 2 peer groups that agree the 
least (column A), gives the 2-times 
desirable bias limits from biological 
variation (2 times because of comparison 
with the peer group differences) (column 
B), and the ratio of column A/column B. 
Several analytes exhibit ratios ≥2, 
indicating a significant lack of 
comparability between manufacturers. 
This holds particularly true for enzymes 
due to the use of different method 
principles (transaminases with and without 
pyridoxal phosphate activation; LDH 
forward and reverse reaction). Significant 
differences are also observed for albumin, 
total-bilirubin, chloride, CRP, glucose, and 
magnesium. 
The observations correspond 
closely to those of the MCs surveys (19) 
(for example, chloride: Fig 2). Data is 
presented as plots with the patient 
medians in blue, and sample means (in 
the 2014 MCs survey) in red (for each 
device). Note that the sample means for 
this survey were normalized to the patient 
medians. Except for Vitros, the relative 
differences between the instruments are 
quite similar in the MC and the Percentiler 
application, with Cobas showing the 
lowest values. 
Test stability 
Test stability is assessed against desirable 
bias limits derived from biological variation 
or from state-of-the-art performance (Table 
2). The latter limits were applied for 
analytes with small biological variation 
where state-of-the-art performance cannot 
meet the challenging bias limits from 
biological variation (albumin, calcium, 
glucose, potassium, magnesium, and 
sodium). However, the maximum bias is 
set to ~10%. Limits were set in units rather 
than percentage, e.g., for CRP 0.2 mg/L 
which results in a limit of 11%. 
Typically, >90% of the laboratories 
showed a stable performance over 1 year 
within the chosen limits. Peer group 
influences could be investigated for only 5 
instruments (Architect, AU, Cobas, 
Synchron, and Vitros). Among them, Vitros 
scored lowest with only ~80% of the 
laboratories achieving stable performance 
over the year. Six examples can be found 
in Figure 3 to 5. 
Figure 3 shows the time course of 
the chloride median in a laboratory for ~2 
years. Stability and comparability of the 2 
instruments were excellent (long-term 
median ~103 mmol/L, stability ±1 mmol/L), 
with the exception of a small shift in July  
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Table 1. Peer group medians, %-differences of the 2 most deviating peer groups (column A), 
2-times the desirable bias from biological variation (column B), and ratio of column A/column 
B for the 5 major peer groups present in “The Percentiler” application; ratios A/B ≥2 indicated 
in bold. (Note, data on biological variation shows values as they were at December 2014.) 
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ALB g/L 41.0 42.6 40.0 40.5 44.0 3.7 9.6 2.6 
ALP U/L 69.5 83.0 70.4 75.8 74.0 1.4 18 12.8 
ALT U/L 18.7 20.0 20.0 27.4 18.0 2.0 45 22.8 
AST U/L 20.0 22.6 21.0 26.0 20.0 2.5 27 10.8 
BIL-T µmol/L 9.5 10.0 11.5 9.2 6.8 2.2 50 22.8 
CA mmol/L 2.37 2.38 2.36 2.39 2.37 0.8 1.3 1.6 
CHOL mmol/L 5.06 4.89 4.95 4.67 4.78 1.0 8.0 8.0 
CL mmol/L 105.1 104.1 104.7 102.5 100.5 4.4 4.4 1.0 
CREA µmol/L 71.6 74.9 73.5 75.1 76.0 0.7 5.9 8.0 
CRP mg/L 2.1 2.5 3.1 6.2 2.7 2.8 124 43.6 
GGT U/L 25.0 25.0 21.5 27.0 22.0 1.1 23 21.6 
GLUC mmol/L 5.35 5.62 5.83 5.50 5.27 2.3 10 4.4 
K mmol/L 4.35 4.30 4.15 4.30 4.38 1.5 5.4 3.6 
LDH U/L 191.5 183.0 178.5 489.5 172.5 15.2 131 8.6 
MG mmol/L 0.84 0.83 0.86 0.79 0.82 2.4 8.5 3.6 
NA mmol/L 140.0 139.0 139.0 140.5 140.6 1.8 1.1 0.6 
P mmol/L 1.09 1.07 1.17 1.21 1.13 1.9 12 6.4 
PROT g/L 71.0 70.1 69.3 72.2 69.5 1.7 4.1 2.4 
UREA mmol/L 5.32 5.59 5.05 5.66 5.00 1.1 12 11 
UA µmol/L 321 312 320 315 324 0.4 3.8 9.8 
Albumin (ALB), alanine aminotransferase (ALT), alkaline phosphatase (ALP), aspartate 
aminotransferase (AST), calcium (CA), chloride (CL), C-reactive protein (CRP), creatinine (CREA), γ-
glutamyl transferase (GGT), glucose (GLUC), inorganic phosphor (P), lactate dehydrogenase (LDH), 
magnesium (MG), potassium (K), sodium (NA), total-bilirubin (BIL-T), total-cholesterol (CHOL), total-
protein (PROT), urea, and uric acid (UA). *Calculation example for ALP: ∆ = 100*[83 (AU) –69.5 
(Architect)]/75.8(Average of all) = 18%. 
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Table 2. Bias limits set for “The Percentiler” project and compared to desirable bias from 
biological variation. In the application, the limits are set on a unit basis and are considered 
violated if the bias lasts >1 week; state-of-the-art limits are in bold. 
  Biology Percentiler Biology Percentiler  
  (%) (%) (unit) (unit) Unit 
ALB 1.43 2.4 0.62 1 g/L 
ALP 6.72 6.8 5.0 5 U/L 
ALT 11.48 9.5 2.2 2 U/L 
AST 6.54 6.5 1.4 1.5 U/L 
BIL-T 8.95 10.0 0.73 1 µmol/L 
CA 0.82 1.7 0.019 0.04 mmol/L 
CHOL 4.1 3.8 0.20 0.2 mmol/L 
CL 0.5 1.0 0.51 1 mmol/L 
CREA 3.96 3.9 3.0 3 µmol/L 
CRP 21.8 9.6 0.40 0.25 mg/L 
GGT 11.06 9.1 2.4 2 U/L 
GLUC 2.34 3.1 0.12 0.15 mmol/L 
K 1.81 2.4 0.08 0.1 mmol/L 
LDH 4.3 4.6 7.7 8 U/L 
MG 1.8 3.0 0.015 0.025 mmol/L 
NA 0.23 0.7 0.32 1 mmol/L 
P 3.38 4.4 0.038 0.05 mmol/L 
PROT 1.36 1.4 0.95 1 g/L 
UREA 5.57 6.0 0.30 0.3 mmol/L 
UA 4.87 4.8 15.6 15 µmol/L 
Abbreviations used for the different analytes are identical as in Table 1. Note, values were 
updated to the most recent numbers (October 2016). 
 
2013. Similar good stability was observed 
for sodium and calcium (see Figures 5A 
and 5B). 
Figure 4 shows the time course of 
the ALT median in a laboratory over more 
than 1 year. The data are characterized by 
drifts and calibration/lot shifts, with 
maximum values at ~37 U/L and minimum 
values at ~22 U/L. Other examples of test 
instabilities for chloride and creatinine can 
be found in Figures 5C and 5D. Problems 
for the chloride test have been observed 
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several times, mainly due to shorter 
electrode lifetimes than those claimed by 
manufacturers. 
Laboratory bias 
To date, assessment of laboratory bias is 
done with caution as only the Cobas peer 
group target is calculated from sufficient 
instruments. In addition, more experience 
needs to be gained about the potential 
influence of population effects. 
Nevertheless, some grossly deviating 
results have been reported by individual 
laboratories, findings that were confirmed 
by sample exchange experiments. 
Pre-analytical effects 
Pre-analytical effects are seen in certain 
private laboratories. Follow up determined 
that this is due to a considerable delay 
between sample collection and processing. 
For potassium, this led to high values in 
winter and normal values in summer. The 
opposite pattern was observed for LDH 
medians. 
 
Figure 1. Global geographic distribution of the participants in the “The Percentiler” project 
(December 2014) 
 
Discussion 
We showed that “The Percentiler” project 
provides a real-time monitoring tool for test 
comparability and stability across 
laboratories and manufacturers. Typical 
attributes make the approach different 
compared to conventional external quality 
assessment/proficiency testing [20]. It 
uses samples that are “as commutable as 
can be” and data that are already available 
in the laboratory at little extra costs. It 
provides the mid- to long-term analytical 
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Figure 2. Peer group comparability for chloride in “The Percentiler” and “Master 
Comparisons” 2014 survey (patient medians in blue, MCs sample means in red) 
 
 
 
Figure 3. Time course of the chloride moving median in a laboratory with low analytical 
variability and excellent instrument comparability over ~2 years. 
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Figure 4. Time course of the ALT moving median in a laboratory with high analytical 
variability due to calibration and lot effects. 
 
stability assessment against realistic limits 
guided by biological variation [18]; if this 
was not feasible, state-of-the-art 
performance limits were adopted. The 
application is useful for all type of 
laboratories, from small-sized (for example, 
250 beds) to high-throughput ones. The 
only difference is that the former have to 
choose a higher n (8 to 16) for calculation 
of the moving median, and hence, will see 
instability/changes later than the high-
throughput laboratories. Global interest is 
demonstrated from the geographic 
distribution of the participants, which is 
another advantage over many nationally 
operating external quality 
assessment/proficiency schemes.  
Monitoring of outpatient medians 
and instrument-based peer groupings 
demonstrates significant differences 
among manufacturers for many of the 20 
tests we currently monitor (for details, see 
Table 1, ratio A/B). The observations are 
concordant with the differences we have 
seen in our previous MCs surveys, in 
particular, for commonly measured 
enzymes, albumin, phosphate, total-
bilirubin, and chloride [12, 13, 19]. We 
admit that the observed differences may 
be influenced by instrument-based peer 
groupings without accounting for the 
method principle employed, e.g., for 
creatinine, on certain platforms the Jaffe 
assay is installed, while on others the 
enzymatic assay is utilized. From this point 
of view, it might be beneficial to consider 
this distinction. On the other hand, we 
think it also makes sense to point to the 
fact that different assays for measurement 
of common analytes still lead to non- 
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Figure 5. Selected time course examples from “The Percentiler” application (stability limits 
in gray; peer group indicated as broken line). (A) Sodium moving median in a laboratory with 
a 2-year lasting “1 mmol/L stability” and excellent instrument comparability. (B) Calcium 
moving median in a laboratory with >1 year excellent stability and instrument comparability. 
(C) Chloride moving median in a laboratory with robustness problems of the ion selective 
electrode. (D) Creatinine moving median in a laboratory with long-term drift and shifts, partly 
due to lot changes. 
 
comparable results and thus need better 
standardization. Nevertheless, we will 
consider peer grouping based on system 
and method principle, however, 
interpretation at that level will require 
many more participants, as well as 
modifications in the LIS data transfer logic. 
Other observations show that test 
variability due to confirmed calibration and 
lot changes is still a significant problem for 
several laboratories and manufacturers, 
which holds particularly true for certain 
enzymes (ALT, AST). The project further 
confirms that the ion selective electrode 
technique still has robustness issues for 
chloride measurement (occasionally also 
for sodium), which, typically, can be solved 
by replacement of the electrodes earlier 
than claimed by the manufacturers [21]. It 
is comforting that many laboratories are 
able to achieve a long-term stability (>1 
year) within the desirable bias limits 
inferred from biological variation data for 
most of the tests, as also shown in other 
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studies [22-24]. For analytes with narrow 
biological variation, they accomplish a 
stable performance of 1 mmol/L for sodium 
and chloride, 1 g/L for total-protein and 
albumin, and 0.05 mmol/L for calcium. In 
certain private laboratories, significant pre-
analytical problems due to delayed sample 
processing jeopardize the reliability of 
potassium and LDH testing. Laboratory 
bias is generally more difficult to uncover 
from patient medians because of the 
potential influence of a lower sample size 
and higher population variation in certain 
laboratories. Indeed, in low- to medium-
sized laboratories the effects from 
biological variability (e.g., gender, race 
and age), or inclusion on certain days of 
data for special patient categories (e.g., 
dialysis or oncology patients often are 
registered as outpatient in the LIS) might 
not be leveled off as they do in high 
throughput laboratories. Nevertheless, we 
were able to confirm certain cases where 
we suspected laboratory biases. This was 
possible because the laboratories 
concerned were eager enough to perform 
sample exchanges with other participants. 
Therefore, at the current stage of this 
project, we recommend to our participants, 
especially those from small- and medium-
sized hospitals, to investigate laboratory 
bias by participating in peer group internal 
quality control programs, while using the 
monitoring of patient medians for longer-
term quality management. Notwithstanding 
this, it is worth noting that the project may 
benefit from better information concerning 
the population variation. Once it has grown 
sufficiently, we will try to expand our 
information base, however, again, this will 
require adaptations for the data transfer 
logic by the LIS companies.  
In this project, we use to share 
critical observations concerning test 
instability over time by taking contact with 
individual laboratories and inviting them to 
do further investigations. As a result, we 
could confirm that biases/trends can be 
frequently attributed to lot changes or 
calibration events, or, as discussed above, 
that the laboratory itself was the cause. 
Likewise we share peer group 
observations with the respective 
laboratories and the relevant 
manufacturers. If the sole achievement of 
this project is just to evoke a response 
from the concerned parties, “The 
Percentiler” project will be of significant 
benefit to all stakeholders involved in 
laboratory medicine (laboratories, 
manufacturers, physicians, society, 
patients).  
The project provides the individual 
laboratory with a direct, real-time quality 
indicator for its analyses of patient 
samples, not confounded by commutability 
issues [25]. There is no minimum number 
of data points required, however, the 
laboratory should be aware that the lower 
the number, the higher the resulting 
variability of the medians. As stated before, 
this requires that small-sized laboratories 
choose a higher n for calculation of the 
moving median. Despite this, they still will 
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be able to investigate the stability of their 
analytical performance, but they will see 
changes later than the high-throughput 
laboratories. Together with data from 
internal quality control, the project helps 
the laboratory to build evidence about mid- 
to long-term stability of 
assays/performance, as well as of the 
reasons for variation: laboratory 
performance or manufacturer performance 
(for example, lot-to-lot-variation) [22, 23]. 
Thus, it generally strengthens the overall 
quality management/quality assurance 
system. This evidence is backed-up by 
information from other laboratories using 
the same assay. Knowledge of the above 
effects can also strengthen the 
laboratory/manufacturer dialogue. Cross 
comparison between manufacturers allows 
insight into the mid- to long-term 
performance of other tests and may aid in 
selection of future test systems. Monitoring 
of patient data also creates a tool for 
developing realistic quality goals [22, 24]. 
The project provides manufacturers 
with real-time data about field performance 
of their instruments and application issues 
in particular laboratories. Because the 
employed data are from analysis of patient 
samples, discussion about performance of 
third party quality assurance samples 
becomes obsolete. Also, the possibility 
offered by the project to see peer group 
trends and/or to be informed about peer 
group problems, allows manufacturers to 
verify issues more easily than by 
communication with single laboratories. 
Cross comparisons with other peer groups 
allow the identification of state-of-the-art 
performance and give impetus for test 
improvement when significant sub-
standard performance is observed for 
certain tests. 
The project may improve the 
physician/laboratory interface because 
communication is about patient results and 
not, for example, about trends observed 
for quality control samples. At the same 
time, it helps physicians to develop 
realistic expectations about inevitable 
variability of laboratory data. Ultimately, 
interoperable and stable laboratory data 
facilitate and improve care that physicians 
can offer to their patients. 
The project is beneficial for the 
society, and finally for the patient. The 
data can serve as a “clearinghouse” for 
potential future EHR applications. This is 
particular important when laboratory data 
are intended for use in epidemiological or 
toxicological research on a national or 
global scale. Continuous evidence for test 
comparability and stability is of paramount 
importance for long-term follow-up of 
chronic diseases (diabetes, thyroid-, 
kidney- and cardiovascular disease) and 
linking laboratory data to mortality risk [e.g., 
16, 17]. However, only when laboratory 
data is interoperable, can it fulfill the 
promise of “Big Data”, such as cost 
reduction, improvement of current 
practices, and creation of new insights for 
early diagnosis and long-term public 
health care management. 
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Of course, the monitoring of patient 
data also has limitations: the greater the 
test volume and the more careful the 
selection of outpatient results, the greater 
the utility of the data. In addition, 
monitoring is most effective at the median 
level because “outer percentiles” (for 
example, 2.5th or 97.5th percentiles) 
exhibit a significantly higher population 
variation than do central tendencies such 
as the median. 
Conclusion 
“The Percentiler” project has the potential 
to build a continuous, global evidence 
base on in vitro diagnostic test 
comparability and stability. As such, all 
stakeholders could profit from it, that is, 
laboratories, manufacturers, physicians, 
society, and naturally the patient. The 
medical laboratory, in particular, may be 
empowered for future tasks, such as 
contribution to the development, 
implementation, and management of 
global health-care policies. 
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Annex to Chapter 2 
Comparison of IQC and Percentiler data 
  
  
  
Supplemental figure 1A. Comparison of IQC (black) and Percentiler data (blue) for ALT, 
AST, albumin, ALP, CRP, and calcium. 
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Supplemental figure 1B. Comparison of IQC (black) and Percentiler data (blue) for 
chloride, creatinine, GGT, glucose, inorganic phospor, LDH, magnesium, and potassium. 
  
106 
 
  
  
  
Supplemental figure 1C. Comparison of IQC (black) and Percentiler data (blue) for 
sodium, ureum, uric acid, total-bilirubin, total-cholesterol, and total-protein. 
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3 Chapter III The Flagger 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter is based upon: 
• Goossens K, Brinkmann T, Thienpont L. On-line flagging monitoring – A new quality 
management tool for the analytical phase. Clin Chem Lab Med 2015;53:e269-70. 
• Goossens K, Thienpont L. On-line flagging monitoring – A new quality management 
tool for the analytical phase (manuscript in preparation). 
• Goossens K, De Grande L, Stöckl D, Van Uytfanghe K, Thienpont L. On-line 
flagging monitoring – A new quality management tool for the analytical phase. 
Euromedlab – 21st IFCC – EFML European congress of clinical chemistry and 
laboratory medicine (22-24 June 2014), Paris, France & 2015 AACC Annual 
Meeting and Clinical Lab Expo (26-30 July 2015), Atlanta, US [poster]. 
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Highlights 
The Percentiler has the potential of visualizing the effects of analytical instability directly on 
the results for patient samples, but it can’t show what effect instability has on the clinical 
outcome. Making the link between analytical variation and clinical outcome is very difficult, 
therefore we looked for an alternative in the form of the Flagger. This tool is capable of 
visualizing the instabilities of the hypo- and hyper-flagging rates, which we also refer to as 
“surrogate clinical outcome”. 
 
Highlights of the research: 
 An automatic platform for monitoring hypo- and hyper-flagging rates (“The Flagger”) 
was built. 
 The Flagger data provide global evidence about test stability at low and high 
concentration ends. 
 Both individual laboratories and manufacturers can use the Flagger to assess their 
problem analytes. 
 The Flagger is capable of showing what stability can be achieved by current-state-of-
the-art performance at low and high concentration ends. 
 Combining data from the Flagger with the Percentiler has the potential to translate the 
effect of analytical variation on the flagging rate. 
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1. Introduction 
With the Percentiler, participants are capable of assessing the stability of their instruments 
versus the limits we set. The latter are guided by the systematic error limits based on 
biological variation (“desirable” values from the Westgard website; 1), but they also take the 
current capability of diagnostic assays into account. When these limits are violated, however, 
it is difficult to define the clinical outcome of this aberration, because the link between 
analytical variation and clinical outcome is often unclear (2). That’s why outcome-based 
analytical performance specifications, which reflect the clinical need of patients are so 
important. These specifications are at the top of the hierarchy of analytical performance limits 
as decided at the Stockholm conference of 1999 (3) and confirmed in the revision document 
written after the Milano congress in 2014 (4). These types of specifications are most valuable, 
but they are also difficult to calculate because testing is only indirectly linked to the clinical 
outcome of the test (2). To avoid the need of performing complex and expensive outcome 
studies, we will discuss a more practical alternative to translate the impact of analytical 
stability on laboratory medicine practice. 
The first information of quantitative tests is usually expressed as a flagging outcome. 
When the value of a test result is located within the borders of a reference interval, the value 
is not flagged and not considered “suspicious”. When it falls outside the reference interval, 
either lower or higher, the value is flagged. Although the outcome of the test isn’t directly 
linked with analytical performance, the flagging outcome, or better said the flagging 
frequency of an assay, is. In fact, if one starts from the easiest model based on normal 
distribution, one is capable of calculating the effect of analytical variation or bias on the 
flagging rate. If one expresses those analytical changes relative to the biological variation of 
an analyte, one can determine, for example, theoretical limits which allow for a maximum 
relative change in the false discovery rate of 30%, as is described in the research of 
Stepman et al (5). But this is a theoretical model, and if one wants to learn what the real 
effect of analytical changes on the flagging rate is, one needs to establish a big database. 
Therefore, we developed an online tool for monitoring flagging rates, which is called 
the Flagger. The tool makes use of the fact that the LIS alerts clinical biochemists about 
values which exceed locally chosen cut-offs. Similar to the Percentiler, the Flagger is a freely 
available online web tool, which receives instrument-specific, daily outpatient hypo- and 
hyper-flagging rates. The latter are calculated and transmitted by a laboratory from their 
middleware or LIS. The data are transmitted by e-mail, which is automatically read by 
software into a MySQL database. In the pilot phase the project focuses on the same analytes 
as in the Percentiler. 
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2. Flagger functionality 
The Flagger functionality is analogous to the Percentiler functionality (pages 60-66). Only the 
differences between the two applications are discussed here. Just like the Percentiler, the 
Flagger application has been created by IT engineer Bruno Neckebroek. 
Login 
 
Figure 1. The Flagger login screen. 
The Flagger is accessible online on: https://www.theflagger.be/. Usernames (not case 
sensitive) and passwords (case sensitive) are available for individual labs, for groups (e.g. 
organizations with multiple sites), and for the entire database (see Figure 1). Those who do 
not yet participate can make use of a demo-account (Username: DEMOLAB; Password: 
demo1234). Note that the data for the demonstration laboratory is only available for a limited 
number of analytes and for a short period in time. User guides are not available for the 
Flagger because this functionality mostly resembles the Percentiler. 
The “Quality” tab 
The selections which are made in the Quality tab, i.e., the laboratory in the “Lab” box, the 
peer group in the “Device model” box, the data range, and the n for the moving median, are 
structured in the same manner as in the Percentiler. However, after the selection, not one, 
but two charts will appear, without a summary table. The charts (example in Figure 2) show 
for the selected lab i) the moving median of hypo- (left graph) and hyper-percentage (right 
graph) of the selected devices over the selected period (full colored lines); ii) the long-term 
median (long-broken grey line) and the limits for the respective analyte (short-broken grey 
lines; the area in-between is shaded); iii) the peer group moving median (black broken line). 
It is possible to print and download the charts by pressing the respective buttons. 
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Figure 2. Demonstration of “The Flagger”, enabling a laboratory to track the moving 
median of hypo- (left graph) and hyper-percentage (right graph) per instrument over time 
(Quality tab). The chart shows for the selected lab i) the moving median of the selected 
devices over the selected period (full colored lines); ii) the long-term median (long-broken 
grey line; represents the median calculated from all daily hypo- and hyper-flagging rates 
provided by the laboratory to which the graph applies) and the limits for the respective 
analyte (short-broken grey lines; the area in-between is shaded); iii) the peer group moving 
median (black broken line). 
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The “Samples” tab 
Figure 3. Demonstration of “The Flagger” (Samples tab). The table shows 9 attributes for 
the selected lab: Lab identification number; date; median value (for hypo- or hyper-flagging 
rate); analyte; device identification; vendor or manufacturer; laboratory name; and lab ID 
code. 
This window shows all entries in the database of the chosen laboratory for either the hypo- or 
hyper-flagging rate (see example Figure 3). Note, however, that data are mapped to the 
“Flagger” analyte names and units (not necessarily identical to the names and units given by 
the participants). One can filter the data (for example, according to analyte, to select in the 
“Analyte” box, always followed by pressing the “Filter” button) and sort () (e.g. according 
to date, value, etc…). This tab also contains an excel exporting feature, where one can 
download the data, either completely or filtered. The other tabs available to the project team 
(Labs, Devices, Analytes, Units, and Mails) are similar as for the Percentiler; described in 
chapter 2. 
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Data transmission 
Transition of the data is similar as for the Percentiler. Again, The data of each participant 
should be stratified for outpatients and ordered in a “table” consisting of data-related number 
of rows with ten fields. However, unlike for the Percentiler, data for the Flagger can be sent in 
two different formatting styles. The first possibility was already described in chapter 2 (page 
64). The second option also makes use of ten fields which can be mentioned in any order (an 
example is shown in Figure 4): 
1. Laboratory ID: chosen by the laboratory or already assigned by the laboratory 
2. Date 
3. Instrument ID: as already assigned by the laboratory 
4. Outpatient code: three letters (e.g. OUT) or as already assigned by the laboratory 
5. Analyte name: as already assigned by the laboratory 
6. Unit: as already assigned by the laboratory 
7. % flagged hypo 
8. % “healthy” 
9. % flagged hyper 
10. Number of results used for calculating the median 
Data can be transmitted as: i) e-mail embedded table; ii) e-mail attached EXCEL-file; or iii) e-
mail attached text-file. Data are sent to a database-specific email address (flagger@stt-
consulting.com) and is automatically read into a MySQL database. 
e-mail embedded Table 
From: *** 
Sent: Saturday, 21 september 2015 06:31 
To: flagger@stt-consulting.com 
Content: Empower Flagger Project 
 
Time produced : 27-09-2013 00:00 - 27-09-2013 23:59 
 
ABCDEF;27/09/2013;C16000-5;POL;NA;mmol/L;140.9 
ABCDEF;08/04/2015;COBAS8000C1;POL;ALB;g/L;            -    86%    14%     35   
ABCDEF;08/04/2015;COBAS8000C2;POL; ALB;g/L;            -    87%    15%     37   
ABCDEF;08/04/2015;COBAS8000C1;POL;ALT;U/L;            -    90%    10%    126   
ABCDEF;08/04/2015;COBAS8000C2;POL; ALT;U/L;            -    72%    28%    57   
ABCDEF;08/04/2015;COBAS8000C1;POL; CA;mmol/L;         4%    96%      -    119   
ABCDEF;08/04/2015;COBAS8000C2;POL;CA;mmol/L;         6%    94%      -    102   
ABCDEF;08/04/2015;COBAS8000C1;POL; CL;mmol/L;       12%    73%    15%     45   
ABCDEF;08/04/2015;COBAS8000C2;POL;CL;mmol/L;        15%    83%     2%    104   
ABCDEF;08/04/2015;COBAS8000C1;POL; GGT;U/L;           -    75%    25%    130   
ABCDEF;08/04/2015;COBAS8000C2;POL;GGT;U/L;           9%    77%    14%    108   
Figure 4. Example of data transition to the MySQL database of the Flagger. 
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3. Limits 
Stability limits 
Flagger limits, indicated with the horizontal, grey dotted lines in the graphs, are chosen so 
that they are in agreement with current state-of the-art performance at the higher and/or 
lower concentration ranges. Just like in the Percentiler, they are assigned semi-arbitrarily for 
each analyte (by spending a lot of time interpreting the Flagger data) so most of the 
participating laboratories belonging to the best performing peer group are able of achieving 
the set specifications. These limits are calculated relatively to the long-term flagging rate, but 
set an absolute minimum when the long-term flagging rate is low. For example, the relative 
limit for AST equals 30% with an absolute minimum of 1%. This means when a laboratory’s 
long-term flagging rate equals 10%, the limits will be ± 3% (= 30% of 10%). When the long-
term flagging rate equals 2.5% the limit equals the minimal 1%, and not 0.75%. An overview 
on the Flagger limits is provided in Table 1 of Article 3. This table shows that state-of-the-art 
performance for several analytes is capable of restricting the change of flagging rates to a 
maximum of 30% (relative compared to the long-term flagging rate). Even analytes with small 
biological variation, like potassium, can achieve this stringent quality specification. However, 
this table also indicates that current state-of-the-art performance at the low and high 
concentration levels requires increased stability especially for albumin, calcium, chloride, 
magnesium, sodium, inorganic phosphor, total-protein and uric acid (Flagging limit ≥ 50%). 
Note, similar to the Percentiler the Flagger limits are dynamic, meaning they are 
adapted according to changes in state-of-the-art performance. Therefore, some Flagger 
figures in this thesis might still show a grey stability zone flanked by limits representing 
former numbers. Whenever the limits are functional to the provided explanation, however, 
the values and figures for the limits are adapted to the most recent numbers. 
Target values 
Typically, the reference interval used by a laboratory for a certain analyte is defined by 95% 
of the values in apparently healthy people. Theoretically, flagging rates of about 2.5% for 
both hypo-, and hyper-conditions are expected. However, for a number of analytes the 
normal distribution is skewed, e.g. for enzymes to higher concentrations (more hyper values). 
For other analytes general recommendations are applied, e.g. for total-cholesterol 
laboratories apply age-dependent treatment limits provided by The National Cholesterol 
Education Program (NCEP). As a consequence, the expected flagging rate will differ for all 
analytes, and due to a lack of consensus on the applied reference intervals, a target value is 
not provided for the Flagger application.  
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4. Comparison with Percentiler data 
The stability of the hypo- and hyper-flagging rate is closely correlated to the calibration of the 
IVD instruments at the concentration ends of the reference interval. Therefore, the primary 
objective of the Flagger is monitoring the stability at the lower and higher concentration ends. 
Whilst separate monitoring of either patient percentile or flagging is extremely suited to follow 
the stability of the individual instrument, combining the two tools has the additional potential 
of comparing the trends in patient medians with the trends in the hypo- and hyper flagging 
rate (discussed in the article on pages 121-123). In principle this link between the Percentiler 
and Flagger tool is quite clear. When the values for the patient medians increase, the hypo-
flagging rate will drop, and the hyper-flagging rate will increase and vice versa. In Figure 5, 
the Percentiler graphs (part 1) show instability for a glucose (A) and an LDH assay (B). 
These observations are also visible in the low and high concentration ranges, resulting in a 
significant difference for both the hypo- and hyper-flagging rate (respectively part 2 and part 
3 of Figure 5). Note, for panel B2 the hypo-flagging rate doesn’t follow the trend from the 
Percentiler because the long-term flagging rate equals zero. 
In addition, when the population variation is low (or when the number of daily samples 
measured on a single instrument is high), it becomes possible to translate even small effects 
of an analytical shift on the flagging frequency. In Figure 6, the patient medians for calcium 
shift to values that are ~0.03 mmol/L lower. Although this effect is considered insignificant, 
the Percentiler and Flagger graphs are still concordant. In this way, the laboratory is able to 
translate the effect of the shift in the Percentiler on the flagging frequency. The hypo-flagging 
rate increases, insignificantly, from ~3% to ~4%, and the hyper-flagging rate decreases, 
again insignificantly, from ~5% to ~3%. 
Note, however, that the link between Percentiler and Flagger observations is not 
always confirmed. If a bias-related issue or another analytical problem occurs, which is 
restricted to a certain concentration level, then the Percentiler will not always confirm Flagger 
observation or vice versa. In Figure 7 the Percentiler shows a bias between two instruments 
which measure magnesium. The hyper-flagging rate is concordant with this bias observation, 
while the hypo-flagging rate is similar for both instruments. Although this might seem strange, 
this observation can be explained by a difference in calibration at different concentration 
ranges. This also indicates that several assays might be more stable at lower and/or higher 
concentration levels than they are at the median concentration, or vice versa. 
An extensive discussion on the Percentiler-Flagger link, with an example for each 
analyte, can be found in the manuscript in preparation on pages 124-144. 
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A1
 
B1
 
A2
 
B2
 
A3 
 
B3
 
Figure 5. Percentiler graph showing trends for the moving median of patient results (1) for 
(A) glucose and (B) LDH, which is mirrored in the Flagger for both the hypo- and hyper-
flagging rate (2 and 3 respectively). 
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C 
 
Figure 6. Percentiler graph showing trends for calcium: the patient medians for calcium shift 
to values which are ~0.03 mmol/L lower (A). This is mirrored in the Flagger: the hypo-
flagging rate increases from ~3% to ~4% (B), and the hyper-flagging rate decreases from 
~5% to ~3% (C). 
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A 
 
B 
 
C 
 
Figure 7. Percentiler graph showing a bias between two instruments measuring magnesium 
(A). The effect of the bias is translated in the hyper-flagging rate (C), but not in the hypo-
flagging rate (B). 
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5. Conclusion on the Flagger 
With our previously discussed Percentiler application we can show the currently achievable 
state-of-the-art performance. However, this tool cannot give an indication of the effect of 
violations of the stability limits on the clinical outcome or medical decision. Here we 
discussed a second application, called the Flagger which monitors the stability of the flagging 
rate in relation to the stability of the patient medians. Just like the Percentiler, the Flagger 
has several advantages and disadvantages over the existing QC tools. The information given 
by the Flagger also originates from materials which are “as commutable as possibly can be”. 
They are again available without additional costs. Naturally, the Flagger’s utility improves 
when the population variation of the data is low. In theory, participants can use the Flagger 
just like the Percentiler to monitor the stability of their IVD instruments. Combining the two 
tools has the additional potential of comparing the trends in patient medians with the trends 
in the hypo- and hyper flagging rate. A laboratory, thereby, still cannot translate the effect of 
violations of bias limits on the clinical outcome, but it can at least visualize the effect on the 
flagging rate. 
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Article 2. The Flagger concept (letter to editor) 
On-line flagging monitoring – A new quality management tool for the 
analytical phase 
Kenneth Goossens1, Thomas Brinkmann2, Linda M Thienpont1* 
1Laboratory for Analytical Chemistry, Faculty of Pharmaceutical Sciences, Ghent 
University, Ghent, Belgium 
2Labor Lademannbogen MVZ GmbH, Hamburg, Germany 
 
Traditionally, it is difficult to demonstrate 
the impact of analytical quality on daily 
medical decision making (1). This is partly 
due to the fact that analytical quality 
should relate to its effect on clinical 
decisions (2). Strictly, this requires 
complex and expensive outcome studies, 
however, in the field of laboratory 
medicine these are still lacking. We, 
therefore, looked for alternative tools to 
translate the impact of analytical quality, 
particularly assay stability, on daily 
laboratory medicine practice. We 
conducted 2 pilot studies to investigate the 
utility of a tool demonstrating the effect of 
analytical shifts on so-called “surrogate” 
medical decisions, such as flagging of 
laboratory results exceeding locally used 
cut-offs (3, 4). On the basis of the 
observations made in these preliminary 
studies, we elaborated a theoretical 
concept (5). Because of the encouraging 
comments we received for that preliminary 
work, we developed an on-line tool for 
monitoring flagging rates, which we called 
“The Flagger” (www.theflagger.be; login: 
demolab, password: demo1234). The tool 
makes use of the fact that laboratory 
information systems (LIS) alert clinical 
biochemists about values that exceed 
locally chosen cut-offs, for example, by 
making them bold in the report or by 
adding an asterisk to the result (here 
referred to as “flagging”). The LIS is 
programmed for our application to 
calculate the daily %-flagging rates. Those 
numbers are automatically assembled, 
either in e-mail embedded lists, EXCEL-
files, or text files. These files are 
automatically sent to our database and 
visualized by our Flagger application. 
 Here, we report our first 
experiences with “hypercalcemia” as 
example of surrogate medical decision 
(see Fig. 1). We used age-dependent 
flagging cut-offs: 2.6 mmol/L (10 days of 
age); 2.75 mmol/L (2 years), 2.7 mmol/L 
(12 years); 2.55 mmol/L (18 years); 2.5 
mmol/L (60 years); 2.55 mmol/L (90 years); 
and 2.4 mmol/L (>90 years). The daily 
medians were calculated from ~75 
outpatient results and the data had a CV 
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of ~4%. The figure shows the time-course 
of the daily calcium medians (left graph) 
and the flagging frequency indicating 
“hypercalcemia” (right graph) for two 
instruments in a laboratory. Instrument B 
(red lines) was stable over the observed 
time-period, instrument A (blue lines) 
exhibited a shift of ~0.06 mmol/L (~2.5%). 
Typically, laboratories would not consider 
a shift of this magnitude of major concern. 
However, if they are alerted by a tool like 
the Flagger that this shift translates into a 
~3-fold increase of the flagging rate (from 
~3% to ~9%), they should be given an 
incentive to stricter quality control, in 
particular, for analytes that are under 
narrow physiological control (such as 
sodium, or calcium). In the given case, it 
may be desirable to keep the stability of 
the calcium assay within 0.04 mmol/L. 
Note that the aforementioned increase 
corresponds very well to the expected 3.5-
fold increase when the shift is ~0.63 times 
the CV (5), as is in our case (2.5% shift/4.0% 
CV = 0.63). We would like to emphasize 
that the Flagger can be used “generic”, 
meaning that the bias/population CV ratio 
can predict to a good extent the expected 
change in flagging rate also for other 
analytes. 
The Flagger is an interesting new 
quality management tool because it 
directly translates analytical shifts into 
surrogate medical decision. The actual 
utility of the Flagger and its impact on 
medical decisions, naturally, will have to 
be inferred from practice. However, in view 
of the experience that requestors of 
laboratory analyses such as general 
practitioners use to highly rely on flagging 
of the reported results, it can be expected 
that an “analytically stable” flagging rate  
 
Figure 1. Moving medians for calcium in time calculated from 8 daily outpatient medians (left 
graph) and associated flagging percentage indicating “hypercalcemia” (right graph) for two 
instruments (A: blue lines; B: red lines) used in a laboratory; the mmol/L axis ranges over 
~5% (2.275 – 2.4 mmol/L). 
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consequently, to related medical decisions. 
Currently, this tool is still to be 
programmed by the local IT-department, 
however, we found laboratory information 
system providers interested to develop 
generally applicable solutions. Moreover, 
with our Flagger platform, we are able to 
peer group monitoring of flagging rates 
opening all the benefits of peer group 
comparisons. 
 In conclusion, we consider on-line 
monitoring of the flagging rate in the 
individual laboratory, but also externally at 
the peer group level, an additional quality 
management tool for the analytical phase. 
It is particularly useful because it directly 
translates analytical quality into quality of 
medical decision making against locally 
important cut-offs. 
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Introduction 
The laboratory medicine community is 
concerned about analytical performance, 
however, struggles since long with 
defining specifications to assess quality. 
First laboratory inter-comparisons were 
validated by use of arbitrary specifications 
inferred from expert advice (1). Later on, 
several scientific approaches were 
developed based on the biological 
variation of the analytes (2, 3). Those were 
followed by many other models, including 
specifications derived from questionnaires 
to clinicians and requirements for 
decisions in specific clinical situations (4). 
A milestone was the Stockholm 
conference, defining a five-level hierarchy 
for establishing analytical performance 
specifications, with specifications derived 
from “clinical situations” at the top (5). 
Unfortunately, little progress was made 
with implementing generally accepted 
“numbers”, which gave rise to holding a 
conference that addressed the situation 15 
years later (6, 7). In principle, the original 
proposal was re-iterated, however, the 
five-level hierarchy was streamlined into 
three levels with the clinically derived 
specifications at the top. Unfortunately, the 
latter give only very few generally 
accepted numbers for routine practice in 
the laboratory. Therefore, specifications 
based on biological variation are still the 
most widely used ones. Only, there is no 
consensus about the actually desired 
numbers (optimum, desirable, minimum) 
and numbers that really can be applied in 
practice. Because of that, we expanded 
the ideas of Klee (8), investigating 
analytical instabilities (in fractions of the 
biological variation) onto their effect on 
surrogate medical decisions (9). Based on 
that theoretical framework, we developed 
the Percentiler and Flagger applications 
that monitor analytical stability (Percentiler) 
and its effect on flagging rates (surrogate 
medical decisions) in the individual 
laboratory (10-16). Combining both 
applications has the chance to bridge the 
medium hierarchy level (biological 
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variation) with the top hierarchy level 
(clinical outcome) and thus helping the 
individual laboratory in their local situation 
to define realistic, but ambitious analytical 
performance specifications. 
 Here, we report our longer term 
experience with both applications and 
demonstrate the effects of analytical 
variation on the local hypo and hyper 
flagging rates with the aim of developing 
analytical performance specifications that 
can be applied in daily routine practice and 
different laboratory surroundings. 
Materials and methods 
The Flagger is a freely available online 
web tool that receives instrument-specific, 
daily outpatient hypo- and hyper-flagging 
rates (in percentage of the total number of 
daily results). The latter are calculated and 
transmitted by the participating 
laboratories from their middleware or 
laboratory information system. The data 
are sent by e-mail and automatically read 
by software into our MySQL database. In 
the pilot phase the project focuses on 20 
analytes from clinical chemistry tests, i.e., 
albumin (ALB); alkaline phosphatase 
(ALP); alanine aminotransferase (ALT); 
aspartate aminotransferase (AST); total-
bilirubin (BIL); calcium (CA); total-
cholesterol (CHOL); chloride (Cl); C-
reactive protein (CRP); γ-
glutamyltransferase (GGT); glucose (GLU); 
potassium (K); creatinine (CRE); lactate 
dehydrogenase (LDH); magnesium (MG); 
sodium (NA); inorganic phosphor (PHOS); 
total-protein (PROT); urea or bound urea 
nitrogen (UREA; BUN); and uric acid 
(UAC). In a later stage, the database was 
extended to free thyroxine (FT4) and 
thyroid-stimulating hormone (TSH) in the 
context of the IFCC standardization/ 
harmonization of thyroid function tests (11). 
The Flagger is accessible online on: 
https://www.theflagger.be/. Usernames 
and passwords are available for individual 
laboratories, for groups (e.g. organizations 
with multiple sites), and for the entire 
database. Those who do not yet 
participate can access the online web tool 
by use of a demo account (Username: 
DEMOLAB; Password: demo1234). Only 
the Empower team has access to the data 
of all laboratories, while participants are 
restricted to view their own data. Currently, 
51 laboratories are participating in the 
Flagger application with 135 instruments. 
The longest participation time is 2.5 years. 
Cost-free automatic data sending by 
several Laboratory Information Systems is 
available since 1.5 years. All “Flagger” 
laboratories, also, participate in the 
Percentiler application (12). 
The Flagger charts (example 
shown in the online Supplemental, Figure 
1S) show for the selected laboratory (i) the 
moving median of the daily hypo- and 
hyper percentage, (ii) the long-term 
median and the limits for the respective 
analyte (relative to the long-term flagging 
median), and (iii) the all or peer group 
moving median. In the web application 
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Supplemental Figure 1S. The Flagger charts show (i) the moving median of daily hypo- and 
hyper-percentage of the selected devices over the selected period (full colored lines); (ii) the 
long-term median (long-broken grey line) and the limits for the respective analyte (short-
broken grey lines; the area in-between is shaded); (iii) the all or peer group moving median 
(black broken line). 
 
several selections (via buttons) are 
possible. One can choose the device type, 
in- or exclude weekend data and the time 
frame. The latter can be done by pushing 
the buttons “Start date”, “Stop date” or “3M” 
(months), “6M”, “1Y” (year), and “All”. One 
also needs to choose the n for calculating 
the moving median (default setting is 5), 
and finally the analyte for which the chart 
should be shown. For more information on 
the Percentiler functionalities we refer to 
our previous publication (12). 
Results 
The combination of the Flagger and 
Percentiler application allowed deriving 
performance specifications for hypo and 
hyper flagging rates and their comparison 
with the respective analytical performance 
specifications for 22 commonly measured 
analytes (see Table 1). The limits were 
achievable by at least one quarter of the 
laboratories. The most stringent ones 
(20%) were derived for CHOL and GLU 
because of their paramount importance for 
public health policies (coronary artery 
disease and diabetes). A Flagger limit of 
30% could be applied for 11 analytes. 
Higher limits (50% and 70%) had to be 
used for the remaining 8 analytes, in 
particular, those with a quite small 
biological variation (CA, MG, NA). 
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Table 1. Limits for the Flagger and Percentiler applications and desirable bias from biological 
variation (17); #note: the minimum absolute %-limit in the flagger is 1%; table sorted by 
increasing Flagger limit. 
Analyte 
Flagger# limit 
(%) 
Percentiler limit 
(%) (Absolute) 
Desirable stability 
limit (%) (17) 
CHOL 20 3.8 (0.2 mmol/L) 4.1 
GLUC 20 3.1 (0.15 mmol/L) 2.3 
ALKFOS 30 6.8 (5 U/L) 6.7 
ALT 30 9.5 (2 U/L) 11.5 
AST 30 6.5 (1.5 U/L) 6.5 
BILTOT 30 10.0 (1 µmol/L) 9.0 
CREAT 30 3.9 (3 µmol/L) 4.0 
CRP 30 9.6 (0.25 mg/L) 21.8 
FT4 30 3.3 (0.5 pmol/L) 3.3 
GGT 30 9.1 (2 U/L) 11.1 
K 30 2.4 (0.1 mmol/L) 1.8 
LDH 30 4.6 (8 U/L) 4.3 
TSH 30 7.7 (0.12 mU/L) 7.8 
UREA 30 6.0 (0.3 mmol/L) 5.6 
ALB 50 2.3 (1 g/L) 1.4 
CL 50 1.0 (1 mmol/L) 0.5 
PHOS 50 4.4 (0.05 mmol/L) 3.4 
PROT 50 1.4 (1 g/L) 1.4 
URIC ACID 50$ 4.8 (15 µmol/L) 4.9 
CA 70 1.7 (0.04 mmol/L) 0.8 
MG 70 3.0 (0.02 mmol/L) 1.8 
NA 70 0.7 (1 mmol/L) 0.2 
$50% instead of 30% because of seasonal variation 
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The effect of analytical variation – 
and eventual violation of the Flagger limit 
– is exemplified for five selected examples 
(see the Supplemental Figures 2S to 22S 
for all 22 analytes). 
Cholesterol 
Figure 1 shows a major downwards shift in 
total-cholesterol median values from ~4.7 
mmol/L to ~4.4 mmol/L. The hypo flagging 
rate is nearly unaffected and is in the order 
of ~1%, while the hyper flagging rate 
decreases from ~36% to nearly 23%. 
Operating the test within the ±0.2 mmol/L 
limit would result in hyper flagging rates 
between 24 and 37%. 
Glucose  
Figure 2 shows three shifts in glucose 
values, i.e., a first time from ~5.1 mmol/L 
to ~5.3 mmol/L, then a shortly lasting shift 
up to 5.5 mmol/L followed by a return to 
~5.4 mmol/L, and finally a third shift up to 
~5.6 mmol/L. The hypo flagging rate is 
little affected and is in the order of 1% to 
2%, while the hyper flagging rate mainly 
increases due to the last upwards shift 
from ~35% to nearly 55%. Operating the 
test within the ±0.15 mmol/L limit would 
result in hyper flagging rates between 33 
and 50%. 
 
 
Figure 1. The figure shows the time courses of (i) the moving median of daily total-
cholesterol values (full black line), (ii) the hypo flagging rate (full blue line), (iii) the hyper 
flagging rate (full red line), and (iv) the respective limits indicated by broken lines in the 
same color as the parent lines. Note, the Percentiler limit is 0.2 mmol/L (= 3.8%; 
“desirable” = 4.1%) and the Flagger limit is 20% of the long-term laboratory median. 
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Figure 2. Similar to Figure 1, but for glucose. Note, the Percentiler limit is 0.15 mmol/L (= 
3.1%; “desirable” = 2.3%) and the Flagger limit is 20% of the long-term laboratory median. 
 
ALT  
Figure 3 shows a drift of the ALT values 
from ~24 U/L to ~18 U/L and a sharp shift 
to ~30 U/L. The hypo flagging rate 
increases from ~10% to ~28% and drops 
to 0%. The hyper flagging rate decreases 
from ~7% to nearly 0% and increases, 
again, to ~8%. Operating the test within 
the ±2 U/L limit would result in hypo 
flagging rates between 9 and 17%. Note, 
typically, ALT tests were stable within the 
selected Flagger limit of 30% (data not 
shown). Note also that most laboratories 
have hyper flagging limits, only, for ALT 
and the other monitored enzymes. 
Calcium  
Figure 4 shows moderately varying 
calcium values, i.e., they first shift upwards 
from ~2.33 mmol/L to ~2.38 mmol/L, then 
they fall back to 2.33 mmol/L, followed by 
a second gradual increase to ~2.42 
mmol/L, to finally drop back to 2.30 
mmol/L. The hypo flagging rate decreases 
more strongly with the analytical shifts 
from ~13% to ~3%, then increases to ~9%, 
falls back to 4% to finally increase a 
second time to ~15%. The hyper flagging 
rate is very low so that no effects are 
observed. Operating the test within the 
±0.04 mmol/L limit would result in hypo 
flagging rates between 2 and 10%. 
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Figure 3. Similar to Figure 1, but for ALT. Note, the Percentiler limit is 2 U/L (= 9.5%; 
“desirable” = 11.5%) and the Flagger limit is 30% of the long-term laboratory median. 
 
 
Figure 4. Similar to Figure 1, but for calcium. Note, the Percentiler limit is 0.04 mmol/L (= 
1.7%; “desirable” = 0.8%) and the Flagger limit is 70% of the long-term laboratory median. 
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Sodium  
Figure 5 shows a drift in sodium values 
from ~140 mmol/L up to ~141.4 mmol/L, 
followed by a downwards shift to ~139 
mmol/L, and a normalization back to 141.5 
mmol/L. The hypo flagging rate is affected 
by the shift and changes from ~2% to ~5%, 
and normalizes back to ~2%. The hyper 
flagging rate is affected by the drift as it 
increases from ~3% up to ~12%; due to 
the downward shift it drops from ~12% to 
nearly 2% and then increases back to 
~12%. Operating the test within the ±1 
mmol/L limit would result in hyper flagging 
rates between 2 and 12%. 
 
Figure 5. Similar to Figure 1, but for sodium. Note, the Percentiler limit is 1 mmol/L (= 
0.7%; “desirable” = 0.2%) and the Flagger limit is 70% of the long-term laboratory median. 
 
Discussion 
The long-term experience of our Flagger 
and Percentiler applications allowed the 
investigation of the relationship between 
analytical performance specifications and 
surrogate medical decisions, i.e., flagging 
rates against locally used reference 
interval or decision limits. However, it is to 
note that the Flagger and Percentiler 
applications monitor laboratory data at 
different concentration levels. Therefore, 
analytical variation observed in the 
Percentiler may not directly reflect change 
in flagging rates. Nevertheless, most 
examples in this publication show that the 
most prominent flagging rate (be it hypo or 
hyper) correlates quite well with analytical 
variations seen in the Percentiler 
application. 
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 We could demonstrate that 
restricting the increase in flagging rates to 
20% is realistic for some of the most 
important analytes (total-cholesterol and 
glucose) despite the fact that their 
relatively low biological variation requires 
ambitious analytical stability limits (2.3% 
for glucose, for example; see Table 1). 
This contrasts with the phosphate test 
(analytical stability limit of 3.4%), where we 
needed to operate the Flagger with a 50% 
limit. We speculate that this is because 
manufacturers (and laboratories) give 
special attention to analytes that are in the 
public or scientific focus which, 
unfortunately, is not the case for the 
phosphate test. We could apply 30% 
Flagger limits for most of the other tests 
which nicely corresponds to analytical 
stability limits derived from biological 
variation and, consequently, limits applied 
in the Percentiler. For analytes with low 
biological variation (ALB, CL, PROT, CA, 
MG, NA) we had to set the Flagger limits 
higher (50% or 70%). Note, we also had to 
apply a 50% limit for uric acid because of 
its seasonal variation (somewhat higher in 
the summer). With the selected examples, 
we can give insight in the effect of 
analytical variation on locally used flagging 
rates. 
The selected examples may 
demonstrate in more detail the utility of the 
Flagger/Percentiler combination. The total-
cholesterol example (Figure 1) 
demonstrates the maturity of the test. 
Certain laboratories were able to keep the 
test within the 20% Flagger limit for over 2 
years, corresponding to an analytical 
stability within ±0.2 mmol/L (desirable 
stability = 4.1%). Similar holds true for the 
glucose test which, even, requires better 
stability (desirable stability = 2.3%) 
because of its lower biological variation as 
compared to total-cholesterol (Figure 2). 
ALT tests, typically, were stable within the 
recommended limits (not shown), except 
the one of Ortho Clinical Diagnostics used 
to construct Figure 3 and demonstrating 
that the analytical instability gave 
significant changes in flagging rates (hypo 
from 0% to 28%; hyper from 0% to 8%). 
Analytical stability in the order of 2 IU for 
concentrations in the reference interval 
could greatly support the utility of the ALT 
test for newer applications, such as early 
detection of metabolic changes 
(“metabolic syndrome”) (18-20). In that 
connection, cut-offs for high-normal may 
be useful as most laboratories, only, flag 
very high results. As reported earlier, 
calcium flagging rates are very much 
influenced by analytical instability because 
of the low biological variation (12). The 
hypo flagging rate was ~15% at 2.30 
mmo/L, whereas it was only ~3% at 2.42 
mmol/L in the example shown in Figure 4. 
This means that operation of the calcium 
test with an instrument or laboratory bias 
of ~0.12 mmol/L could result in five-fold 
different hypo flagging rates. For sodium, 
we confirmed our earlier observations (16). 
In the example of Figure 5, the hyper 
flagging range nearly triplicated (3% to 9%) 
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due to a drift from 140 to 141 mmol/L. 
Achieving a 1 mmol/L stability could 
significantly improve the utilization of the 
sodium test by clinicians (21, 22). Indeed, 
several laboratories were able to reach 
such a stability over more than 2 years, 
supporting the applicability of the 1 mmol/L 
stability which, however, still can result in 
significant increase in flagging rates. 
The Flagger application is of limited 
value for low-throughput laboratories 
because of high variability of the flagging 
rates that cannot be compensated for by 
choosing a higher n for calculating the 
moving median. On the other hand, also 
those laboratories profit from the 
application simply by being part of it and 
learning from the other participants via the 
reports we regularly send. Currently, the 
number of participants is too low to 
compare flagging rates across laboratories 
or peer groups. 
Future plans are the comparison of 
locally used cut-off points for flagging. 
Either, they may reveal justified reasons 
why different cut-offs are used or give the 
opportunity for harmonization when no 
reason can be identified. 
Conclusion 
Overall, we showed that the combination 
of monitoring flagging rates together with 
daily patient medians is capable of 
translating the effect of analytical variation 
into its effect on surrogate medical 
decisions. Our results re-iterated the utility 
of the concept of setting analytical 
performance specification from biological 
variation. The Flagger/Percentiler 
application can form a bridge of the 
“medium-level” hierarchy for setting 
analytical specifications (biology) to the 
“top-level” (clinical situations). The 
advantage of the application is the direct 
visualization of analytical instability at the 
laboratory level using data readily 
available in the laboratory itself. 
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Supplemental Figures 2-18 
  
Figure 2S and 3S. Albumin and ALP. 
Figure 2S. The figure shows a drift of albumin values from ~ 39 g/L to ~35 g/L, followed by a 
shift back to ~38 g/L. The hypo flagging rate increases from ~20% to ~42% and falls back to 
~20%. This laboratory has, like most laboratories, no hyper flagging for albumin. Note, the 
Percentiler limit is 1 g/L (= 2.3%; “desirable” = 1.4%) and the Flagger limit is 50% of the long-
term laboratory median. 
Figure 3S. ALP assays are among the most stable assays across laboratories and 
manufacturers. The figure here shows several moderate shifts of the alkaline phosphatase 
values, first the values drop from ~73U/L to ~68 U/L, second they go up to ~76 U/L, third they 
fall to ~70 U/L and fourth return to ~73U/L. The hypo flagging rate is very low, as mostly is 
the case. The hyper flagging rate varies concordantly with the analytical shifts between ~3 % 
to ~5%. Note, the Percentiler limit is 5 U/L (= 6.8%; “desirable” = 6.7%) and the Flagger limit 
is 30% of the long-term laboratory median. 
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Figure 4S and 5S. AST and total-bilirubin. 
Figure 4S. The figure shows AST values varying from ~20 U/L to ~24 U/L and back to ~20 
U/L. The hypo flagging rate decreases concordantly with the analytical variation from ~13% 
to ~4% and increases again to ~22%. The hyper flagging rate slightly drops from ~8% to 
~6%. Note, the Percentiler limit is 1.5 U/L (= 6.5%; “desirable” = 6.5%) and the Flagger limit 
is 30% of the long-term laboratory median. 
Figure 5S. The total-bilirubin assay is among the most stable assays across manufacturers 
and laboratories; typically, the limits are never violated. The figure shows total bilirubin 
values shifting from ~6.8 µmol/L up to ~7.5 µmol/L; then they decrease to ~7.0 µmol/L 
followed by an increase to ~7.6 µmol/L. The hyper flagging rate is concordantly affected by 
both analytical shift as it goes from ~2.5% up to nearly 4% and comes back to ~3%. As 
expected, the hypo flagging rate is almost zero %. Note, the Percentiler limit is 1 µmol/L (= 
10%; “desirable” = 9.0%) and the Flagger limit is 30% of the long-term laboratory median. 
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Figure 6S and 7S. Chloride and CRP. 
Figure 6S. The figure shows two shifts in the chloride values, i.e., from ~ 103 mmol/L to 
~100.5 mmol/L, and to ~99 mmol/L. The hypo flagging rate is most influenced by both 
analytical shifts as it increases from ~5% to ~21%. The hyper flagging rate decreases by the 
first downward shift from ~2% to nearly 0%. Note, the Percentiler limit is 1 mmol/L (= 1.0%; 
“desirable” = 0.5%) and the Flagger limit is 50% of the long-term laboratory median. 
Figure 7S. The figure shows four major shifts in the CRP values, i.e., from ~7.0 mg/L to ~ 
9.9 mg/L, then down to ~5.8 mg/L, up to ~9.5 mg/Land down to ~5 mg/L. The hyper flagging 
rate is influenced by the analytical shifts as it first increases from ~35% to ~48%, then drops 
to ~28% to increase again to ~35-45%, and then decreases to ~15-20%. The hypo flagging 
rate is and remains zero as expected. Note, the Percentiler limit is 0.25 mg/L (= 9.6%; 
“desirable” = 21.8%) and the Flagger limit is 30% of the long-term laboratory median. 
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Figure 8S and 9S. Creatinine and FT4. 
Figure 8S. The figure shows drifting creatinine values from ~84 µmol/L down to ~74 µmol/L, 
followed by a shift to~78 µmol/L. The hypo flagging increases concordantly with the drift from 
~3% to ~7.5% to normalize again to ~3%. The hyper flagging rate gradually decreases from 
~15% down to nearly 8% and then normalizes to ~11%. Note, the Percentiler limit is 3 µmol/L 
(= 3.9%; “desirable” = 4.0%) and the Flagger limit is 30% of the long-term laboratory median. 
Figure 9S. The figure shows FT4 values drifting and shifting from 15.5 pmol/L up to 17 
pmol/L. The hypo flagging rates decrease from ~10% to ~0%, while the opposite happens for 
the hyper flagging rate (increases from ~8% to nearly 16%). Note, the Percentiler limit is 0.5 
pmol/L (= 3.3%; “desirable” = 3.3%) and the Flagger limit is 30% of the long-term laboratory 
median. 
  
140 
 
  
Figure 10S and 11S. GGT and LDH. 
Figure 10S. The figure shows a downward shift in GGT values from ~28 U/L to ~24U/L. The 
hypo flagging rate increases concordantly with the analytical shift from ~ 3% to ~10%. The 
hyper flagging rate drops from ~22% to nearly 10%. Note, the Percentiler limit is 2 U/L (= 
9.1%; “desirable” = 11.1%) and the Flagger limit is 30% of the long-term laboratory median. 
Figure 11S. The figure shows drifting LDH values from ~200 U/L up to to ~230 U/L. The 
hyper flagging rate gradually increases from ~18% to nearly 33%. As is the case for other 
enzymes, the hypo flagging rate is nearly 0%. Note, the Percentiler limit is 8 U/L (= 4.6%; 
“desirable” = 4.3%) and the Flagger limit is 30% of the long-term laboratory median. 
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Figure 12S and 13S. Magnesium and inorganic phosphate. 
Figure 12S. The figure shows several shifts in the magnesium values, i.e., a first drop from 
~0.83 mmol/L to ~0.79 mmol/L, followed by an increase to ~0.84 mmol/L, to drop back to 
~0.81 mmol/L and finally increase to 0.835 mmol/L. The hypo flagging rate decreases from 
~7.5% to ~2.5%, then returns to ~7.5-9.0%, comes down to ~2.5%, to normalize again to 
~7.5%. The hyper flagging rate is nearly 0%. Note, the Percentiler limit is 0.02 mmol/L (= 
3.0%; “desirable” = 1.8%) and the Flagger limit is 70% of the long-term laboratory median. 
Figure 13S. The figure shows several shifts in the inorganic phosphor values, the major 
ones being from ~1.13 mmol/L to ~1.03 mmol/L and back to ~1.17 mmol/L. The hypo 
flagging rate concordantly increases from ~2% to ~12% and drops back to ~2%. The hyper 
flagging rate mainly decreases due to the downwards analytical shift from ~7% to nearly 
2.5%. Note, the Percentiler limit is 0.05 mmol/L (= 4.4%; “desirable” = 3.4%) and the Flagger 
limit is 50% of the long-term laboratory median. 
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Figure 14S and 15S. Potassium and total-protein. 
Figure 14S. The potassium assay is among the most stable assays across manufacturers 
and laboratories; typically, the limits are never violated. The figure shows potassium values 
going down from ~ 4.15 mmol/L to ~4.05 mmol/L. The hypo flagging rate increase 
concordantly from ~3% to ~5%, while the inverse happens for the hyper flagging rate 
decreasing from ~7% to nearly 4%. Note, the Percentiler limit is 0.1 mmol/L (= 2.4%; 
“desirable” = 1.8%) and the Flagger limit is 30% of the long-term laboratory median. 
Figure 15S. The figure shows a major shift in the total protein values from ~67.5 g/L to ~70.5 
g/L. The hypo flagging rate decreases concordantly from ~5% to ~2%. The hyper flagging 
rate triplicates (from ~0.2% to nearly 0.6%), however, is generally low. Note, the Percentiler 
limit is 1 g/L (= 1.4%; “desirable” = 1.4%) and the Flagger limit is 50% of the long-term 
laboratory median. 
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Figure 16S and 17S. TSH and urea. 
Figure 16S. The figure shows variable TSH values ~1.8 mIU/L to ~1.55 mIU/L. The hypo 
flagging rate follows the trend grossly and varies between ~5% and 12%. The hyer flagging 
rate follows the analytical trend nicely and varies between ~7% and 13%. Note, the 
Percentiler limit is 0.12 mmol/L (= 7.7%; “desirable” = 7.8%) and the Flagger limit is 30% of 
the long-term laboratory median. 
Figure 17S. The figure shows drifting urea values from ~5.2 mmol/L to ~4.6 mmol/L and, 
finally slightly increasing to ~4.8 mmol/L. The hypo flagging rate <1% gradually increases up 
to ~2.5% and levels off at ~1.5%, while the hyper flagging rate decreases from ~12% to 
nearly 7.5%. Note, the Percentiler limit is 0.3 mmol/L (= 6.0%; “desirable” = 5.6%) and the 
Flagger limit is 30% of the long-term laboratory median. 
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Figure 18S. Uric acid. 
Figure 18S. The figure shows a downward and upward shift in the uric acid values from 
~335 µmol/L to ~315 µmol/L and back to ~340 µmol/L. Due to the downward analytical shifts, 
the hyper flagging rate at ~7% falls to ~2.5%; it returns to nearly 7% after the upwards shift. 
As expected, the hypo flagging rate is very low and little affected by the variation and varies 
between 0 and 1%. Note, the Percentiler limit is 15 µmol/L (= 4.8%; “desirable” = 4.9%) and 
the Flagger limit is 50% of the long-term laboratory median. 
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Highlights 
Comparability of measurement results can best be achieved by establishment of traceability 
to a higher order method. If those methods are absent, harmonization to a lower-order 
reference material or to a surrogate target, such as the All Manufacturer Trimmed Mean 
(AMTM), is the best alternative. To maintain comparability between routine methods there is, 
amongst others, a constant need for QC in the clinical laboratory. EQA has proven to be a 
valuable tool to address that QC, however, it remains limited to the objectives that can be 
reached because of the use of non-commutable materials. This is why we developed our 
Master Comparison initiative in order to assess the comparability status of five commonly 
measured enzymes and three electrolytes by use of commutable, single donation serum 
samples. 
 
Highlights of the research: 
 Reference Measurement Procedures (RMP’s) are used to demonstrate the 
standardization status of eight routine procedures for ALT, AST, LDH and GGT. 
 Reference Measurement Procedure - corrected All Manufacturer Trimmed Mean 
(RMP-corrected AMTM) target values are superior over RMP values when 
investigating causes of dispersion of results from routine procedures. 
 Peer performance and assay comparability were generally good for chloride, 
potassium and sodium. An exception was the negative bias of the Roche assays for 
chloride. 
 For enzyme assays both manufacturers and laboratories still have a lot to do to 
accomplish traceability of measurement results. 
o There is a need to phase out the non-IFCC assay variants. 
o The quality, comparability, and standardization of the ALT assays needs to be 
improved. 
o GGT and LDH assays require better comparability. 
o There exists a general need for improving peer comparability at low 
concentration levels. 
o Nearly all enzymes studied require single-manufacturer efforts for 
improvement of comparability. 
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1. Introduction 
One of the main concerns in laboratory medicine is a lack in comparability between different 
assays, different laboratories, and even between different instruments in a single laboratory. 
If this problem occurs patient data cannot be exchanged between different sites or even 
between different instruments on a single site. Non-comparability is not only caused by the 
use of different methods or assays and different instrumentation, it can also find its origin in 
the use of different calibration material and the occurrence of commutability issues (1). In 
order to avoid non-comparability, the establishment of traceability to a higher order method 
has been proposed. However, in practice, this is not always achievable, simply because of 
the non-existence of higher order methods/material. In other cases, the implementation of 
existing traceability chains can fail in achieving the comparability aimed at (2). 
A major tool to address the current status of comparability between different assays 
and laboratories is the compulsory participation of laboratories to EQA surveys. These 
mostly make use of proficiency testing materials which are measured by each participant in 
the same manner as done for their patient samples (3-6). If these materials are commutable 
with the examined assays, they can be used to compare inter-assay results. However, if they 
are not, which is quite often the case, then a false impression about the trueness of 
laboratory results might be introduced (7-8). Therefore, non-commutable materials should 
only be used to address comparability between instruments/laboratories within the same 
peer group. 
In our Master Comparison studies we make use of single donation serum samples 
from 20 apparently healthy donors. These samples are as commutable as possible and are 
therefore ideally suited to address comparability between both the laboratories within a single 
peer group and across assays (9). In addition, by measuring several analytes with a RMP we 
were also able to demonstrate the standardization status of the different assays. However, 
our approach has some limitations: because we restricted our method design to apparently 
healthy donors, our results don't show the comparability/standardization status over the 
entire concentration range (i.e. including “diseased” samples). In addition, because the 
serum volume available from a single donor is limited, our approach to EQA is only suited to 
serve a small number of laboratories. 
Previously performed Master Comparison studies assessed the comparability status 
of albumin, calcium, creatinine, glucose, HDL-cholesterol, LDL-cholesterol, magnesium, 
phosphate, total protein, total cholesterol, triglycerides, and uric acid (10-12). In our 2014 
study we focused our efforts on five common enzymes and three electrolytes. 
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2. Study design 
The Master Comparisons are EQA surveys performed with 20 freshly frozen, single donation 
sera from apparently healthy volontueers. In the 2014 survey eight analytes were assessed 
in eight different peer groups. The studied analytes were: ALP, ALT, AST, LDH, GGT, 
potassium, sodium, and chloride. Participants were selected to obtain carefully controlled 
peer groups for Abbott Architect (n = 21), Beckman AU (n = 19), Beckman DxC (n = 11), 
Ortho Vitros (n = 19), Roche Cobas (n = 26), Roche Modular (n = 9), Siemens Advia (n = 12), 
Siemens Vista (n = 8), and Siemens Xpand (n = 1) systems. Also manufacturers participated 
in the study with a minimum of three systems in their central application laboratories. 
Because different variants were used for the measurement of certain enzymes, it was not 
always possible to establish a peer group. For example, ALT and AST assays are performed 
either with or without pyridoxale phosphate (PP) activation, and for the measurement of LDH 
there are two method principles available on the market. One method applies the forward 
reaction (lactate to pyruvate), the other the reverse reaction (pyruvate to lactate). 
Study objectives 
The objectives of the study were to assess both assay and laboratory performance, as well 
as their comparability at the peer group level and at the “reference level”. The latter is 
obtained by either comparing the measurements of the laboratories to the Reference 
Measurement Procedure -corrected All Manufacturer Trimmed Mean (RMP-corrected AMTM) 
or to the AMTM (the concept behind these targets is explained on page 150). 
Assessment criteria and performance limits 
Assessment criteria or quality indicators (QI) were i) %-Sy/x from linear regression as 
measure for within-run imprecision (laboratory versus the peer group) and as measure for 
combined imprecision and sample-related effects (laboratory versus the AMTM/RMP-
corrected AMTM, note: this measure is also affected by the AMTM/RMP-corrected AMTM 
uncertainty); ii) bias versus the peer and AMTM/RMP-corrected AMTM at three concentration 
levels; iii) peer and AMTM/RMP-corrected AMTM TE; iv) peer group variation at three 
concentration levels (peer group coefficient of variation, CV). 
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In total, the laboratory quality is judged against two targets with three types of limits, 
and the manufacturer quality against two targets with two types of limits (shown 
schematically in Figure 1). Performance limits were hierarchically structured as laboratory 
performance versus (1) variable limits based on peer group estimates; (2) fixed limits based 
on peer group estimates; (3) fixed limits based on AMTM/RMP-corrected AMTM estimates; 
and assay performance versus (4) fixed limits based on peer group estimates; and (5) fixed 
limits based on AMTM/RMP-corrected AMTM estimates. 
 
Figure 1. Hierarchy of target values and acceptance limits. The laboratory quality is judged 
against two targets with three types of limits (, , and ), and the manufacturer/assay 
quality against two targets with two types of limits (, and ). 
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3. Hierarchy of target values and decision limits 
Targets 
A) Peer target 
Peer group target values were calculated as the mean from laboratories, except the outlying 
laboratories. The latter were identified by a two-sided Grubbs test (13), based on 95% 
probability (20 out of 975 tests = 2.1%). These outliers gave no indication for laboratory or 
assay quality, but were mainly related to peer groups with small variation (for example, four 
labs for chloride and three labs for sodium).  
B) AMTM target 
AMTM target values were calculated as the mean of the peer group targets, except the 
outliers. The latter were also identified by a Grubbs test, but no outliers were detected. 
However, for chloride, the Cobas and Modular were not included in the AMTM because the 
suspected difference versus the other assays was supported by measurements with a RMP. 
C) RMP-corrected AMTM target 
The 20 serum samples were measured with RMPs for ALT, AST, GGT, and LDH (14). Target 
values were assigned by the WEQAS Reference Laboratory in Cardiff (15). The laboratory is 
accredited and participates in the IFCC ring trials for reference laboratories (16). 
Measurements were made in triplicate over four days. Median CV of the RMPs were 4.8% 
(ALT), 2.9% (AST), 3.3% (GGT), and 1.8% (LDH). Supplementary RMP values for chloride 
(10 additional samples) were determined in the INSTAND (Düsseldorf) reference laboratory 
(17). The laboratory is accredited and listed in the Joint Committee for Traceability in 
Laboratory medicine (JCTLM) database (18). 
The RMP values were used to correct the AMTM target, to include the bias 
information from the trueness-based methods. This was done to avoid potentially high 
dispersion of the data in method comparison analysis with the RMP as a target. RMPs often 
apply instrumental analytical procedures which require extensive sample clean-up, and 
involve manual steps. This makes them vulnerable to increased imprecision, low throughput 
and creates high measurement cost. This leads to measuring a low number of replicates. 
Routine procedures, on the other hand, are characterized by very low within-run 
measurement imprecision and are relatively cheap, which favors replication. Method 
comparison studies with RMPs with several routine procedures have the potential of 
combining “the best of two worlds”, namely, high accuracy provided by the RMPs and low 
dispersion of the individual results provided by the AMTM.  
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This is demonstrated in Figure 1 of Article 4 for the GGT case, which shows the %-
differences of two platforms versus the RMP and versus the RMP-corrected AMTM. Data 
distribution and R2-values indicate the superiority of the RMP-corrected AMTM values over 
the RMP-values themselves. The dispersion of the data in the RMP comparison can be 
mainly attributed to the uncertainty of the RMP-values (median CV 3.3%). In consequence, 
potential random sample-related effects cannot be uncovered due to the overriding 
imprecision component of the RMP. The comparison with the RMP-corrected AMTM would 
suggest the absence of sample-related effects in the current examples. Note, while the bias 
information is not relevant for the assessment of random sample-related effects, it is 
conserved in the RMP-corrected AMTM because of the high quality of the regression 
equation between the AMTM and the RMP procedure (r = 0.995). An overview of these 
regression equations can be found in the annex (Supplemental Figure 1; pages 184-185). 
In conclusion, the RMP-corrected AMTM target gives the same bias information as 
the RMP one, but has the advantage of lower distribution. We, therefore, chose the RMP-
corrected AMTM as target value. Note, a more extensive explanation on the RMP-corrected 
AMTM can be found in the article on pages 168-170. 
Decision limits for assay performance 
A) Peer group estimates and limits 
Peer group within-run imprecision was calculated as median laboratory peer Sy/x. Peer 
group variation (calculated as CV) was estimated at the concentration range ends (low and 
high), and at the mean concentration. Assay peer performance was assessed versus fixed 
limits which reflect the state-of-the-art performance of the assays (Table 1). Note, testing 
(estimates versus limits) was done without confidence intervals. The reasoning for choosing 
the respective values is outlined below.  
Table 1 Assay fixed limits for peer group estimates 
 ALP ALT* AST* GGT LDH* Cl K Na 
Sy/x 3.0 5.0 5.0 3.0 3.0 1.0 1.0 1.0 
CV (biology) 3.2 9.7 6.2 6.7 4.3 0.6 2.3 0.3 
Peer CV 5.0 7.5 5.0 7.5 5.0 1.5 2.0 1.0 
Peer TE 11.4 17.7 13.9 15.8 11.4 3.5 4.4 2.8 
* Limits are used for both ALT/AST with and without PP, and for both LDH forward and reverse 
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1. Peer Sy/x 
Peer Sy/x (%) is a measure for within-run imprecision. It is calculated by performing ordinary 
lineair regression of the 20 samples for each laboratory against its peer target. The median 
of those peer Sy/x values was compared against the limits. Chloride, potassium, and sodium 
assays typically have within-run CVs of 0.5%, therefore the limits were chosen at 1% for all 
three. We aimed at 3% for the enzymes, however, we had to expand the values to 5% for 
ALT and AST. The table also contains the desirable total CV derived from desirable 
biological variation (19). 
2. Peer CV 
Due to the low biological variation, chloride and sodium (potassium to a lesser extent) require 
a tight control of bias in the laboratory. This is reflected in the generally good laboratory 
comparability for these tests and allows limits in the order of 1-2%. Therefore, limits of 1.5% 
for chloride, 2% for potassium, and 1% for sodium were chosen. According to the biological 
variation, the enzymes would tolerate higher variation, however, state-of-the-art 
comparability should be in the order of 5%. This could be applied for ALP, AST, and LDH. 
The limits for ALT and GGT had to be expanded to 7.5% because of the low concentrations 
(ALT) and/or possible lot variation.  
3. Peer TE 
The peer group TE was calculated as 1.96CVpeer2+median	Sy/x2 because both QIs (peer 
CV and peer Sy/x) are variance components. 
B) AMTM/RMP-corrected AMTM estimates and limits 
Peer group AMTM/RMP-corrected AMTM Sy/x was calculated as median laboratory 
AMTM/RMP-corrected AMTM Sy/x. The latter is calculated by performing ordinary lineair 
regression of the 20 samples for each laboratory against its AMTM/RMP-corrected AMTM 
target. The peer group AMTM/RMP-corrected AMTM bias was calculated as %-difference of 
a peer group from the AMTM/RMP-corrected AMTM target at three concentration levels; the 
respective confidence intervals were calculated from the respective laboratory biases. Peer 
group AMTM/RMP-corrected AMTM TE was calculated as: TE = Bias + 1.645 * Sy/x. 
Different from above, bias is not treated as variance component; the z-multiplier for 95% 
probability is chosen one-sided because of the bias component. 
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AMTM/RMP-corrected AMTM limits (Table 2) are based on the peer limits. The Sy/x 
limits are the same, while the bias limits are calculated from the peer CV limits plus the 
AMTM/RMP-corrected AMTM uncertainty; TE is calculated as Bias + 1.645.Sy/x. The table 
also contains desirable bias derived from biological variation (19) expanded by the 
AMTM/RMP-corrected AMTM uncertainty. 
Table 2 Assay fixed limits for AMTM/RMP-corrected AMTM estimates 
 ALP ALT* AST* GGT LDH* Cl K Na 
Sy/x 3.0 5.0 5.0 3.0 3.0 1.0 1.0 1.0 
Bias 10.2 9.5 7.0 9.5 7.0 1.9 3.0 1.4 
Bias (biology) 11.9 13.5 8.5 13.1 6.3 0.9 2.8 0.6 
Peer TE 15.1 17.7 15.2 14.4 11.9 3.5 4.6 3.0 
AMTM/RMP-corrected 
AMTM unc. 
5.2 2# 2# 2# 2# 0.4 1 0.4 
* Limits are used for both ALT/AST with and without PP, but only for LDH forward 
# Estimates refer to RMP-corrected AMTM targets 
Decision limits for laboratory performance 
A) Peer group estimates and variable limits 
Laboratory within-run imprecision was calculated as %-Sy/x obtained from ordinary linear 
regression (laboratory versus peer group). Laboratory peer bias was calculated at three 
concentration levels (low, mean, high) as %-deviation from the peer group mean. Laboratory 
peer TE was calculated as TE = Bias + 1.645 * Sy/x. 
 Peer group dependent laboratory limits were calculated as 2 * median peer Sy/x, 2 * 
median peer CV, and 1.645 * median peer TE (see Annex, Supplemental Table 1). Testing of 
the estimates versus the limits was done in “absolute” terms (estimate > limit). 
B) Peer group targets and fixed limits 
Assessment of peer performance was also done versus fixed limits based on the “state-of-
the-art” performance of modern multichannel instruments (Table 3). For imprecision (Sy/x) 
the same limits were chosen as for testing assay performance. The limits for bias and TE 
were expanded by the peer group uncertainty for each analyte individually (indicated in the 
bottom row of Table 3). Testing of the estimates versus the limits was done in “absolute” 
terms (estimate > limit), except testing of laboratory peer bias, which was done by use of the 
confidence intervals of the regression line. 
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Table 3 Laboratory fixed limits for peer group estimates 
 ALP ALT* AST* GGT LDH* Cl K Na 
Sy/x 3.0 5.0 5.0 3.0 3.0 1.0 1.0 1.0 
Bias 6.4 13.5 7.2 9.8 7.1 2.0 2.5 1.3 
TE 12.8 23.7 16.1 18.1 13.5 4.0 4.9 3.1 
Peer 
uncertainty 
1.4 6.0 2.2 2.3 2.1 0.5 0.5 0.3 
* Limits are used for both ALT/AST with and without PP, and for both LDH forward and reverse 
C) AMTM/RMP-corrected AMTM estimates and limits 
Assessment of laboratory AMTM/RMP-corrected AMTM performance was done versus the 
same fixed limits as for the assays (see Table 2 above). Testing of the estimates versus the 
limits was done in “absolute” terms (estimate > limit), except testing of laboratory 
AMTM/RMP-corrected AMTM bias, which was done by use of the confidence intervals of the 
regression line (similar as for the peer group targets and fixed limits).  
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4. Main study outcomes – 2014 survey 
Participants and instruments 
A total number of 126 participants contributed to the 2014 survey. Participants were recruited 
worldwide (Figure 2), but mostly Belgian laboratories participated (n = 69). 
Figure 2. Participants in the Master Comparison 2014 survey. 
With regard to the methods typically used in the participating laboratories, we made the 
following observations: for ALP nearly all laboratories apply the IFCC recommended method, 
however, a few “loners” still apply the Deutsche Gesellschaft für Klinische Chemie (DGKC) 
method (distributed over different manufacturers). For the latter no peer groups could be 
established. The IFCC recommended methods for ALT and AST are performed with PP 
activation. Many manufacturers, however, sell methods with and without PP activation. As 
standardization of enzyme measurements is based on establishing traceability to the IFCC 
recommended methods, all results are compared with the latter, also those that work without 
PP activation. In contrast, since the two method principles for the measurement of LDH, the 
forward and reverse reaction, give grossly different results, we treated LDH as two distinct 
analytes: LDH 1 (forward) and LDH 2 (reverse). LDH 1 results are compared to the RMP 
values while LDH 2 results are compared relatively to each other (note: the AMTM is not 
reliable due to its high uncertainty). Nevertheless, peer group estimates were available for 
LDH 2.  
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Table 4. Number of laboratories per specific assay (manufacturer/assay variant) 
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ALP 21 16 10 26 9 9(D) 8 19 
ALP DGKC 0 3 1 0 0 2 0 0 
ALT + PP 2 9 2 5(A) 4 3(D) 8 19 
ALT - PP 19 10 9 21 5 8 0 0 
AST + PP 2 9 2 5(A) 4 3(D) 8 19 
AST - PP 19 10 9 21 5 8 0 0 
GGT 21 19 11 26 9 11(D) 8 19 
LDH forward 21 9(B) 5 16 4(B) 5 8 0 
LDH reverse 0 5(B) 6 10 4(B) 6(D) 0 19 
Chloride 21 13(B) 11 25(C) 9 12 7(F) 19 
Potassium 21 19 11 26 9 12 7(F) 19 
Sodium 21 19 11 26 9 12 7(F) 19 
Shaded fields: No peer group estimates because of low n and/or high variability. 
(A) Backed-up by manufacturer data 
(B) Some Beckman AU and Roche Modular laboratories did not report LDH and chloride 
(C) One Roche Cobas used a radiometer for chloride 
(D) One Siemens Advia used Beckman calibrators for the enzymes 
(E) One Siemens participant used an Dimension Xpand 
(F) One Siemens Vista laboratory did not report chloride, potassium and sodium 
Typical peer group sizes were n ≥ 7, however, we decided to calculate peer group estimates 
for n <7 when i) results were backed up by manufacturer data, or ii) results fitted in the 
general expected picture of other assays (for example, LDH forward and reverse values). 
Because of too few results, peer groups could not be established for ALP DGKC (all), 
ALT with PP (Architect, DxC, Modular, Advia), ALT without PP (Modular, Vista, Vitros), AST 
with PP (Architect, DxC, Modular, Advia), AST without PP (Modular, Vista, Vitros), LDH 
forward (Modular, Vitros), and LDH reverse (Architect, Vista). Note, for LDH reverse from 
Modular the peer group from Cobas was used.  
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Assay performance 
A) Peer group performance 
Peer group performance data are summarized in Supplemental Table 2 (see annex, page 
188-189). We aimed at 3% Sy/x limits (= measure for within-run imprecision) for the enzymes, 
but expanded them to 5% for ALT and AST because of the low concentration of both 
analytes in the reference interval (the study samples were from apparently healthy 
individuals; some samples were even at the limit of quantitation of certain assays). 
1) Enzymes 
Median Sy/x (%) values were generally in the order of 1.5% for ALP, 4% for ALT, and 2-2.5% 
for AST, GGT and LDH. ALT limits were exceeded by AU (5%), Vitros (8.1%), and Advia 
(5.9%). AST limits were exceeded by Vista (5.4%) while GGT limits were exceeded by DxC 
(4.6%). 
 At the mean concentration, peer CV limits for ALP were only exceeded by AU (5.1%). 
For ALT, the peer CV was generally high (median ~9%) and all but three assays exceeded 
the limits. Peer CV limits for AST were exceeded by Cobas (5.4%), and Vista (7.8%). Peer 
CV values for GGT were somewhat high (median ~7%) and GGT limits were exceeded by 
Modular (8.3%), Advia (8.8%), and Vista (8.1%). For LDH reverse the limits were exceeded 
by AU (8.8%). Peer CV limits at low concentration were exceeded frequently, with many 
additional violations as compared to the ones at mean concentration. However, violations 
were distributed among analytes and test systems so that individual listing is not useful. The 
data indicate a general need for improving peer comparability for enzymes at low 
concentration levels. The number of peer CV violations at high concentration is similar to the 
one at mean concentration, however, with a slight change in violation pattern. Limits for ALP 
were only exceeded by Advia (5.6%). For ALT, all assays (except Cobas + PP) exceeded the 
limits. Limits for AST were only exceeded by AU + PP (5.2%). Also for GGT only AU violated 
the limits (9.4%). DxC exceeded the limits for LDH forward (11.8%) and Advia for LDH 
reverse (7.4%). The observations for peer TE, generally, follow the ones for peer CV.  
Most problems were observed for ALT and GGT. LDH forward and reverse peer 
performance was generally good. 
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2) Ion selective electrode assays (chloride, potassium, sodium) 
Median Sy/x (%) values were generally in the order of 0.5% for all ion selective electrode 
(ISE) assays (chloride, potassium, sodium) and none exceeded the 1% limit. Median peer 
CVs were 1% for chloride, 1.2% for potassium, and 0.8% for sodium. Peer CV limits were 
only exceeded for Modular potassium (2.2%) and Modular sodium (1.1%). 
 At the low concentration range peer CV limits for chloride were exceeded by DxC 
(2.1%), Modular (1.9%), Advia (1.7%), and Vista (1.8%). In the high concentration range, 
limits were exceeded borderline for sodium (AU 1%, Cobas 1%, Modular 1.2%, and Vitros 
1.1%). 
Median peer TE values were 2.2% for chloride, 2.7% for potassium, and 1.6% for 
sodium. Peer TE limits were only exceeded for Modular potassium (4.5%). 
B) AMTM/RMP-corrected AMTM performance 
The assay performance for each analyte is discussed extensively in the manuscript on pages 
171-183. 
Figure 3 shows a graphical overview of the assay %-difference at the mean concentration. 
The bias limits (based on the biological variation model; see Table 2) were exceeded for ALP 
by only the DxC assay (-14.8%); for ALT, by all assays with PP activation but two (Vista and 
Vitros) and by all without PP (range: -25 to -40%); for AST by one assay with PP (Vista: -
26.5%) and two without PP (Architect: -18.6%; Cobas: -18.8%); for GGT by four assays 
(biases ~ 15%, even -28% for the DxC) and two were borderline within the limits (Advia: -
12.7%; Vista: 12.7%); for LDH, the forward reaction, by only one assay (DxC: -17.5%), for 
the reverse reaction, the most deviating assays (Vitros and Modular) differed by ~30%. For 
electrolytes, the assay comparability was good, except for chloride, particularly the Roche 
Cobas assay (-3.6%).  
Table 5 shows similar information in numerical form. Bias differences are tabulated at 
low, mid (mean), and high concentration. Differences that exceed the limits (this time, based 
on state-of-the-art performance) are underlined. 
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Figure 3. Assay %-difference at the mean concentration for ALT (26.0 U/L), AST (25.5 U/L) 
both with and without PP, GGT (25.9 U/L), and LDH forward (174.7 U/L) versus RMP target 
values, and for ALP (68.7 U/L), chloride (104.7 mmol/L), potassium (4.32 mmol/L) and 
sodium (140.1 mmol/L) versus AMTM target values. Note, LDH reverse data are not shown 
because of the high uncertainty of the AMTM. The black-broken boxes indicate the bias 
limits based on desirable biological variation. 
  
160 
 
Table 5. AMTM/RMP-corrected AMTM bias estimates (at low, mid, and high concentration) 
for each assay. 
Bias (%) Limits Architect AU DxC Cobas Modular Advia Vista Vitros 
ALP 10.2 1 7.9 -14.4 -1.9 -5.2 3.5 6.8 1 
  1.1 8.5 -14.8 -1.1 -4.9 5.2 6.5 -0.5 
  1.3 9 -14.9 -1.2 -4.8 3.9 6.4 -1.5 
ALT + PP 9.5 N.A. -39.8 N.A. -29 N.A. N.A. 15.1 50.6 
  N.A. -31.7 N.A. -26 N.A. N.A. -8 4.4 
  N.A. -28.7 N.A. -25.4 N.A. N.A. -12.8 -12.6 
ALT - PP 9.5 -41 -38.3 -8.6 -39.2 N.A. -24.2 N.A. N.A. 
  -33.8 -33.9 -24.2 -37.4 N.A. -30.4 N.A. N.A. 
  -31 -31.2 -30 -36.3 N.A. -29.9 N.A. N.A. 
AST + PP 7 N.A. -9.5 N.A. -9.2 N.A. N.A. -40.5 -0.5 
  N.A. -3.9 N.A. -7.2 N.A. N.A. -26.5 2.2 
  N.A. -2.7 N.A. -6.2 N.A. N.A. -18.5 2.5 
AST - PP 7 -26 -11.3 -0.5 -21.7 N.A. -2.1 N.A. N.A. 
  -18.6 -6.4 -7 -18.8 N.A. -6.6 N.A. N.A. 
  -14.3 -3.2 -10.8 -16.2 N.A. -5.1 N.A. N.A. 
GGT 9.5 -19 -8.9 -31 -18.4 -20.8 -20.3 16.3 -5.8 
  -15.1 -6 -28.3 -14.3 -16.7 -12.7 12.7 -6.7 
  -12 -5.7 -30.5 -11.1 -12.3 -7 9.7 -7.4 
LDH FW 7 -0.4 -1.4 -10.4 -2.9 -5.2 -1.5 5.3 N.A. 
  -0.3 -2.7 -17.5 -3.8 -5.6 -2.7 4.7 N.A. 
  -0.2 -3.5 -14.5 -4.5 -5.8 -4.7 4.2 N.A. 
LDH RV N.A. N.A. N.A. N.A. N.A. N.A. N.A. N.A. N.A. 
  N.A. -3.6 13.5 -10.4 -12.6 -6 N.A. 19.2 
  N.A. N.A. N.A. N.A. N.A. N.A. N.A. N.A. 
Chloride 1.9 0.5 -0.4 -0.2 -3.7 -2.8 -0.2 -0.4 -0.9 
  0.4 -0.2 0.6 -3.6 -2.3 0.2 -0.3 -0.7 
  0.3 -0.2 0.2 -3.6 -2.5 0 -0.9 -0.6 
Potassium 3 -1.6 0.2 -0.6 1.1 -0.1 0.7 -2 2.3 
  -1.6 0.1 -0.3 1.1 0.4 0.4 -2.2 2.2 
  -1.5 -0.2 0.3 1.2 0.1 0.4 -2.5 2.2 
Sodium 1.4 -0.7 -0.1 -0.1 0.1 0 0.6 -0.2 0.5 
  -0.5 -0.2 -0.3 0.2 0.4 0.3 -0.6 0.6 
  -0.4 0 -0.5 0.4 0.4 0.5 -0.9 0.7 
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Chloride AMTM 
The chloride results were characterized by good comparability of the assays, except the 
ones from Roche (Cobas and Modular). The latter ones were considerably lower than the 
others. We decided, therefore, to verify the results with the RMP procedure. Because we had 
no samples of the survey left, we let measure ten other samples in three Cobas routine 
laboratories (with two ISE units each, n = 6) that took part in the study and with the RMP (see 
Table 6 below). 
The Cobas results were, on average, 4.3% (confidence interval 0.6%) lower than the 
RMP results. Similar to that, the Cobas results were ~3.6% lower than the AMTM without 
inclusion of the results by the Roche assays (which is visualized in the scatterplot of Figure 
4). This let us conclude that the Roche ISE results were significantly biased and, therefore, 
were to be excluded them from the calculation of the AMTM. The RMP results, indirectly, 
support the validity of the AMTM. 
 
  
Table 6. Chloride measurements  
 
RMP 
(mmol/L) 
Cobas Mean 
(mmol/L) 
% difference  
105.9 101.0 -4.7  
112.4 107.0 -4.8  
108.0 103.4 -4.3  
106.8 101.8 -4.7  
103.3 100.5 -2.7  
98.0 94.5 -3.6  
104.2 100.5 -3.6  
103.6 97.1 -6.3  Figure 4. Scatter plot for chloride: RMP 
versus Cobas values. 105.7 101.0 -4.4  
101.1 97.3 -3.8   
Average difference: -4.3 (0.6)  
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Laboratory performance 
Table 7 describes the combined imprecision (AMTM/RMP-corrected AMTM Sy/x) and bias 
(versus AMTM/RMP-corrected AMTM target) of all participating laboratories, including those 
which do not have a peer group. These values result from the combined effects of 
laboratories and assays. The differences between the laboratories are particularly influenced 
by assay bias. 
One observes huge differences between the laboratories for all estimates. Maximum 
Sy/x values exceeding two times the AMTM/RMP-corrected AMTM limits (Table 7) are 
indicated by red shading. Very high Sy/x values are observed for enzymes (in particularly, for 
ALT, AST and GGT) and borderline for chloride. 
Maximum absolute biases >15% (red shading) are observed for all enzymes in each 
concentration range. This leads frequently to differences >30% (blue shading) for the most 
deviating laboratories (= Diff 1) and even still for the third most deviating laboratories (= Diff 
3). These differences mainly reflect the assay biases visualized in Figure 3. Maximum 
absolute biases >5% for chloride and potassium, and >2.5% for sodium (red shading) with 
the accompanying differences of >10% and >5% (blue shading) respectively, occur 
occasionally. However, most violations are borderline. A more graphical presentation of the 
complete distribution of laboratory averages, AMTM/RMP biases and AMTM/RMP Sy/x 
values can be found in the annex (Supplemental Figure 2). 
A) Peer FAILs versus Peer Limits  
Laboratories with poorer performance were identified by the frequency of peer failures (n ≥ 5 
failures). 10% of the laboratories (n = 12) accounted for 52% FAIL decisions based on peer 
limits. The respective laboratories are advised to revisit their practices and/or consult the 
manufacturer for assistance.  
B) Peer FAILs versus Fixed Limits 
Laboratories which may profit from an improvement in performance were identified by the 
frequency of peer failures (n ≥ 6 failures) versus fixed limits. 11% of the laboratories (n = 14) 
accounted for 36% FAIL decisions based on fixed limits. The respective laboratories may see 
these results as an incentive for more rigorous QC. 
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Table 7. Overview of the AMTM/RMP-corrected AMTM of all laboratories 
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AMTM/RMP-corrected AMTM Sy/x 
Median 1.5 5.7 4.5 3.5 2.8 2.6 2.0 0.6 0.7 0.5 
Min 0.7 2.3 1.7 2.1 1.4 1.0 1.1 0.2 0.1 0.2 
Max 5.2 15.0 10.6 15.7 6.8 20.5 4.2 2.1 1.4 1.0 
AMTM/RMP-corrected AMTM Bias 
Min -19.5 -46.4 -54.7 -33.2 -23.8 -54.8 -20.1 -5.7 -5.2 -2.2 
Max 18.5 28.2 -2.7 7.1 10.4 29.5 10.8 2.2 4.3 2.9 
Diff 1 33.8 74.1 36.1 38.0 29.7 84.3 30.8 7.9 9.5 5.1 
Diff 2 32.5 65.8 31.1 36.4 17.5 52.7 25.0 7.2 8.8 4.6 
Diff 3 30.5 56.4 27.1 32.9 17.4 49.6 24.3 7.0 8.6 4.2 
AMTM/RMP-corrected AMTM Bias Low 
Min -19.0 -68.7 -67.4 -48.4 -32.1 -74.3 -19.1 -7.8 -5.5 -2.1 
Max 22.2 112.6 26.4 9.6 21.2 52.1 12.4 2.0 4.6 2.8 
Diff 1 37.3 174.6 69.8 57.8 45.6 126.4 31.5 9.8 10.0 4.9 
Diff 2 32.2 147.3 47.8 54.9 31.9 75.9 28.1 8.1 8.9 4.5 
Diff 3 31.2 122.2 42.4 50.5 29.8 60.2 25.9 7.8 8.8 4.5 
AMTM/RMP-corrected AMTM Bias High 
Min -19.9 -40.7 -51.2 -24.6 -22.0 -39.4 -20.8 -5.8 -4.8 -2.3 
Max 18.0 8.4 -11.1 9.2 4.1 14.6 9.8 2.3 4.5 2.9 
Diff 1 33.8 49.1 26.9 30.1 20.7 54.0 30.6 8.1 9.3 5.2 
Diff 2 30.6 34.7 25.8 28.2 16.3 46.2 26.4 7.2 8.5 4.9 
Diff 3 30.2 33.1 24.1 26.1 15.6 44.2 24.9 6.6 8.0 4.6 
Note: LDH reverse is not mentioned since its AMTM is highly uncertain. 
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Study outcomes - laboratory communication: report and laboratory guide 
Participating laboratories received two different Word documents and analyte-specific Excel 
files. One document, the general report, addressed all aspects of the survey (both laboratory 
and assay performance). The other document, the laboratory guide for data interpretation, 
assisted participants in interpreting the Excel files.  
These files were anonymously coded. To interpret their data, participants could open 
the Excel report files and type in cell “A1” their laboratory code (and/or “spin” until their code 
appears). Each file contained four pages. Interpretation of the data was started with the 
investigation of the FAIL decisions in the “Overview” page 4 (see annex page 197). With this 
short summary the participants could easily see how their laboratory and how their assay 
performs versus peer group and AMTM/RMP-corrected AMTM targets. The PASS/FAIL 
decisions on this page were based on an interplay between the laboratory’s and assay’s 
performance. This combined-target approach was applied so laboratories weren’t, for 
example, blamed for bad quality when this was caused by poor assay performance (8). At 
the bottom of page 4 some recommendations were formulated of a general nature that 
should be “translated” into the laboratory and regulatory environment. For example, deviation 
of a laboratory from its peer group is a signal for the respective laboratory to contact the 
manufacturer, whilst violation of a manufacturer’s assay versus biologically derived bias 
limits might be a signal for the manufacturer for improving the calibration stability or the 
assay standardization or harmonization. 
Afterwards, data could be investigated in more detail in the scatter-, %-difference, 
and %-residuals plots (pages 1 to 2; example annex page 196). Page 1 showed how the 
laboratory performs in comparison with its peer, and page 2 showed the comparison with the 
AMTM or RMP-corrected AMTM. Page 3 showed the distribution of the participants for the 
average analyte values, and histograms for the bias-% and Sy/x-% compared to the RMP-
corrected AMTM. An overview of these distributions can be found in the annex 
(Supplemental Figure 2). Participants were recommended to “Spin” through the whole 
dataset to get an impression of the performance of other laboratories.  
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5. Conclusions on the Master Comparison 2014 survey 
The design of our recent EQA study was well suited for monitoring the between-assay 
comparability and/or traceability of assays for five enzymes and three electrolytes. Peer 
performance (within-run imprecision and peer group variability) and assay comparability were 
generally good for all electrolytes. An exception was the negative bias of the Roche assays 
for chloride. 
For enzyme assays both manufacturers and laboratories still have a lot to do to 
accomplish trueness of measurement. Peer performance (within-run imprecision and peer 
group variability) strongly depended on the enzyme measured. ALT assays were particularly 
problematic, possibly due to the nature of the samples (concentrations typically lie in the 
reference interval, whilst the higher concentrations are considered to be more clinically 
important). AMTM/RMP-corrected AMTM Sy/x values were similar to the peer estimates, 
indicating little influence of random sample-related effects. Comparability, or bias versus the 
RMP-corrected AMTM procedure, strongly depended on the enzyme measured. 
 In general, the conclusion for this Master Comparison survey is similar as its 
predecessors: “As good as conventional proficiency testing may be, we can do better” (20). 
The data show the need (i) to phase out the non-IFCC assay variants; (ii) to improve the 
quality, comparability, and standardization of the ALT assays; (iii) to improve the 
comparability of the GGT and LDH assays; (iv) to improve peer comparability at low 
concentration levels; (v) to aim for single-manufacturer efforts for improvement of 
comparability for nearly all enzymes studied. 
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Article 4. Reference measurement procedure corrected all method trimmed 
mean (letter to editor) 
Reference measurement procedure corrected all method trimmed mean 
- The best of two worlds 
Kenneth Goossens1, Linda M Thienpont1* 
1Laboratory for Analytical Chemistry, Faculty of Pharmaceutical Sciences, Ghent 
University, Ghent, Belgium 
 
Reference measurement procedures 
(RMPs) are a vital part of the metrological 
traceability chain (1). They have one 
essential feature: they can break the 
commutability barrier for trueness transfer 
from artificial calibrations solutions (e.g., 
ethanolic standards) to the matrix of 
patient samples. RMPs often apply 
instrumental analytical procedures (e.g., 
mass spectrometry), require extensive 
sample clean-up, and involve manual 
steps (e.g., RMPs for enzymes) (2). These 
features may make them vulnerable to 
increased measurement imprecision, low-
through-put and high measurement costs. 
Particularly the latter is prohibitive for 
RMPs performing a significant number of 
replicate measurements to reduce the 
analytical random error component. In 
contrast, routine procedures generally are 
characterized by very low within-run 
measurement imprecision in the order of 
1-2% and performance at relatively low 
cost, which favors a high number of 
measurements. From this perspective, 
method comparison studies between a 
RMP and several routine procedures have 
the potential of combining “the best of two 
worlds”, i.e., the high trueness provided by 
the RMP and the low dispersion of the all 
method trimmed mean (AMTM) inferred 
from the results by the routine procedures. 
This can be accomplished by correcting 
the bias of the method comparison AMTM 
on the basis of its relationship to the RMP, 
to result in the so-called RMP-corrected 
AMTM. This requires that first linear 
regression is performed between the RMP 
and AMTM measurement results for the 
samples of the method comparison study. 
Then the regression equation is used to 
calculate the RMP-corrected AMTM values. 
This approach requires that the AMTM is 
sufficiently reliable and has a reduced 
random error component. The latter is 
accomplished if the AMTM is calculated 
from the results of a sufficient number of 
assays, i.e., 6 to 8. It can indeed be 
assumed that under these conditions the 
random sample-related effects in the 
measurement results are cancelled out. 
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 Here, we investigated the potential 
of using the above described RMP-
corrected AMTM for the assessment of 
imprecision and random sample-related 
effects of individual routine procedures. 
The data we used are from a method 
comparison study using 20 single donation 
samples from apparently healthy 
volunteers. The samples were measured 
for γ-glutamyltransferase (GGT) in singlet 
on the platforms of 8 manufacturers by a 
representative number of laboratories and 
the IFCC RMP performed in triplicate (2). 
The platforms were the Abbott Architect 
(used by 21 laboratories), Beckman AU (n 
= 19), Beckman DxC (n = 11), Ortho Vitros 
(n = 19), Roche Cobas (n = 26), Roche 
Modular (n = 9), Siemens Advia (n = 11) 
and Siemens Vista (n = 8). The AMTM for 
each sample was calculated as mean of 
the 8 peer group means, after 
investigation for outlying assays (3). 
Performing a Grubbs test did not identify 
any outlying assay. Also no single outlying 
values (z-value > 4) were identified, which 
means that trimming in this specific case 
was not necessary. Linear regression of 
the AMTM and the RMP values gave the 
following equation (including the 95% CI of 
slope and intercept): AMTM = 0.924 (± 
0.045) RMP - 0.816 (± 1.25) (R2 = 0.99), 
hence the RMP-corrected AMTM was 
obtained as (AMTM + 0.816)/0.924. We 
want to clarify that, because the data 
below are a comparison between RMP 
and RMP-corrected AMTM, the absolute 
values for both are practically the same. 
Figure 1 shows the %-difference 
plots of the GGT results obtained by 2 
routine procedures installed on 2 different 
modern platforms compared to the RMP 
(left) and the RMP-corrected AMTM values 
(right) as target. Using the magnitude of 
the R2-values as a criterion, the 
relationship of the procedures’ differences 
to the respective targets was best 
described by a logarithmic equation. 
However, the logarithmic relation was only 
used for the purpose of fitting, and should 
not be interpreted as a causal connection 
between the two methods. Data 
distribution and R2-values indicate the 
superiority of using RMP-corrected AMTM 
values as target over the RMP-values as 
such. Indeed, from visual inspection of 
the %-difference plots the decrease of the 
scatter around the regression line is 
obvious when comparing the left and right 
part of the figure. Also the increase of the 
R2-values is spectacular, i.e., from 0.17 to 
0.73 for one platform and from 0.34 to 
0.94 for the other. The dispersion of the 
data for regression to the RMP values (left) 
can mainly be attributed to the uncertainty 
of the RMP (in the order of 2 - 10%). In 
consequence, under these circumstances, 
random error effects specifically related to 
routine procedure (from high analytical 
imprecision and/or random sample-related 
effects) cannot be uncovered due to the 
overriding imprecision component of the 
RMP. While the bias information is not 
relevant for the assessment of combined 
random error effects, it is conserved in the 
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Figure 1. Demonstration of the effect of using RMP and RMP-corrected AMTM values on 
data dispersion around regression lines (logarithmic relationship); %-difference plots of 
results for γ-glutamyltransferase (GGT) by 2 different routine procedures compared to RMP 
values as such (left part) and RMP-corrected AMTM values (right part). The squared 
symbols and triangles used in the plots represent the differences of the respective routine 
procedures. 
 
RMP-corrected AMTM approach because 
of the high quality of the regression 
equation relating the AMTM and the RMP 
values (R2 = 0.99). 
In conclusion, we demonstrated the 
superiority of using the RMP-corrected 
AMTM over RMP values as such when 
investigating causes of dispersion of 
results from routine procedures 
(imprecision and/or random sample-
related effects) in a method comparison 
study. It is also an interesting approach in 
commutability studies in which one of the 
procedures is a RMP. These studies 
indeed may be limited by a high scatter of 
the results for the patient samples around 
the regression line due to the potentially 
higher measurement imprecision of the 
RMP, if not performed with sufficient 
replication because of too high costs. 
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Article 5. Master Comparison 2014 survey 
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Introduction 
Current trends in healthcare policy are 
about reducing overall costs, while 
preserving quality of patient care. 
Examples of initiatives undertaken in this 
context are: promoting the development of 
uniform clinical practice guidelines for 
disease diagnosis and patient 
management, and/or algorithms for risk 
estimation from biochemical profiles (1, 2); 
providing evidence about the impact of 
treatment options on patient quality of life 
and survival (3); creating awareness of the 
general public about the importance of a 
healthy lifestyle and reacting towards early 
signals of health issues (4). Other 
initiatives are more compelling, such as 
the introduction of the electronic health 
record system (5). Laboratory medicine 
can substantially contribute in aiding these 
new developments, their implementation, 
and control, however, it is crucial that the 
discipline ensures that the data they 
generate are interchangeable and 
consistent. This is because guidelines, risk 
estimates and outcome related studies 
require aggregation of results from 
different research clinical trials or 
population studies, also because the 
informed patient of today often seeks for a 
second clinical opinion and might be highly 
confused by numerically different 
laboratory results from another source. 
Differences in laboratory results are 
caused by test principle and design, 
instrumentation, calibration material and 
commutability, etc. To eliminate the effect 
of these contributing factors, the concept 
of traceability in laboratory medicine has 
been developed (6). However, the success 
of this concept entirely depends on proper 
implementation by the stakeholders 
interested in providing and using 
standardized and interoperable laboratory 
medicine data (7). To fulfill this promise, 
initiatives likely to be successful are, 
among others, those creating evidence of 
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the currently achieved standardization 
status, and/or awareness of laboratories 
and manufacturers where there are still 
limitations. External quality assessment 
(EQA) has earned a well-deserved 
position in this regard (8-11). However, the 
information provided by a common EQA 
design might be limited because of the use 
of processed materials not exactly 
behaving like patient samples (12). In 
addition, the focus is sometimes too much 
on “complex” analytes in the belief that the 
commonly performed high volume tests 
pose little problems (13). We emphasized 
these limitations in a recent study on the 
standardization status of diagnostic 
assays for 8 clinical chemistry analytes 
with use of single-donations samples (14). 
The conclusion of the accompanying 
editorial was “As good as conventional 
proficiency testing may be, we can do 
better. We are indebted to these authors 
for shedding light on a problem we may 
have assumed we did not have and, more 
important, for providing a powerful tool to 
help us make things better” (15). 
Therefore, we think there is a need to 
rebuild the system from scratch, meaning 
to start with the common high volume tests. 
In addition, it should be done from 
descriptive data that create reliable 
evidence and are in the same time 
appealing enough to be translated into 
action by laboratories and manufacturers. 
In that connection, we continued our 
initiative towards performing EQA surveys 
with a dedicated design to emphasize the 
trueness of assays and their comparability 
across manufacturers (14, 16, 17). This 
time we focused on widely used assays on 
modern platforms for analysis of 5 
common enzymes and 3 electrolytes in 
serum. 
Materials and methods 
Study design and samples  
Our EQA design consisted of the use of a 
panel of 20 fresh frozen, single donation 
serum samples (from Solomon Park 
Research Laboratories) [for a detailed 
description of the protocol for sample 
collection, storage, and handling we refer 
to (14)]. The samples were shipped on dry 
ice with the request to measure them for 8 
analytes, i.e., alkaline phosphatase (ALP), 
alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), lactate 
dehydrogenase (LDH), gamma-glutamyl 
transferase (GGT), potassium, sodium and 
chloride. The measurements were done in 
singlet under within-run conditions. In total 
126 laboratories were selected for 
participation to end up with 8 carefully 
controlled peer groups using the 
Abbott/Architect (n = 21), Beckman/AU (n 
= 19), Beckman/DxC (n = 11), Ortho/Vitros 
(n = 19), Roche/Cobas (n = 26), 
Roche/Modular (n = 9), Siemens/Advia (n 
= 12), and Siemens/Vista (n = 8) platforms. 
One loner participated with a 
Siemens/Xpand (n = 1) system. Also the 
manufacturers participated in the study 
with a minimum of 3 systems in their 
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central application laboratories (data not 
shown nor discussed here). In spite of the 
selection of 8 peer groups, Table 1 shows 
that for certain enzymes quite often 
different methods are in use on one and 
the same platform, i.e., for ALP, the 
Deutsche Gesellschaft für Klinische 
Chemie (DGKC) versus International 
Federation of Clinical Chemistry (IFCC) 
method, for ALT/AST, with or without 
pyridoxal phosphate (PP) activation, for 
LDH, the forward and reverse reaction. 
The peer group sizes typically were at 
least 7; if a peer group had less than 7 
participants, its estimates were only 
calculated provided the results were 
backed up by manufacturer data, or fitted 
in the generally expected picture of other 
assays (for example, LDH forward and 
reverse results). Certain peer groups could 
not be established because of too few 
participants, i.e., for ALP DGKC, ALT with 
PP (Architect, DxC, Modular, Advia), ALT 
without PP (Modular, Vista, Vitros), AST 
with PP (Architect, DxC, Modular, Advia), 
AST without PP (Modular, Vista, Vitros), 
LDH forward (Modular, Vitros), and LDH 
reverse (Architect, Vista). 
Statistical data treatment 
Reported results were all converted to 
Système International d’Unités (SI) Units. 
In case a laboratory reported use of a 
factor, its results were converted to the 
original value (without factor). 
Single outlying results were 
identified by their z-value (>4) based on 
the median SD for the 20 samples of the 
respective peer group. Outlying 
laboratories (not included in the peer 
group) were identified by a 2-sided Grubbs 
test, based on 95% probability (18). 
Outlying assays (not included in the 
calculation of the all manufacturer trimmed 
mean (AMTM), see below) were also 
identified by a Grubbs test. 
Target setting  
Target values for data assessment were 
obtained from calculating the AMTM (in 
the case of ALP, LDH reverse, chloride, 
potassium and sodium) (14). For the 
enzymes AST, ALT, GGT and LDH 
forward the AMTM was corrected with the 
values set by the IFCC reference 
measurement procedures (RMP) (RMP-
corrected AMTM) performed in the 
reference laboratory of WEQAS (Cardiff) 
(19-23). The RMP-corrected AMTM was 
calculated using the linear regression 
equation between the AMTM and the RMP 
values (AMTM = a RMP + b; RMP-
corrected AMTM = (AMTM – b)/a). For 
chloride, 10 additional samples were 
measured with the Roche Cobas assay in 
3 laboratories and by the ISO 
17025/15195 reference laboratory of 
INSTAND (Düsseldorf) (24, 25). The 
above reference laboratories are ISO 
17025/15195 accredited and take regularly 
part in the RELA - IFCC EQA scheme for 
Reference Laboratories in Laboratory 
Medicine (26). 
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Table 1 Assay fixed limits for AMTM/RMP-corrected AMTM estimates 
 ALP ALT* AST* GGT LDH* Cl K Na 
Sy/x 3.0 5.0 5.0 3.0 3.0 1.0 1.0 1.0 
Bias 10.2 9.5 7.0 9.5 7.0 1.9 3.0 1.4 
Bias (biology) 11.9 13.5 8.5 13.1 6.3 0.9 2.8 0.6 
Peer TE 15.1 17.7 15.2 14.4 11.9 3.5 4.6 3.0 
AMTM/RMP-corrected 
AMTM unc. 
5.2 2# 2# 2# 2# 0.4 1 0.4 
*Limits are used for both ALT/AST with and without PP, but only for LDH forward 
#Estimates refer to RMP-corrected AMTM targets 
 
Specifications used for the assessment of 
the between-assay comparability and/or 
assay bias  
The between-assay comparability and/or 
assay bias against the AMTM or RMP-
corrected AMTM, as applicable, was 
estimated at 3 concentration levels (low, 
mid, and high). For assessment of the bias, 
specifications (Table 1) that accounted for 
the state-of-the-art performance were 
used. The bias limits were analyte-specific 
established from the peer group CV limits 
and the uncertainty of the AMTM or RMP-
corrected AMTM target, as applicable. The 
former were set on the basis of the median 
peer group variation observed from the 
survey data (5% for ALP, AST and LDH; 
7.5% for ALT and GGT; 1.5% for chloride, 
2% for potassium, and 1% for sodium). 
Also bias specifications derived from 
biological variation were given, but for 
information, only (27, 28). Again the 
desirable limits were expanded for the 
uncertainty of the AMTM or RMP-
corrected AMTM target. 
Results 
Outliers 
Fifty-two single outliers out of 19480 
results were identified (0.3%). Most of 
them were clerical errors. In addition, 20 
laboratory outliers out of 975 tests were 
excluded (2.1%). These outliers gave no 
indication for assay quality, but were 
mainly related to peer groups with small 
variation (e.g., 4 outliers for chloride, 3 for 
sodium). No assay outliers were detected.  
Assay comparability and bias 
Figures 1 to 3 show the assay difference 
plots (%) versus the AMTM or RMP-
corrected AMTM target values, with 
inclusion of the bias limits based on state-
of-the-art performance (red dotted line) 
and biological variation (blue dotted line). 
Note, the here described data 
interpretation is against the above state-of-
the-art limits. 
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Enzymes 
For ALT with PP activation (Figure 1, top 
left) only the Vitros and Vista assays are at 
the mean concentration level within the 
±9.5% bias limits compared to the RMP 
corrected-AMTM, however none of the 
assays meets the bias specifications over 
the whole concentration range, e.g., at the 
low concentration end the bias ranges 
from -40% to 50%, at the high end all 
assays are negatively biased (range from -
29% to -13%). These biases generally 
results in poor between-assay 
comparability. Although the between-
assay comparability is better for those 
without PP activation (Figure 1, top right), 
they again all are negatively biased over 
the whole concentration range (biases in
 
 
 
 
Figure 1. Assay %-difference for alanine transaminase (ALT), aspartate transaminase 
(AST) both with and without pyridoxal phosphate (PP) versus RMP-corrected AMTM target 
values, as applicable, for Abbott Architect (red diamond), Beckman AU (blue square), 
Beckman DxC (black triangle), Roche Cobas (yellow circle), Roche Modular (red square), 
Siemens Advia (blue diamond), Siemens Vista (red triangle), and Ortho Vitros (white circle). 
The red-broken bias limits are fixed limits based on state-of-the-art performance; the blue-
broken limits are desirable bias limits from biological variation (both are listed in 
Supplemental Table S2) (25, 26). 
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the order of -30% to 40%) and exceed the 
limits. The Cobas assay without PP is ~10% 
lower than the variant with PP, while the 
two AU variants have a similar bias.  
For AST with PP activation (Figure 
1, bottom left), all assays but one (Vista) 
compare well and are within the ±7% bias 
limit (Cobas is borderline: -7.2%); their 
bias is independent of the concentration 
range. The Vista assay has a significantly 
negative bias in the high concentration 
range (-20%), which increases to -40% in 
the low range. The AST assays without PP 
activation (Figure 1, bottom right) are 
again all negatively biased over the whole 
concentration range, with the Architect and 
Cobas assays outside the bias limits (bias 
~-20% at the mean concentration level. 
 
 
 
 
Figure 2. Assay %-difference for alkaline phosphatase (ALP), gamma-glutamyl transferase 
(GGT), lactate dehydrogenase (LDH) forward (FW) and reverse (RV) versus RMP-
corrected AMTM or AMTM target values, as applicable, for Abbott Architect (red diamond), 
Beckman AU (blue square), Beckman DxC (black triangle), Roche Cobas (yellow circle), 
Roche Modular (red square), Siemens Advia (blue diamond), Siemens Vista (red triangle), 
and Ortho Vitros (white circle). The red and blue broken limits are the same as described 
for Fig. 1. The Grey zone in the LDH RV figure represent the uncertainty of the AMTM 
target. 
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and even higher at the low end). The 
Cobas assay without PP is in addition ~10-
15% lower than the variant with PP. AU 
without PP is again similar to the variant 
with PP. 
For ALP (Figure 2, top left), 7 of the 
8 assays compare quite well with each 
other and meet the bias specifications of 
~10.2%. Only the DxC assay exceeds the 
limits (-15%). The differences are 
proportional over the whole range.  
The GGT assays (Figure 2, top 
right) show a significant between-assay 
discrepancy, with the 2 most deviating 
assays (Vista and DxC) differing by ~40-
45%. Six out of eight assays (Architect, 
DxC, Cobas, Modular, Advia, Vista) are 
outside the bias limit of ±9.5%. The bias is 
nearly constant over the concentration 
range, apart from a moderate increase at 
the low end. 
For the LDH forward reaction 
(Figure 2, bottom left) 6 out of 7 assays 
(Architect, AU, Cobas, Modular, Advia, 
Vista) are within the bias limit of ~7%. The 
Vista assay is positively biased, while the 
others negatively (with the AU most 
extremely), resulting in a difference of ~23% 
between the most discrepant assays. 
Assays applying for LDH the 
reverse reaction (Figure 2, bottom right) 
give ~2 times higher values than those 
applying the forward one. Their AMTM is 
quite uncertain (~±10%), which is 
indicated in the figure with the grey zone. 
Therefore, those assays are not assessed 
versus the bias limit. Nevertheless, the 
maximum difference between the assays 
amounts to ~30% (Vitros +19.2%, Modular 
-12.6%). Note, although only a low number 
of laboratories measured LDH with the 
Modular forward and reverse reaction, the 
assay is shown because its performance is 
quite similar to the Cobas peer group. 
Electrolytes 
For chloride (Figure 3, bottom left), the 2 
Roche assays (Cobas and Modular) are 
negatively biased as compared to the 
others (Modular: -2.3%, Cobas: -3.6% at 
the mean concentration) and exceed the 
±1.9% limits, therefore, they were not 
included in the calculation of the AMTM. 
This was supported by the results 
obtained by a reference measurement 
procedure confirming the negative bias 
(results not shown here). The other assays 
even met the biological variation bias limit 
(±0.9%). 
All potassium assays (Figure 3, top 
left) are within the state-of-the-art (±3%) 
and even the biological variation bias limits 
(±2.8%); the most deviating assays (Ortho 
and Vista) differ by ~4.5%.  
For sodium, also all assays (Figure 
3, top right) are within the state-of-the-art 
bias limits of ~1.4% and, even, nearly 
within the very tight limits (±0.6%) derived 
from biological variation. 
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Figure 3. Assay %-difference for chloride, potassium, sodium versus AMTM target values, 
as applicable, for Abbott Architect (red diamond), Beckman AU (blue square), Beckman 
DxC (black triangle), Roche Cobas (yellow circle), Roche Modular (red square), Siemens 
Advia (blue diamond), Siemens Vista (red triangle), and Ortho Vitros (white circle). The red 
and blue broken limits are the same as described for Fig. 1. 
 
Discussion 
Targets and limits 
As described, the limits used for 
assessment of bias respect the technical 
capabilities (state-of-the-art performance) 
and account for the uncertainty of the 
targets. Also the desirable bias limits 
inferred from biological variation are given, 
but for information only.  
Samples were assigned with 
reference measurement procedure values 
for ALT, AST, GGT and LDH. These 
values were then used to correct the 
calculated and linearly related AMTM 
values. The resulting RMP-corrected 
AMTM target combines the high accuracy 
provided by the RMP and the low 
dispersion of the results on the basis of 
the AMTM. In addition, the trueness of the 
RMP values is conserved in the RMP-
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corrected AMTM approach, because of the 
high quality of the regression equations.  
For chloride, measurement of 10 
additional serum samples with the 
reference measurement procedure and 
the Roche Cobas assay in 3 laboratories 
indirectly proved the trueness of this 
study’s AMTM target with exclusion of the 
Roche test results. For ALP, LDH reverse, 
sodium and potassium only the AMTM 
target was used. For sodium and 
potassium this was justified because of the 
low between-assay variation, and because 
the AMTM suits the purpose of this study. 
For ALP the AMTM uncertainty was 
relatively low, which justified the use of 
bias limits, whilst for LDH reverse the high 
uncertainty of the AMTM target excluded 
that any bias specification should be used. 
Enzymes 
ALP, ALT, AST, GGT, and LDH are key 
enzymes commonly requested for 
laboratory evaluation of liver - and bone 
disease, myocardial and pulmonary 
infarction (29, 30). Therefore, 
standardization of these assays received 
considerable attention in the past (19-22). 
Although it was strongly hoped that the 
combined effect of the availability of 
reference measurement procedures and 
the traceability requirement of European 
legislation would contribute to improving 
the between-assay comparability for 
enzymes, our study and others prove the 
opposite (31-33). We observed that 
several laboratories still use non-IFCC 
recommended methods (e.g., the DGKC 
methods for ALP and LDH). Also, the 
IFCC recommendation for PP activation in 
the assays for transaminases is not 
adopted, since the majority of laboratories 
belonging to certain peer groups still use 
the methods without PP. This points to the 
need for laboratories to take the 
responsibility of moving to the IFCC 
recommended methods, when available 
on the platform they use. Unfortunately, 
this is not always the case, e.g., on the 
Ortho Vitros system using the LDH reverse 
reaction. As far as concerns the peer 
groups using the IFCC recommended 
methods, our study strikingly revealed 
significant between-assay differences 
and/or biases. This holds particularly true 
for ALT and GGT, 2 assays for LDH, and 1 
assay for ALP and AST. Because of these 
persistent problems, in the Netherlands it 
was decided to harmonize 7 common 
enzyme results through EQA, which 
showed quite successful (34). Naturally it 
would be more cost effective and less 
burdensome for the laboratories if 
standardization could be reached at the 
manufacturer level. Therefore, our study 
included the respective manufacturers 
(results not presented here) in the hope 
that the unique experimental design of our 
EQA study (20 single donations, carefully 
selected peer groups, manufacturer 
participation) will be an extra stimulus for 
further efforts toward global 
standardization of enzyme assays. With 
regard to the individual enzyme assays, 
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our study showed that the AMTM trueness 
is good for AST. In contrast, the ALT 
assays exhibit, in general, a bias of -20% 
in the upper normal range. The 
transaminase assays without PP activation 
showed an expected negative bias of 
approximately -30% (ALT) and -10 to -15% 
(AST). The GGT group as a whole was 
slightly negatively biased, but as already 
indicated above, the major problem for this 
enzyme was the difference between the 
assays. The trueness of the LDH forward 
assay group was good. These 
observations demonstrates that, apart 
from the ALT case, the introduction of the 
IFCC reference measurement procedures 
positively impacted the global trueness of 
enzyme results, but that more effort is 
needed from the individual manufacturer 
to reach satisfactory trueness of their 
assay. 
 A potential weakness of our study 
might be seen in the fact that it used 
samples from apparently healthy 
volunteers, which resulted in enzyme 
concentrations in the normal range, where 
standardization might be considered less 
critical. However, it has been stressed that, 
at least in the upper normal range, 
standardization is as important, in 
particular, for longitudinal assessment (35). 
Also mildly elevated enzyme levels are 
becoming more important for diagnostic 
workup, and offer the potential for new 
applications (29, 30). But again, the full 
merit of traditional and new applications 
depends on the use of properly 
standardized and stable assays. 
Electrolytes 
The comparability between the electrolytes 
assays was generally quite satisfactory, 
giving evidence that all are traceable to 
the respective reference measurement 
procedures. Apart from the Roche chloride 
assays, most had biases to the AMTM 
even meeting (or almost) the biological 
limits. In view of this excellent 
standardization status, the most important 
parameter to control is the 
reagent/calibrator lot-to-lot variation in the 
manufacturing process and the stability of 
performance of the individual laboratory. 
As described, there are strong indications 
that the Cobas and Modular assays are 
effectively biased. 
Conclusion 
The design of our recent EQA study was 
again well suited for monitoring the 
between-assay comparability and/or 
trueness of assays for 5 enzymes and 3 
electrolytes. The agreement between 
electrolyte assays, apart from one for 
chloride, was very good. For enzyme 
assays both manufacturers and 
laboratories still have a lot to do to 
accomplish trueness of measurement. 
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Annex to chapter 4 
Regression equations and %-difference plots between the AMTM and the RMP 
procedure: 
  
  
  
Supplemental Figure 1 (part 1). Regression equations and %-difference plots between the 
AMTM and the RMP for ALT and AST (both with and without PP), GGT, and LDH forward 
(FW). 
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Supplemental Figure 1 (part 2). Regression equations and %-difference plots between the 
AMTM and the RMP for ALT and AST (both with and without PP), GGT, and LDH forward 
(FW). 
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Peer group dependent laboratory limits: 
Supplemental Table 1. Peer group-dependent laboratory limits 
2 * Median Peer Sy/x (%) Architect AU DxC Cobas Modular Advia Vista Vitros 
ALP 2.5 2.7 4.3 1.9 1.2 2.2 4.3 3.0 
ALT  NA 10.1 NA 5.4 NA NA 6.4 16.2 
ALT - PP 8.3 10.3 9.3 6.8 NA 12.7 NA NA 
AST NA 4.6 NA 7.3 NA NA 10.9 4.1 
AST - PP 4.6 5.6 6.0 5.4 NA 6.0 NA NA 
GGT 3.8 3.7 9.1 3.9 4.2 5.0 5.9 5.4 
LDH FW 4.3 3.5 3.9 3.3 NA 3.0 4.1 NA 
LDH RV NA 4.3 4.4 3.0 3.3 4.7 NA 5.4 
Chloride 0.8 1.0 1.1 1.1 1.1 1.0 0.9 0.8 
Potassium 1.3 1.1 1.3 1.0 1.3 1.2 1.5 1.5 
Sodium 0.8 0.9 0.9 0.8 1.1 0.6 1.0 0.9 
2 * Peer CV (%) Architect AU DxC Cobas Modular Advia Vista Vitros 
ALP 5.2 9.5 5.5 5.2 3.7 11.2 9.8 9.5 
ALT NA 21.9 NA 15.9 NA NA 10.3 24.6 
ALT - PP 37.1 32.3 14.7 11.1 NA 34.7 NA NA 
AST NA 5.6 NA 9.7 NA NA 14.4 6.6 
AST - PP 7.9 7.6 9.2 6.5 NA 5.8 NA NA 
GGT 9.9 9.1 7.8 13.5 16.2 16.0 16.2 13.9 
LDH FW 4.2 6.6 5.7 4.3 NA 7.3 5.5 NA 
LDH RV NA 17.6 5.6 4.2 2.1 10.7 NA 4.5 
Chloride 1.4 1.5 1.9 2.2 2.6 2.1 1.6 2.2 
Potassium 3.7 1.7 2.1 3.0 5.0 2.3 0.9 2.5 
Sodium 1.3 1.5 1.5 1.9 2.2 0.9 1.1 2.0 
2 * Peer CV Low (%) Architect AU DxC Cobas Modular Advia Vista Vitros 
ALP 6.0 10.3 5.7 7.4 3.8 9.4 12.3 11.4 
ALT NA 34.5 NA 41.1 NA NA 17.5 38.1 
ALT - PP 52.6 27.5 13.0 27.4 NA 56.7 NA NA 
AST NA 9.9 NA 11.3 NA NA 29.2 12.7 
AST - PP 9.5 7.8 11.7 11.4 NA 21.6 NA NA 
GGT 10.6 10.0 42.0 14.0 18.8 27.6 32.5 22.8 
LDH FW 5.3 10.3 30.7 5.1 NA 7.3 6.3 NA 
LDH RV NA 11.0 7.0 6.1 2.8 12.9 NA 9.8 
Chloride 1.6 1.6 4.2 3.0 3.8 3.4 3.5 2.3 
Potassium 4.0 2.0 2.5 3.2 6.6 2.3 1.1 2.6 
Sodium 1.4 1.9 1.6 1.8 2.3 1.9 1.5 1.9 
NA: not applicable   
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2 * Peer CV High (%) Architect AU DxC Cobas Modular Advia Vista Vitros 
ALP 4.9 8.9 5.5 7.1 3.7 11.2 8.2 8.5 
ALT NA 20.0 NA 9.4 NA NA 23.1 16.8 
ALT - PP 33.1 26.5 16.6 19.3 NA 24.5 NA NA 
AST NA 10.4 NA 6.4 NA NA 9.0 8.4 
AST - PP 8.1 6.0 8.5 9.4 NA 8.9 NA NA 
GGT 10.6 18.8 11.3 13.4 15.0 9.5 4.7 7.6 
LDH FW 5.6 8.8 23.5 4.7 NA 7.4 5.7 NA 
LDH RV NA 8.8 5.4 3.1 2.6 14.7 NA 8.3 
CL 1.4 1.5 3.9 2.1 2.2 3.0 2.8 2.3 
K 3.3 1.8 1.7 2.9 4.8 2.5 1.3 2.6 
NA 1.5 2.0 1.5 2.0 2.5 1.6 1.0 2.1 
Lab Peer TE (%) (1.645x) Architect AU DxC Cobas Modular Advia Vista Vitros 
ALP 9.3 15.9 11.2 9.0 6.3 18.5 17.3 16.1 
ALT NA 38.9 NA 27.0 NA NA 19.7 47.5 
ALT - PP 61.2 54.7 28.1 21.0 NA 59.6 NA NA 
AST NA 11.7 NA 19.5 NA NA 29.0 12.5 
AST - PP 14.8 15.2 17.7 13.6 NA 13.5 NA NA 
GGT 17.1 15.8 19.4 22.6 27.0 27.1 27.8 24.1 
LDH FW 9.7 12.1 11.2 8.8 NA 12.8 11.0 NA 
LDH RV NA 29.3 11.5 8.4 6.2 18.9 NA 11.4 
CL 2.6 3.0 3.5 3.9 4.6 3.7 3.0 3.8 
K 6.3 3.2 4.0 5.1 8.4 4.2 2.8 4.6 
NA 2.5 2.8 2.8 3.3 4.0 1.7 2.4 3.5 
NA: not applicable 
  
188 
 
Peer group performance data: 
Supplemental Table 2. Peer group estimates for Sy/x, CV, and TE (values exceeding the 
limits are shaded in red; limits are listed in red in the left column) 
Median Peer Sy/x (%) Architect AU DxC Cobas Modular Advia Vista Vitros Median 
3 ALP 1.3 1.3 2.1 0.9 0.5 1.1 2.2 1.5 1.3 
5 ALT NA 5.0 NA 2.9 NA NA 3.2 8.1 3.4 
5 ALT - PP 4.2 4.4 4.7 3.4 NA 5.9 NA NA 4.4 
5 AST NA 2.3 NA 4.2 NA NA 5.4 2.1 2.3 
5 AST - PP 2.3 2.7 3.0 2.7 NA 2.5 NA NA 2.7 
3 GGT 1.9 1.8 4.6 1.9 2.2 2.4 3.0 2.7 2.3 
3 LDH FW 2.2 1.7 2.0 1.7 NA 1.2 2.1 NA 1.7 
3 LDH RV NA 2.2 2.2 1.5 1.6 2.4 NA 2.7 2.2 
1 CL 0.4 0.5 0.5 0.5 0.5 0.5 0.5 0.4 0.5 
1 K 0.6 0.5 0.6 0.5 0.6 0.6 0.7 0.7 0.6 
1 NA 0.4 0.4 0.4 0.4 0.5 0.3 0.5 0.5 0.4 
Median 1.3 1.8 2.1 1.7 1.1 2.2 2.1 1.8 
Peer CV (%) Architect AU DxC Cobas Modular Advia Vista Vitros Median 
5 ALP 2.6 5.1 2.8 2.6 1.9 2.0 4.9 4.8 2.7 
7.5 ALT NA 11.0 NA 8.7 NA NA 5.2 12.3 8.7 
7.5 ALT - PP 18.5 13.3 7.4 5.6 NA 9.5 NA NA 9.5 
5 AST NA 2.8 NA 5.4 NA NA 7.8 3.3 3.1 
5 AST - PP 4.0 2.9 4.6 3.3 NA 3.2 NA NA 3.6 
7.5 GGT 5.0 4.2 3.9 6.7 8.3 8.8 8.1 7.0 6.9 
5 LDH FW 2.1 3.3 2.9 2.2 NA 3.9 2.7 NA 2.7 
5 LDH RV NA 8.8 2.8 2.1 1.0 5.3 NA 2.3 2.5 
1.5 CL 0.7 0.7 1.0 1.1 1.1 1.1 0.8 1.1 1.0 
2 K 1.8 0.8 1.1 1.5 2.2 1.2 0.5 1.2 1.2 
1 NA 0.7 0.7 0.8 0.9 1.1 0.4 0.5 1.0 0.8 
Median 2.1 3.3 2.8 2.6 1.8 2.7 3.8 2.8 
Peer CV Low (%) Architect AU DxC Cobas Modular Advia Vista Vitros Median 
5 ALP 3.0 5.2 2.9 3.7 1.9 4.7 6.2 5.7 4.2 
7.5 ALT NA 17.3 NA 20.6 NA NA 8.7 19.0 18.1 
7.5 ALT - PP 26.3 13.8 6.5 13.7 NA 30.2 NA NA 13.8 
5 AST NA 4.9 NA 5.6 NA NA 14.6 6.3 6.0 
5 AST - PP 4.8 3.9 5.9 5.7 NA 10.8 NA NA 5.7 
7.5 GGT 5.3 5.0 21.0 7.0 9.4 13.8 16.3 11.4 10.4 
5 LDH FW 2.7 5.1 15.4 2.6 NA 3.7 3.2 NA 3.4 
5 LDH RV NA 5.5 3.5 3.0 1.4 6.4 NA 4.9 4.2 
1.5 CL 0.8 0.8 2.1 1.5 1.9 1.7 1.8 1.1 1.6 
2 K 2.0 1.0 1.2 1.6 2.8 1.2 0.5 1.3 1.3 
1 NA 0.7 1.0 0.8 0.9 1.2 1.0 0.7 1.0 0.9 
Median 2.8 5.0 3.5 3.7 1.9 4.7 4.7 5.3  
Peer CV high(%) Architect AU DxC Cobas Modular Advia Vista Vitros Median 
5 ALP 2.4 4.4 2.7 3.6 1.8 5.6 4.1 4.3 3.8 
7.5 ALT NA 10.0 NA 4.7 NA NA 11.6 8.4 9.2 
7.5 ALT - PP 16.6 13.3 8.3 9.6 NA 13.0 NA NA 13.0 
5 AST NA 5.2 NA 3.2 NA NA 4.5 4.2 4.3 
5 AST - PP 4.0 3.0 4.2 4.7 NA 4.5 NA NA 4.2 
7.5 GGT 5.3 9.4 5.6 6.7 7.5 4.8 2.3 3.8 5.5 
5 LDH FW 2.8 4.4 11.8 2.4 NA 3.7 2.9 NA 3.3 
5 LDH RV NA 4.4 2.7 1.5 1.3 7.4 NA 4.2 3.4 
1.5 CL 0.7 0.8 2.0 1.1 1.1 1.5 1.4 1.1 1.1 
2 K 1.7 0.9 0.9 1.5 2.1 1.3 0.7 1.3 1.3 
1 NA 0.8 1.0 0.8 1.0 1.2 0.8 0.5 1.1 0.9 
Median 2.6 4.4 2.7 3.2 1.6 4.5 2.6 4.0  
NA: not applicable (low number of laboratories)  
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Peer TE (%) Architect AU DxC Cobas Modular Advia Vista Vitros Median 
11.4 ALP 5.6 10.3 6.8 5.5 3.8 4.4 10.5 9.8 6.2 
17.7 ALT NA 23.6 NA 18.0 NA NA 11.9 28.9 18.0 
17.7 ALT - PP 37.2 27.5 17.1 12.8 NA 22.0 NA NA 22.0 
13.9 AST NA 7.1 NA 13.5 NA NA 18.5 7.6 7.4 
13.9 AST - PP 9.0 7.8 10.7 8.3 NA 8.0 NA NA 8.6 
15.8 GGT 10.4 9.0 11.8 13.7 16.9 17.9 16.9 14.6 14.2 
11.4 LDH FW 5.9 7.4 6.8 5.3 NA 8.0 6.7 NA 6.7 
11.4 LDH RV NA 17.8 7.0 5.1 3.8 11.5 NA 6.9 7.0 
3.5 CL 1.6 1.8 2.2 2.4 2.4 2.3 1.8 2.3 2.2 
4.4 K 3.8 1.8 2.4 3.1 4.5 2.6 1.7 2.8 2.7 
2.8 NA 1.5 1.7 1.7 2.0 2.4 1.0 1.4 2.2 1.7 
Median 5.6 7.8 6.8 5.5 4.2 7.8 8.6 7.3 
NA: not applicable (low number of laboratories) 
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Graphical presentation of the complete distribution of laboratory averages, 
AMTM/RMP biases and AMTM/RMP Sy/x values: 
  
  
  
Supplemental Figure 2 (part 1 – ALT with and without PP). Distribution of laboratory 
averages (blue dotted line represents the RMP-corrected AMTM), AMTM/RMP-corrected 
AMTM bias and AMTM/RMP-corrected AMTM Sy/x. 
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Supplemental Figure 2 (part 2 – AST with and without PP). Distribution of laboratory 
averages (blue dotted line represents the AMTM/RMP-corrected AMTM), AMTM/RMP-
corrected AMTM bias and AMTM/RMP-corrected AMTM Sy/x. 
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Supplemental Figure 2 (part 3 – LDH forward (FW) and reverse (RV)). Distribution of 
laboratory averages (blue dotted line represents the AMTM/RMP-corrected AMTM), 
AMTM/RMP-corrected AMTM bias and AMTM/RMP-corrected AMTM Sy/x. 
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Supplemental Figure 2 (part 4 – ALP and GGT). Distribution of laboratory averages (blue 
dotted line represents the AMTM/RMP-corrected AMTM), AMTM/RMP-corrected AMTM 
bias and AMTM/RMP-corrected AMTM Sy/x. 
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Supplemental Figure 2 (part 5 – chloride and potassium). Distribution of laboratory 
averages (blue dotted line represents the AMTM/RMP-corrected AMTM), AMTM/RMP-
corrected AMTM bias and AMTM/RMP-corrected AMTM Sy/x. 
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Supplemental Figure 2 (part 6 – sodium). Distribution of laboratory averages (blue dotted 
line represents the AMTM/RMP-corrected AMTM), AMTM/RMP-corrected AMTM bias and 
AMTM/RMP-corrected AMTM Sy/x. 
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Screenshot of the analyte-specific Excel files (page 1-3): 
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Extract from the laboratory guide for data interpretation - example of page 4 on the 
analyte-specific Excel files: 
PASS/FAIL Example 1 
FAIL limits 
Your PEER Performance Your FAIL's Peer Group Quality 
Peer Sy/x (%) 3.6 FAIL Median Sy/x (%) 3 
Bias (%) 7.8   Group CV (%) 7.5 
Bias Low (%) 9.3   Group TE (%) 15.8 PEER 
Bias High (%) 6.4   Group 
Results >TE 0   PEER Group Performance FAIL's 
Abs. Total error (%) 13.7 1 Median Sy/x (%) 0.9   
Remark 1 Group CV (%) 5.3   
Group CV Low (%) 7.8 FAIL 
Group CV High (%) 1.4   
PEER Failure Remarks Group TE (%) 10.5   
Peer Sy/x (%) Please check the Imprecision of your system 
FAIL limits 
Your REF c-AMTM Performance Your FAIL's Reference Quality 
REF c-AMTM Sy/x (%) 3.4 FAIL Sy/x (%) 3 
Bias (%) 12.3 FAIL Bias (%) 9.5 
Bias Low (%) 14.2 FAIL Total Error (%) 14.4 PEER 
Bias High (%) 4.9   Group 
Results >TE 16 FAIL PEER Group REF Perf. FAIL's 
Abs. Total error (%) 17.9 7 REF c-AMTM Sy/x (%) 2.5   
Remark 1 Bias (%) 7.5   
Bias Low (%) 10.6 FAIL 
Bias High (%) 3.2   
REF c-AMTM Failure Remarks Total Error (%) 11.6   
REF c-AMTM Sy/x (%) Your FAIL is most probably due to combined Laboratory/System Sy/x 
 Bias (%) Your FAIL is most probably due to combined Laboratory/System Bias 
 Bias Low (%) 
 
Your FAIL is most probably due to high system Bias 
Bias High (%) 
 Results >TE Your FAIL is most probably due to combined Laboratory/System Total error 
Peer FAILS 
You FAIL the Peer Sy/x, which indicates precision problems because most systems operate with Peer 
Sy/x values <3%. 
The Peer Group itself has a high variation at the low concentration (see Group CV Low (%)); this puts 
you at risk to FAIL the comparison with the reference (indeed, you also FAIL the REF low bias limit). 
REF c-AMTM FAILS 
You FAIL most of the REF performance limits. Some of them are most probably a combination of your 
own and your systems performance. The “Low Bias FAIL”, however, is most probably due to system 
bias at low concentration; also the systems shows a FAIL there. 
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5 Chapter V The Empower Project 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter is based upon: 
• De Grande L, Goossens K, Van Uytfanghe K, Stöckl D, Thienpont L. The Empower 
Project – A new way of assessing and monitoring test comparability and stability. 
Clin Chem Lab Med 2015;53:1197-204. 
• Goossens K, Stöckl D, Thienpont L. Empower IVD ● Globe - a status update 
(meeting report). http://www.westgard.com/empower-ivd-globe-2014.htm  
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Highlights 
Each the Percentiler, Flagger and Master Comparison are useful tools for the assessment of 
IVD test stability and comparability. In order to inform stakeholders – both laboratories and 
manufacturers – on the different aspects and outcomes of these studies, a communication 
platform was created which is called the Empower Project. 
 
Highlights of the research: 
 The Empower project is the overarching communication platform on different tools 
with utility to assess the quality of IVD assays. 
 The Empower project informs interested parties worldwide on its progress and 
perspectives by the means of oral and written communication (conferences, posters, 
industry-sponsored workshops, etc.). 
 The Empower project informs participating parties on the outcome of the different 
tools it covers, by the means of reports, both individual and general, and peer-
reviewed publications. 
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1. Introduction – What is the Empower project? 
The primary objective of the Empower project is not only to assess, but also to improve the 
comparability and stability of laboratory tests. To accomplish these goals the project was 
founded on four pillars (see Figure 1): 
1. The Master Comparisons (see chapter 4). 
2.  Virtual EQA 1: mid- to long-term monitoring of patient percentiles using the 
Percentiler (see chapter 2) and the Flagger (see chapter 3). 
3. Virtual EQA 2: mid- to long-term monitoring based on IQC data. This pillar was not 
further investigated. 
4. Conceptual and statistical education tailored to the analytical quality needs of the 
clinical laboratory. 
 
Figure 1. The four pillars of the Empower project. 
To manage the goal of quality improvement, the Empower project aims at establishing a 
bottom-up cooperation between stakeholders interested in quality of performance, i.e. 
laboratories and IVD manufacturers. The project organizers, thereby, try to act as mediator 
between all involved parties. Through this cooperation, reliable evidence should be created 
about quality and stability of laboratory tests from data which are appealing enough to be 
translated into action by the above stakeholders. The work which has been conducted in the 
framework of the Empower project so far, is summarized in the publication on pages 207-218. 
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2. Communication with the participants 
Role of communication in the Empower project 
A key aspect of the Empower project is sustained contact with all stakeholders 
(manufactures, laboratories, LIS providers). This communication is vital to keep the 
interested parties informed on the major findings of the project and is important for the 
recruitment of new participants.  
Forms of communication 
To make laboratories aware of the goals and work of the Empower project, both written and 
oral communication was used: 
• Industry sponsored workshops were held at the IFCC Worldlab – 22nd international 
congress of clinical chemistry and laboratory medicine (22-26 June 2014) in Istanbul 
(Turkey) and at EuroLabFocus – 3rd EFLM-UEMS congress (7-10 October 2014) in 
Liverpool (UK). 
• Posters on different aspects of the Empower project were submitted and presented at 
congresses worldwide. 
• The project was presented on GLIMS user meetings in Paris, Utrecht and Ghent. 
• Manuscripts and invitations were published in different journals. “The Bottom Up 
Approach to Quality Assurance” was published in The Pathologist (1) and was 
translated by Dr. Hassan Bayat in Farsi for an Iranian magazine called the Laboratory 
News magazine in a special issue for the Tehran Quality Improvement Congress 
(extract available in Annex on page 220). A Czech magazine, called the FONS 
bulletin, published an invitation to participate to the Percentiler (2; extract available in 
Annex on page 219). 
• Flyers were distributed at every possible occasion. An extract of this flyer can be 
found in the Annex (page 222). 
In addition, stakeholders were kept informed on the progress and findings of the project: 
• Participants were contacted individually with both short communications and more 
extensive reports which addressed the quality of their own IVD systems compared to 
their peer group and to the state-of-the-art quality. 
• Global reports were written which addressed several aspects of the Empower project 
going from the project status of both the Percentiler and Flagger, and explanation on 
data analysis, to a comparison of the Percentiler findings with the Master Comparison 
results, and a summary on quality-related issues for the different peer group (peer 
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group reports). All these reports were made available on www.stt-consulting.com 
(Empower tab).  
• User meetings were held in Ghent on December 10th 2014 and on December 9th 2015. 
The aim of these meetings was to report on the status of the Empower project. As 
mostly users of the project had registered to attend the meeting, it was the intention 
to have a lively discussion: to learn what they think of the project, and how they use it; 
to know what they appreciate in the project, what is missing or what they would like to 
see changed. The meeting report of the first meeting was published as a guest assay 
on the Westgard website (3; extract available in Annex on page 221). 
Last but not least, several publications in peer-reviewed journals were published: 
• Manuscript in Clin Chem Lab Med: “The Empower project – a new way of assessing 
and monitoring test comparability” (4). 
• Editorial in Clin Chem Lab Med: “A new integrated tool for assessing and monitoring 
test comparability and stability” (5). 
• Percentiler manuscript in Clin Chim Acta: “Monitoring laboratory data across 
manufacturers and laboratories – A prerequisite to make “Big Data” work” (6). 
• Letter to Editor in Clin Chem Lab Med: “On-line flagging monitoring – a new quality 
management tool for the analytical phase” (7). 
• Manuscript in The Pathologist on the use of the Percentiler and Flagger for FT4 and 
TSH: “Monitoring the stability of the standardization status of FT4 and TSH assays by 
use of daily outpatient medians and flagging frequencies” (8). 
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Article 6. The Empower Project 
The Empower Project – A new way of assessing and monitoring test 
comparability and stability 
Linde AC De Grande1, Kenneth Goossens1, Katleen Van Uytfanghe1, Dietmar Stöckl2, 
Linda M Thienpont1* 
1Laboratory for Analytical Chemistry, Faculty of Pharmaceutical Sciences, Ghent 
University, Ghent, Belgium 
2STT-Consulting, Horebeke, Belgium 
 
Introduction 
Manufacturers and laboratories have 
common interest in precise, unbiased, and 
stable in vitro diagnostic assays enabling 
optimal patient care. Although they both 
monitor the above test attributes, they 
have different objectives and access to 
existing data, which are facts that might 
hamper the dialogue between them. For 
example, manufacturers are mainly 
interested in the global performance of 
their assays (= peer performance), while 
laboratories rather focus on their own 
performance. However, for trouble-
shooting purposes, peer performance is 
also of interest to laboratories. 
Manufacturers monitor laboratories by an 
online link with their systems, while 
laboratories have easy access to their own 
data. The data sources can be bridged by 
independent third party programs for peer 
group based combined internal quality 
control (IQC)/external quality assessment 
(EQA). However, this approach has 
limitations. Commutability issues of the 
used materials make that peer group 
assessment cannot give information on 
trueness of performance. Additionally, it 
may cause that variations in patient data 
(e.g., trends and shifts due to reagent lot 
changes) are not well reflected (1-3). 
Besides, continuous monitoring of the 
results is rather the exception and, even if 
done, the data are usually not accessible 
in real-time. In addition, the external 
program providers mostly do not critically 
review or publish the data, but leave the 
interpretation to the participating 
laboratories. This practice is of course 
driven by the commercial surrounding in 
which they operate, which hampers them 
to disclose performance data of individual 
diagnostic manufacturers. In contrast, 
independent national or regional EQA 
schemes theoretically are in the position to 
openly demonstrate the performance of 
commercial test systems. However, this 
requires that sufficient laboratories 
participate, so that the peer groups can be 
well defined. This is for most of the 
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schemes not possible, therefore, they 
rather restrict to assessing the 
competence of laboratories (2, 3). This is 
in turn limited by the fact that EQA 
schemes seldom work with fully 
commutable materials, conduct surveys at 
low frequency and report retrospectively. 
From this perspective, it would be 
desirable to implement an independently 
operated “online” tool that enables to 
monitor comparability and stability 
between peer groups and laboratories 
without being confounded by non-
commutability issues, because it uses real 
patient samples. To maximize the utility of 
the tool, the information should be shared 
between participants and manufacturers 
but within confidentiality constraints. This 
means that an individual evaluation report 
should only be available to the laboratory 
to which it applies. The tool could in the 
same time serve to empower laboratories 
for the future tasks they face, among 
others, providing input for the development 
and implementation of global health-care 
policies.  
In response to these needs, we 
initiated the so-called “Empower” project. It 
is intended to establish a bottom-up 
cooperation between laboratories and 
manufacturers, so that they can pursue 
the common objective of assessing and 
improving test comparability and stability, 
whereby we see our role as independent 
third party mediator. It is our strong belief 
that such a transparent cooperation will be 
of benefit to all stakeholders involved in 
laboratory medicine. The project stands on 
four pillars: i) master comparisons with 
fresh-frozen single-donation serum 
samples; ii) monitoring of patient 
percentiles and iii) IQC, both across 
laboratories and manufacturers; iv) 
conceptual and statistical education about 
analytical quality in the medical laboratory 
(e.g., analytical performance specifications) 
and elaboration of statistically sound and 
“actionable” experiments for analytical 
quality management and assurance. 
Laboratories are free to participate in all 
pillars of our project, or to select the most 
appropriate one(s) for their purpose. Here, 
we report on the status of the project with 
respect to the master comparisons and 
patient percentile monitoring, and share 
the first observations on test comparability 
and stability of performance. 
Materials and methods 
Master comparisons 
As previously described, we conduct the 
master comparison surveys for diagnostic 
assays with panels of 20 fresh frozen, 
single-donation, commutable serum 
samples (each available in a volume of 
~180 mL) (4-6). The samples are prepared 
by the Clinical and Laboratory Standards 
Institute C37-A protocol, however, without 
pooling and filtration, and are dispatched 
on dry ice (7). Participation is made 
conditional of the use of a homogeneous 
test system, i.e., instrument, reagent and 
calibrator from the same manufacturer. 
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The number and selection of laboratories 
is adapted to obtain peer groups 
representing the main manufacturers/ 
diagnostic test systems (~20 laboratories 
per manufacturer/ system). Participation 
also includes the in-house laboratories of 
the respective manufacturers. For each 
survey, we select 8 different analytes from 
the clinical chemistry test menu of modern 
platforms (for the analytes covered up to 
now, see Table 1). The participants are 
requested to do the measurement in 
singlet under within-run conditions. The 
quality of assays and laboratories is 
assessed from 4 quality indicators at the 
peer group and “reference” level. The 
latter uses either the all manufacturer 
trimmed mean (AMTM) or reference 
method values as target: i) the standard 
error of the estimate (% Sy/x) from linear 
regression analysis; if data are compared 
to the peer group mean, the Sy/x is a 
measure for within-run imprecision, if 
compared to the reference target, it 
reflects the combined imprecision (both 
random and sample related effects); ii) 
bias (%) at the mean concentration and 
the range limits (low and high 
concentration end); iii) total error (%); iv) 
the number of results observed outside the 
total error limits. These estimates are 
tested against a hierarchy of decision 
limits, i.e., limits that account for state-of-
the-art performance, but, also limits 
derived from biological variation data (8). 
 
Table 1. Analytes covered in the master comparisons (MC) and patient percentile monitoring 
(PPM) 
Alanine aminotransferasea Glucosec 
Albuminb Lactate dehydrogenasea 
Alkaline phosphatasea Magnesiumb 
Aspartate aminotransferasea Phosphatec 
Calciumb Potassiuma 
Chloridea Sodiuma 
Total cholesterolc Total proteinb 
Creatininec Total triglyceridesc 
Gamma-glutamyl transferasea Uric acid (urate)c 
Analytes only covered in the MC Analytes only covered in the PPM 
HDL-cholesterolc C-reactive protein 
LDL-cholesterolc Total-bilirubin 
a, b, c Analytes covered in references (10), (5) and (6), respectively. 
  
208 
 
Patient percentile monitoring 
We monitor the daily medians of the 
results for 20 commonly measured 
analytes in serum or plasma. All types and 
sizes of laboratories can participate. The 
laboratories calculate instrument-specific 
daily medians from outpatient results and 
send the data by e-mail to our database. 
Several vendors of laboratory information 
systems offer cost-free solutions for 
automatic calculation and electronic 
transfer. Alternative solutions are 
extraction of weekly/monthly data from the 
system and shipment in batch. Formats 
readable in our database are an e-mail 
embedded table, Excel-files, and text-files . 
Note that we do the mapping of the 
laboratories’ mnemonics for the different 
analytes and units for expression of the 
medians. Via a user interface with 
authentication (access by user name and 
password) for secured authorization, the 
participating laboratory can plot for each 
analyte the course of the moving median. 
If a laboratory reports medians for different 
instruments, the moving medians 
(instrument-specific colored) are shown in 
the same plot. For interpretation, 
preliminary desirable limits for mid- to 
long-term bias are included. These are 
guided by biological variation and state-of-
the-art performance. The user application 
allows selection of i) the number of 
consecutive medians (n = 5, 8, 16) used 
for calculation of the moving median, ii) 
time window and iii) exclusion of data from 
weekends. Each plot also shows the long-
term median of the concerned individual 
laboratory, as well as the peer group or all 
devices median (freely to select). 
Additional numerical information is 
provided on the long-term imprecision (the 
so-called “robust CV”, %), and the bias 
calculated in comparison to the peer group 
or all devices target, as well as a 
“desirable” target. Currently we use the 
medians of the reference intervals 
determined in the trueness-based “Nordic 
Reference Interval Project (NORIP)” as 
preliminary reference source for that target 
(9). The user can download and print the 
plots. He has also access to his own 
entries in the database with the possibility 
to filter/sort according to analyte/date. This 
facilitates tracing back on which date 
graphical aberrant observations started. 
The graphical user interface can be 
accessed at https://www.thepercentiler.be/ 
(to see the demo version, log in with 
“demolab” as username and “demo1234” 
as password). 
Results 
Status of the project 
Results of the master comparison surveys 
conducted up to now are described 
elsewhere (4-6, 10). In the most recent 
survey (2014) a total of 125 laboratories 
from 21 different countries (15 in Europe, 
and Australia, Canada, Malaysia, South-
Korea, Singapore and the USA) 
participated. The 5 main manufacturers 
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also joined with their in-house laboratories 
(Abbott, Beckman, Ortho, Roche and 
Siemens). In the patient percentile 
monitoring part, currently 100 laboratories 
from 15 different countries (11 in Europe, 
and Australia, India, Russia, the USA) are 
participating with a total of 182 devices. 
Most of the test systems involved in the 
2014 master comparison survey are also 
represented in percentile monitoring. 
Table 1 shows that most analytes covered 
in the master comparisons (20 until now) 
are also addressed in patient percentile 
monitoring. 
Test performance, comparability across 
manufacturers and laboratory performance 
As described elsewhere in detail, the 
design of the master comparisons with 20 
single-donation commutable samples 
allows to assess different performance 
attributes of the examined assays, and 
also individual laboratory performance (4-
6). Apart from some exceptions, assay 
peer group assessment showed a good 
intrinsic analytical quality in terms of 
within-run and combined imprecision, and 
total error. It also demonstrated sufficient 
robustness for satisfactory performance in 
a daily laboratory context. However, there 
was room for improvement at higher and 
lower concentrations. Assessment at the 
reference level showed for several 
analytes good comparability between 
manufacturers/assays, e.g., for total 
protein, cholesterol, glucose, phosphate 
and uric acid (5, 6), while for others 
considerable calibration differences were 
obvious, e.g., for albumin (5). Particularly 
striking in this regard were the biases 
against the targets for enzymes set by the 
IFCC reference methods (10-15). Also 
long-term assay drift/uncorrected biases 
for a single manufacturer were sometimes 
uncovered, e.g., magnesium, creatinine, 
LDL-cholesterol, phosphate, uric acid and 
chloride in (5, 6, 10). Assessment against 
the reference method or AMTM showed 
for most assays and analytes sufficient 
analytical specificity, but for others 
vulnerability to sample-related effects, e.g., 
HDL- and LDL-cholesterol in (6). The bias 
limits used for assessment demonstrated 
that for certain analytes the state-of-the-art 
is such that most assays, apart from some, 
can meet the desirable biological variation 
bias specifications (e.g. for total protein, 
phosphate, triglycerides, uric acid, alkaline 
phosphatase, and potassium (5, 6, 10)). 
For some biologically more tightly 
regulated analytes, the biologically inferred 
limits are not feasible, e.g., glucose, 
cholesterol and chloride (6), or would 
require improvement of lot-to-lot 
consistency, e.g., calcium (5). In contrast, 
sodium assays showed exceptionally well 
performing, almost within the tight 
biological bias limit (10). Assessment of 
the laboratory performance strikingly 
showed that sometimes large between-
laboratory differences (>30%) occurred for 
all analytes (6, 10). 
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Figure 1. Illustration of the match between the peer group means (red rectangles) in the 
2014 survey of the master comparisons and the median values (blue rectangles) in patient 
percentile monitoring for gamma-glutamyl transferase (GGT) and chloride. 
 
These discrepancies could partly be 
ascribed to the biases in the used assays, 
but likely also point to severe laboratory 
effects on performance of assays in daily 
practice.  
Similar observations were made 
from the patient percentile monitoring data. 
For example, the median values matched 
the aforementioned calibration differences 
revealed for gamma-glutamyl transferase 
and chloride in the 2014 master 
comparison survey (Figure 1) (10). Indeed 
the gamma-glutamyl transferase moving 
median values ranged from ~20 to ~32 
U/L, those for chloride from ~101 to ~105 
mmol/L.  
Stability of laboratory/test performance  
First results from patient percentile 
monitoring show that laboratories with high 
daily throughput and/or low variation in 
patient population typically perform with 
low variation and mostly good 
concordance between the different 
instruments. Other laboratories have a 
higher long-term variation in performance. 
If this is due to a lower throughput or 
higher population variation (typical for 
laboratories operating in a medium-size 
hospital), the variation can partly be 
reduced by selecting a higher n for 
calculation of the moving median. Other 
observations are about drifts or shifts, or 
transient to long-term bias, e.g., between 
different instruments used in a laboratory, 
of one particular instrument compared to 
the others, or of the laboratory compared 
to its peer. Interestingly, shifts or drifts 
sometimes apply for several laboratories 
belonging to the same peer, which 
confirms that they are caused by a major 
manufacturer event, e.g., a reagent or 
calibrator lot change (Figure 2A and B). In 
other cases, laboratories can relate the 
observed instability to a calibration event 
(example shown in Figure 2C). 
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Figure 2. Significant test instability for alanine aminotransferase (ALT) and chloride due to a 
confirmed reagent lot change (A), a calibrator lot change (B) and a laboratory calibration 
event (C). In (A) and (B) it is illustrated how lot changes can disturb the stable performance. 
The long-broken grey line represents the median calculated from all daily medians provided 
by the laboratory to which the graph applies. In (C) the moving median for one of the 
instruments (red colored full line) started to drift around the 20th of December 2013, and on 
February the 12th 2014, both instruments (also the blue one) were recalibrated by the 
laboratory, which caused in both a shift. The shifts moved the medians outside the stability 
zone (shaded area between short-broken grey lines). The black short-broken line represents 
the peer group moving medians in (A), (B) and (C). 
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Although certain observations can rather 
easily be explained, longer observation 
times and more solid peer groups are 
needed for a systematic investigation of 
the root causes.  
Discussion 
The Empower project is an integrated 
quality assurance tool for laboratories and 
manufacturers. Its unique design based on 
real patient results allows to 
assess/demonstrate quality aspects 
without being confounded by 
commutability issues (16, 17). It facilitates 
remediating actions, because it reveals 
major bias components/sources, such as 
the manufacturer (assay), laboratory, 
instrument, the reagent/calibrator lot and 
recalibration by the laboratory itself (Figure 
3). 
 
Figure 3. Assessment (and control) of bias components/sources. Components in black can 
be assessed by the above standing pillar, those in orange cannot; those in red probably also 
can in high-throughput laboratories that mainly work with general practitioners (samples 
almost exclusively from outpatients). 
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The focus of the master 
comparisons, which are conducted across 
assays and laboratories, is on how well 
the intrinsic analytical quality of assays on 
release by the respective manufacturers is 
reproduced by the end users under “field” 
conditions all over the world. Target 
setting is based on reference method 
measurements or the AMTM. These 
targets allow to assess either the real 
traceability (standardization status) or the 
comparability between assays and 
laboratories. The information on 
traceability is of utmost use for the 
discipline of clinical chemistry to 
investigate the extent of implementation of 
standardization efforts. Note in this regard 
the striking example of the bias observed 
for enzyme assays. For the individual 
laboratory it is first-hand information that 
can help in decisions on the acquisition of 
new instruments. As such, the master 
comparisons provide the participating 
laboratories with a reliable calibration fix-
point of their own performance within the 
peer group and of the latter compared to 
other peers. Naturally, this is only a point-
estimate in time that should continuously 
be monitored. This is where patient 
percentile (and IQC) monitoring comes 
into play. Indeed, the stability of the peer 
group calibration fix-points can be 
appreciated from concordant medians 
from outpatient results (Figure 1). In 
addition, laboratories can use their 
medians as a tool to monitor the mid- to 
long-term stability of their own calibration 
status, again in comparison to their peer, 
and/or to uncover shifts/drifts and the 
sources thereof (18). Of course this 
requires that the moving medians in time 
truly reflect the analytical variation, without 
being confounded by other sources of 
variation. In a pilot study we showed that 
by working with medians from outpatients 
and omitting medians from weekends and 
holidays (days with lower throughput 
and/or altered ratios of in- to outpatients), 
the effect of patient population variability 
can be suppressed. We inferred this from 
a congruent course in time of the moving 
medians and mean of daily IQC data (18). 
Meanwhile it is our experience that in high 
throughput laboratories mainly serving 
outpatients, the moving medians can be 
calculated from a low number of daily 
medians (n = 5). This is the ideal number 
for detection of analytical instabilities 
(shifts, drifts). In contrast, for laboratories 
in a hospital context, a higher n is required 
to partly compensate for the effect of a 
more variable patient population and lower 
throughput. We offer in the user interface 
n = 8 or 16, however, the latter is the limit 
to prevent too much smoothing and loss of 
resolution. Another asset of the percentile 
monitoring design is that it shows the 
instrument-specific stability in one plot. 
This allows the laboratories to monitor the 
interchangeability of results among 
different instruments, and/or detect the 
occurrence of instrument-specific special 
events.  
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Notwithstanding the above 
potential of the percentile monitoring tool, 
we recommend the users to do the 
interpretation with caution. Indeed, certain 
influential factors may explain aberrant or 
more variable medians. We learned, for 
example, that in hospital laboratories 
dialysis or oncology patients are often 
registered as outpatient, and that their 
samples are preferentially measured on 
one instrument. Note, however, that by 
closely working with our participants, we 
can share our experience to enable more 
critical interpretation. We also recommend 
sample exchange between partner-
laboratories belonging to the same peer 
group and, preferably, participating in 
patient percentile monitoring, since this 
may be very helpful to exclude or confirm 
observed laboratory biases.  
We want to emphasize that 
monitoring of patient medians is not a 
substitute for daily IQC. We advocate it as 
a complementary observation tool from 
patient data that can cover much longer 
observation times. 
A fundamental question in all parts 
of the Empower project is whether the 
observed differences in quality of 
performance or instability are to be 
considered significant. This points to the 
importance of performance specifications 
for meaningful conclusions (19-22). In the 
absence of a consensus on this topic, we 
use preliminary limits that are guided by 
biological variation (8), and also by state-
of-the-art performance. This means that 
for tightly regulated analytes we expand 
the limits based on biological variation to 
account for the current quality offered by 
manufacturers. Note that for patient 
percentile monitoring we express the limits 
for allowable bias in absolute terms 
(tailored to the used SI-units). The reason 
is that this allows us to show them in the 
user interface as so-called stability limits 
that should not be exceeded by longer 
than 1 week. See, for example, the 
shaded zone between 17 and 19 U/L 
(median ± 2 U/L) in Figure 2A for ALT. 
Interestingly, we found the patient 
percentile monitoring an excellent tool to 
test how realistic our quality goals are, e.g., 
the stability limit of 1 mmol/L for sodium 
(23). For other analytes with very high 
biological variation, such as C-reactive 
protein, we set a general upper limit of 
~10%. 
Another important question is 
which targets to use. For the master 
comparisons part, this is discussed 
elsewhere (6). In the percentile monitoring 
part we compare the medians in first 
instance with the peer group medians, but 
also with a reference median. We use the 
median from the NORIP reference 
intervals, which is, to the best of our 
knowledge, the only source that claims to 
be “trueness-based” (9). The reliability is 
high for analytes such as sodium and 
calcium, but the information for some 
enzymes has to be interpreted critically. 
There have been changes in the IFCC 
recommended methods and it is known 
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that these are either not carefully or 
uniformly adopted by manufacturers. 
Therefore, we still consider NORIP as a 
preliminary reference source and will 
follow up, e.g., by cross comparison with 
the reference interval information from 
manufacturers, and new projects. 
Of course, the utility of our project 
has to be improved on a continuous basis. 
For example, we aim at a platform that 
stimulates the dialogue on a basis of trust 
between the participant laboratories and 
manufacturers. We work on this by 
establishing close contacts with both 
parties. We also plan to develop a new 
tool that investigates the effect of 
analytical (in)stability on a surrogate 
medical outcome, such as the frequency 
of “flagged results” (18). Together with 
realistic quality goals that result in 
meaningful conclusions, this tool might be 
an excellent basis to strengthen the 
physician/laboratory interface by more 
transparent communication on 
performance. The Empower database 
potentially can become a source for “big 
data mining” with utility for studies that 
relate the outcome of therapeutic 
strategies to median values in patient 
cohorts (e.g. the Dialysis Outcomes and 
Practice Patterns Study) (24). From the 
perspective that the project’s general 
emphasis is on interchangeability of 
laboratory results, it can potentially also 
contribute to modern clinical needs such 
as the definition of common reference 
intervals or clinical decision limits, 
implementation of electronic health 
records, and development of evidence-
based clinical practice guidelines for 
application of consistent standards of 
medical care.  
Conclusions 
The Empower project provides evidence 
on the intrinsic quality of assays and how 
this quality is sustained under field 
conditions. It also demonstrates how well 
assays and laboratories compare, and 
how stable they perform. In addition, it 
enables to uncover all major bias 
components/sources. The major asset of 
the project is that it works with data 
generated from real patient samples, and 
can be linked to observations in daily IQC 
practice. From this perspective, we believe 
it is a new integrated tool for modern 
quality management of benefit to all 
stakeholders with interest in reliable 
laboratory data. It can help the discipline 
of clinical chemistry to derive realistic 
quality specifications, and can strengthen 
the laboratory/manufacturer dialogue and 
laboratory/physician interface. Ultimately, if 
the evidence provided by the project is 
translated into action by laboratories and 
manufacturers, it can contribute to a yet to 
be established translational laboratory 
medicine and better patient care. 
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Annex to chapter 5 
Extract from “The Percentiler (Patient Percentile Monitoring) – Invitation to participate” 
(FONS bulletin): 
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Extract from the Farsi translation of “The Bottom Up Approach to Quality Assurance” 
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Extract from the report of the Empower IVD●Globe meeting – Guest assay on 
Westgard QC 
https://www.westgard.com/empower-ivd-globe-2014.htm 
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Extract from the commercial flyer distributed for participation to the Percentiler and Flagger 
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6 Chapter VI Statistical analysis from a 
different viewpoint 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter is based upon: 
• Goossens K, De Grande L, Keller T, Weber S, Thienpont L. Verification of 
reference intervals by the C28 protocol – The alpha error/power trade-off. Clin Chim 
Acta 2014;436:18–19. 
• Goossens K, Van Uytfanghe K, Thienpont L. Calculation of non-commutability 
budgets by t-testing. Clin Chim Acta 2015;438:212–213. 
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Highlights 
The appropriate use of statistics is essential for correct data interpretation in the clinical 
laboratory. Several guidelines are available which aid clinical chemists for their local data 
processing and interpretation, e.g. guidelines for reference interval validation and guidelines 
for commutability assessment. These guidelines, however, have some limitations. That’s why 
we decided to discuss the issues for two of these guidelines and propose a valid alternative. 
 
Highlights of the research: 
 The current C28 reference interval validation protocol should be handled with caution. 
Optimized sampling protocols with an increased number of samples might be 
recommendable to achieve more statistical power. 
 Current commutability assessment protocols fail to recognize non-commutability 
when the analytical variation of a measurement method is quite high. 
 Our t-testing approach can be used as an alternative for commutability assessment 
with consideration of a desirable non-commutability budget in relation to the sample 
size. 
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1. Introduction 
As data handling in the clinical environment heavily depends on the use of statistics, clinical 
chemists face the need to analyze data using the most appropriate statistical tools. On the 
one hand the clinical laboratory relies on descriptive statistics, where it needs to 
quantitatively or graphically describe the data. On the other hand, it relies on inferential 
statistics where it makes statements about the population based on a selection of samples. 
Data interpretation also depends on the nature of the data (e.g. qualitative or quantitative 
data, discrete or continuous data) and each data category requires a different approach for 
analysis. To aid the clinical chemist with selecting the correct statistical approach, the CLSI 
provides several guidelines on a range of different topics (1). These guidelines, however, are 
not without limitations. In this chapter, we will briefly discuss two of those guidelines, point to 
the limitations which can occur, and provide an alternative to avoid them. First, we will 
provide an alternative for the double sampling protocol from the C28 guidelines and secondly 
for the current commutability assessment protocols from the EP14 and EP30 guidelines.  
 
2. Verifying Reference intervals in the clinical laboratory 
The C28 guideline from CLSI provides laboratories and manufacturers with specific 
recommendations for procedures which can be applied to establish and verify reference 
intervals for quantitative laboratory tests (2). By using this document laboratories are, 
amongst others, able to verify the appropriateness of reference intervals for their own 
population. The laboratories can assess the validity of existing reference limits by examining 
a small number of reference individuals (n = 20) with a binomial test. This assessment is 
performed with a double sampling protocol. When no more than 2 of the 20 tested individuals 
fall outside the original reference interval, the original limits are considered valid. When 3 or 4 
results fall outside the original reference interval, a second sampling is performed with, again, 
20 reference individuals. Similar to the first sampling, the limits are considered valid when no 
more than 2 test results fall outside the original reference interval. When 3 or more results fall 
outside the limits in the second sampling set, or when 5 or more results fall outside the limits 
in the first set, the laboratory is advised to consider developing its own reference interval. 
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 This double sampling protocol is applied because it significantly lowers the chance of 
falsely rejecting the existing reference interval. The alpha error equals 7.5%, when the 
reference limits are rejected if more than two test results fall outside the reference interval, 
and it drops from 7.5% to less than 1% when the double sampling protocol is used. However, 
at the same time, using this approach will lower the power of the test, thereby increasing the 
chance of falsely accepting the existing reference interval. This trade-off between alpha error 
and power is discussed in the letter to editor on pages 231-233, where we also describe an 
alternative in the form of an increased number of samples, i.e. 100 samples instead of 20 (3). 
 
3. Commutability assessment of reference materials 
As mentioned in the introduction, traceability of laboratory measurements is essential to 
create comparable results irrespective of time, location, and the measurement system which 
was used (4). Reference materials play an important role in the traceability chain because 
they are used to link patient results to the accepted reference. However, certified reference 
materials used for method calibration can only provide metrological traceability of a 
measurement procedure when they are commutable with it (5,6). This means that they 
should mimic patient samples as closely as possible to minimize matrix effects. 
According to the EP30-A CLSI document, commutability is defined as “equivalence of 
mathematical relationship among the results of different measurement procedures targeting 
the same measurement for a reference material and for representative samples of the type 
intended to be measured” (7). In practice this means, when both reference materials and 
clinical samples are measured with two or more analytical methods, the reference materials 
can only be considered as commutable when they have interassay properties similar to those 
of the clinical samples. If a reference material is not commutable, e.g. due to matrix effects, it 
can’t be used as a calibrator, or better said it will not result in traceability of that result. 
Absence of commutability would introduce an artificial bias, thereby making it impossible to 
determine whether an analytical bias exists in calibration. Several statistical analyses have 
been described to assess commutability of a candidate reference material. Current 
approaches investigate whether the reference material is part of the population of clinical 
samples at a certain probability. For example, whether the reference material is within the 95% 
confidence ellipse of multivariate statistics of the clinical samples (8), within the ± 3Sy/x (or 
another multiple of the standard error of regression) range around the mean (9), or within the 
95% prediction interval around the regression line (10). An extensive overview of these 
methods can be found in the review by Vesper et al (11). The aforementioned approach, 
based on prediction intervals, is adopted by the CLSI EP14 guideline (12). This protocol 
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states that commutability is considered likely when the mean value for the reference material 
falls inside the prediction interval around the regression line constructed with the clinical 
samples (under the condition that linear regression analysis is suitable). Usually, 20 clinical 
samples are measured in trifold in order to construct the regression line. The width of the 
prediction interval around that regression line is inversely proportional to the accuracy of the 
applied procedure. When the accuracy is low, the prediction interval will have a high width, 
when the accuracy is high a low width. This means that methods with lower accuracy are 
less likely to detect a non-commutable reference material.  
In our Clinica Chimica Acta manuscript (13), we describe a new approach that 
investigates whether the reference material is equivalent to the average clinical sample. It is 
based on the two-one-sided t-test approach (TOST, 14). Whereas in literature clinical 
samples are chosen within a wide concentration range to cover the entire clinically relevant 
area, the experiment described in our TOST-approach uses a small range: all clinical 
samples are from a concentration range which is very close to the reference material value. 
The data of the experiment are analyzed using the differences of clinical samples as well as 
reference materials. First, the absolute difference between the mean difference of clinical 
samples measured by two measurement methods and the mean difference of reference 
materials measured by the same two measurement methods is calculated (|∆CS - ∆RM| in 
Figure 1). This value will be equal to or greater than zero. Then a 95%-confidence interval is 
calculated around this absolute difference. The size of this interval will depend on the 
number of replicates measured for both the reference material and the clinical samples. The 
higher the number of replicates, the easier it becomes to prove the equivalence of the 
reference material to the clinical samples. The confidence interval around the absolute 
difference is then compared to a certain test limit. In the manuscript we set these limits equal 
to the bias limit based on the biological variation model extracted from the Westgard 
Biodatabase (15). Only if the confidence interval is entirely within the interval indicated by the 
test limit, commutability of reference materials compared to clinical samples is shown at the 
95% certainty level. In case of the confidence interval enclosing the test limit, or when the 
confidence interval is entirely located outside of the interval, commutability has to be denied 
(see figure 1). A more extensive explanation on our t-test approach can be found in article 8 
(pages 234-236). 
Note, our manuscript is not the only literature which provides an alternative method 
for commutability assessment. Also other researchers in the commutability domain are 
moving away from the traditional methods using prediction intervals, and are handling 
commutability assessment with a t-test approach (16). 
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Figure 1. Interpretation of commutability of a reference material to the clinical samples. 
A: The reference material is not significantly different from clinical sample because the two-
sided 95% confidence interval doesn’t cross the test limit. 
B: The reference material is not significantly different from clinical sample but is not 
equivalent because part of the confidence interval lies outside the range indicated by the 
test limit. In this case a higher number of measurements could prove the commutability of 
the reference material. 
C: The reference material is significantly different from clinical sample but not with 95% 
certainty. 
D: The estimate is significantly different from control and is not equivalent to the control, 
because the 95% confidence interval is located completely outside the interval indicated 
with the test limit.  
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Article 7. Verification of reference intervals by the C28 protocol (letter to editor) 
Verification of reference intervals by the C28 protocol – The alpha 
error/power trade-off 
Kenneth Goossens1, Linde AC De Grande1, Thomas Keller2, Stefan Weber2, Linda M 
Thienpont1* 
1Laboratory for Analytical Chemistry, Faculty of Pharmaceutical Sciences, Ghent 
University, Ghent, Belgium; 2ACOMED statistik, Leipzig, Germany 
 
Medical laboratories are required to 
establish their own reference intervals or 
at least verify those published or given by 
the in-vitro diagnostic manufacturer. 
Typically, laboratories use the verification 
protocol recommended in the C28-
guidelines of the Clinical and Laboratory 
Standard Institute [1]. It makes use of 
twenty reference individuals and applies a 
simple binomial test. A reference interval is 
considered valid when no more than two 
out of twenty samples fall outside the 
reference limits. If three or four samples 
are not included in the interval, a second 
sampling is recommended. Again, two 
samples are allowed to fall outside the 
reference limits. If more samples exceed 
the range, the laboratory should consider 
whether or not to develop its own 
reference interval. 
According to the C28 guidelines 
the reason for performing the double 
sampling protocol is to lower the alpha 
error. Indeed, whilst single sampling 
results in an alpha error or false rejection 
of the reference interval under 
investigation in 7.5% of the cases, it drops 
to less than 1% with double sampling. 
However, the change in power (or beta 
error), which is defined as the probability 
to get a significant test, is not considered. 
While power curves are shown in the C28 
guidelines for the single sampling, none 
are described for the protocol in its entirety. 
Also, the power curves shown in the C28 
guidelines for the displacement of the 
mean are not using the SD units of the 
original distribution. 
Here we present a more 
generalized form of these power curves 
and an alternative sampling protocol. We 
performed calculations with Microsoft 
Excel 2010 using the NORMSINV formula 
and calculated the power using the 
binomial formula. Figure 1 shows power 
curves for both the single (blue) and 
double (red) sampling protocol, limited to a 
Gaussian distribution and two-sided 
reference intervals. The x-axis shows the 
difference between the population 
distribution under investigation versus the 
reference population. It is expressed as a 
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Figure 1: Power curves for the single and double sampling C28 protocol. Single 
sampling: two out of twenty samples allowed outside the reference interval (solid blue line), 
eight out of hundred samples (dotted blue line); double sampling (solid red line). The lower 
x-axis is expressed as a shift in SD units, the upper x-axis in true proportion outside the 
reference interval. 
 
shift by 0 to 1.5 times the SD (relative to 
the reference population, assuming equal 
variances and two-tailed distribution). The 
third curve (blue – dotted line) shows a 
single sampling case with a higher sample 
number (allowing eight out of hundred 
samples to fall outside the reference 
interval). For completeness an alternative 
x-axis shows the true proportion outside 
the reference interval. In this case the 
assumption of normal distribution of data 
is not needed. 
The power curves for the single 
and double sampling protocol show that, 
while the alpha error lowers, power is lost 
when using the double sampling protocol. 
Laboratories are more likely to assume the 
existing reference intervals are suited for 
use with their population, while they 
should have made the conclusion that a 
different reference interval is needed. This 
is a classic case of a trade-off between 
false positives and false negatives (or 
alpha error and power). It demonstrates 
that controlling for falsely positive 
assignments, without reporting beta errors, 
can be misleading. 
Therefore, we propose to handle 
current validation protocols with caution. It 
might even be worthwhile to reconsider 
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the C28 approach, and look for optimized 
sampling protocols. One possible 
approach could be to increase the sample 
size towards more statistical power (which 
was already suggested in the C28 protocol, 
e.g. using sixty or hundred samples 
instead of twenty). The third power curve 
in the graph illustrates that allowing eight 
samples out of hundred outside the 
reference interval results in a higher power, 
and still is capable of achieving a 
reasonable alpha error. 
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Article 8. Non-commutability budgets (letter to editor). 
Calculation of non-commutability budgets by t-testing. 
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1Laboratory for Analytical Chemistry, Faculty of Pharmaceutical Sciences, Ghent 
University, Ghent, Belgium 
 
Reference materials used in laboratory 
medicine either for method calibration or 
trueness control, need to be commutable. 
Commutability assessment is done by 
measurement of the reference material 
and clinical samples by at least two 
different analytical methods. 
Commutability is inferred from statistically 
testing the closeness of agreement 
between the mathematical relationship of 
the measurement results obtained by the 
methods for both groups of samples. A 
non-commutable reference material 
potentially causes artificial measurement 
biases, which can be attributed either to 
the presence of matrix effects or a non-
native analyte. This leads necessarily to 
calibration errors or false conclusions 
about the (dis)agreement of results for 
clinical samples among methods [1]. 
Notwithstanding this, we think it is useful 
to define a reasonable budget (= non 
relevant difference between the mean 
concentrations for the reference material 
and clinical samples) by which a reference 
material can be tolerated to be 
commutable. 
Current approaches for 
commutability testing investigate whether 
the reference material is part of the 
population of clinical samples with a high 
probability, typically 95%. For example, 
whether the reference material is within (i) 
the ± 2SD range around the mean, (ii) 
within the 95% prediction interval around 
the regression line, or (iii) within the 95% 
confidence ellipse of multivariate statistics 
of the clinical samples [1]. 
Here, we describe a new approach 
that investigates whether the reference 
material is equivalent to the average 
clinical sample. It is based on the two-one-
sided t-test approach (TOST, [2]) at a 
single target concentration, which requires 
that both reference material and clinical 
sample are concentration-matched. The 
TOST approach allows the calculation of a 
non-commutability budget under given 
conditions for analytical imprecision (5% α-
error and 90% power).  
For a minimum complexity protocol, 
in which each of 2 methods measures 2 
clinical samples in singlicate (= group 1) 
and 1 reference material in duplicate 
(=group 2) commutability can be proven by 
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Table 1. Sample size calculations for non-commutability budgets using the TOST approach 
(conditions: analytical CV = 1.2%, α-error = 5%, power = 90%) 
 
Generic ALP CHOL CA 
Test/Bias limit1 5.39 x SD∆ 6.7% 3% 0.82% 
Ratio limit/SD∆ 5.39 3.95 1.77 0.48 
Budget (%)2 n (per group) 
0 2 3 8 94 
10 3 3 9 99 
20 3 3 10 117 
30 3 4 12 151 
40 3 4 16 205 
50 4 6 23 295 
60 5 8 35 460 
70 8 13 62 816 
80 16 29 138 1835 
90 60 111 549 7337 
1The limit in the first case is set at a minimum for proving commutability by TOST (when n 
= 2), i.e. 5.39 times SD∆, with SD∆= SD∆CS= SD∆RM =,-∆/0 1	,-∆23  with CS = clinical 
samples, RM = reference materials.  
For ALP, CHOL and CA the limit equals the (biological based) bias limit extracted from the 
Westgard Biodatabase. 
2The non-commutability budget represents the % of the original test limit that can be 
consumed by non-commutability. 
 
TOST, from setting the test limits to 5.39 
times the standard deviation of the 
differences (SD∆). Under these conditions 
no budget for non-commutability is allowed. 
This situation is the starting point in Table 
1, and is referred to as test limit (5.39 x 
SD∆) in the column with heading “generic”. 
As explained above, at this point, the non-
commutability budget is 0%. Table 1 
shows that with increasing sample size 
(calculated with the SAS Power and 
Sample Size software - SAS Institute Inc. 
2007), increasing non-commutability 
budgets (expressed as a percentage of 
the test limit) can be tolerated. For 
example, with n = 16, 80% of the original 
test limit can be consumed by non-
commutability. Table 1 further compares 
the generic test limit with 3 real-case limits 
reflected by the bias (%) that can be 
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tolerated on the basis of the biological 
variation data listed in the Westgard 
Biodatabase, i.e., 6.7% for alkaline 
phosphatase (ALP), 3% for cholesterol 
(CHOL) and 0.82% for calcium (CA) [3]. 
Considering a typical analytical CV of 1.2% 
for the test methods (SD∆ = 1.697%), the 
ratio of the respective bias limits to the 
expected SD∆ amounts to 3.95% (ALP), 
1.77% (CHOL) and 0.48% (CA). The table 
also shows the sample size required to 
allow increasing non-commutability budget 
(from 10% to 90%) for each of the cases. It 
is obvious that the lower the ratio, the 
higher the required sample/measurement 
size. For ALP with a ratio of 3.95%, which 
is close to the generic case, the sample 
sizes required for the tabulated non-
commutability budgets are feasible for the 
single laboratory (n = 29 for a budget of 
80%). In contrast, the feasibility of the 
required sample size 23 for the CHOL 
case is restricted to a 50% non-
commutability budget, whilst for CA, 
already quite high sample sizes (94) are 
needed even without room for a non-
commutability budget. 
In conclusion, we showed that our 
t-testing approach can be used for 
commutability assessment with 
consideration of a desirable non-
commutability budget in relation to the 
sample size. The test limits of the TOST 
could potentially be used as margins in 
equivalence tests [4] and depending on 
the ratio of the test limit versus the SD∆, 
one must perform a low to high number of 
measurements to reach the desired 
budget. For quite low ratios this number 
becomes non-realistic for the single 
laboratory, but can be achieved by 
collective measurement of the reference 
material and clinical samples by several 
laboratories, as is possible in external 
quality assessment surveys [5]. 
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By providing a means to assess certain aspects of the quality of IVD assays, this thesis 
project has the potential to improve their quality. As part of the overarching Empower project, 
it can benefit three parties: (1) the individual clinical laboratory, (2) the IVD industry, and (3) 
the patient and healthcare authorities! In addition, this project creates a platform for improved 
communication between all involved parties. 
1) The laboratory 
The laboratory community can greatly benefit from the general information supplied by the 
Empower project. First of all the applications it provides can aid laboratories in achieving the 
quality required by ISO 15189. This international standard specifies requirements for the 
competence and quality of clinical laboratories. As such it is used in the development of 
quality management systems for the assessment of the laboratories’ own quality and for use 
by accreditation bodies (for the endorsement and recognition of the competence of clinical 
laboratories, 1). Accreditation has, therefore, put a pressure on the laboratories to document 
their analytical quality. When a laboratory participates in the Empower project, it can fulfill 
some of the managerial and technical requirements set in the ISO standard. Indeed, the 
Percentiler and Flagger serve as a direct, real-time quality indicator for laboratory analyses of 
patient samples, as requested by the ISO 15189. By combining patient monitoring with their 
own IQC data, laboratories can create evidence about the mid- to long-term variation of their 
IVD instrument, calibrator, and reagent of the manufacturer (lot-to-lot consistency), and, 
thereby, provide the laboratory community with realistic quality specifications. This evidence 
is backed-up by information from other laboratories using the same assay. By collecting the 
information from a complete peer group, the laboratory’s position is strengthened in claims 
versus the manufacturer. Furthermore, the Master Comparison studies give a calibration fix-
point, information on the basic quality of assays and laboratory performance, as well as 
evidence on the standardization status and comparability of the examined assays. Collecting 
information from both the Percentiler and the Master Comparison surveys from several peer 
groups creates the possibility for cross-comparison between manufacturers, which allows 
insight into the quality and performance of other assays and may aid in selection of future 
test systems. Note, however, that the identity of the manufacturers is currently not being 
disclosed to all participants in the Percentiler/Flagger part of the Empower project. The 
laboratories receive information about the stability issues in their own peer group, but not of 
the other peers. This way of working was adopted in the hope to build a trust relationship 
with the manufacturers. When, however, stability issues remain to be long lasting problems 
the identity might still be disclosed. 
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In addition, laboratories which participate in the project can more transparently 
communicate with their clinicians. The Flagger, for example, has the potential to show the 
impact of performance instability on flagging rates. From this information, clinicians can 
better understand the fluctuations in flagging rate of results due to lot changes. It can also 
help the laboratory to keep the extent of the effect within desirable limits. Laboratories can 
also strengthen their position when clinicians attribute certain observations to an erroneous 
laboratory performance, e.g. increased diagnosis of certain diseases in the patient population 
they see. By consulting the Percentiler and Flagger data and observing the stability of 
performance in time, the laboratory is in a position to counter the clinician’s assumption of 
erroneous laboratory performance. 
2) The IVD manufacturer 
IVD manufacturers can benefit from the Empower project in similar ways as the clinical 
laboratory. They can use the different aspects of the Empower project to assess the quality 
of performance of their IVD assays on real samples under “field” conditions. For the 
manufacturers, it is more relevant to discuss an analytical problem or effect of bias from 
patient results rather than from IQC data. The Percentiler provides this type of information 
and gives manufacturers additional insight on the mid- to long-term stability of their assays. 
In addition, it shows which assays are eligible for stability improvements. For example, when 
most assays under field conditions fail to meet stability specifications based on biological 
variation, this can be regarded as an incentive to improve the current state-of-the-art 
performance. Note, just like the laboratories, the manufacturers only receive information 
about the stability of their own assay (via peer group reports). The identity of other peer 
groups is not disclosed. Additionally, the Master Comparison surveys provide correct 
information on the comparability status of assays. Observations of non-comparability 
between manufacturers or assays can pinpoint the need for standardization efforts. 
Previously conducted surveys show that, even for “simple” clinical chemistry measurands, 
the standardization status of certain assays is still a matter of concern and there is much 
room for improvement (2). 
Furthermore, it is a fact that the burden for a manufacturer is less when he needs to 
react on a group of laboratories presenting the same problem, rather than having to deal with 
a single laboratory having a particular issue. In this regard, compilation of the information 
from all project pillars and structuring according to peer group is utmost beneficial for the 
manufacturers. 
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3) The patient and healthcare authorities 
Finally, also patients can benefit from the quality information the Empower project provides. 
As mentioned in the introduction, the individual patient will see the full test variation 
extending from manufacturer (including assay variants), over laboratories to system sites 
(including lot- and calibration variation). When quality of testing is poor, or when the 
introduced error is significant, it are ultimately the patients who suffer most. Therefore, proper 
patient monitoring and diagnosis requires sufficient between-assay comparability and 
sufficient stability of the used assays. Otherwise poor quality of IVD tests can, for example, 
lead to patients who are being misdiagnosed, who are treated for a longer time than 
necessary, who aren’t treated when needed, etc. Also, poor quality of assays can lead to 
repetition of laboratory testing. This, in turn, leads to an unnecessary increase of healthcare 
costs and has a negative impact on the system’s health economy (3). 
“Big Data” projects like the Empower project have the potential of significantly 
improving assay stability and comparability and, thereby, lowering costs in healthcare. By 
showing the quality which is currently achieved by manufacturers and laboratories the project 
can critically inform healthcare authorities and the patients. Or to quote Sten Westgard on his 
essay on the Empower project (4): 
“Empower IVD and other accuracy-based EQA/PT programs threaten to reveal significant 
method and quality differences, as well as critically inform laboratories. When the truth about 
method quality is revealed, some manufacturers will gain, but more manufacturers will lose; 
some laboratories will be pleased, but more laboratories will be unhappy to learn that they 
need to expend more effort and resources, change methods, change their operations, etc., in 
order to achieve the level of quality they thought they were already achieving.” 
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1. Summary 
Chapter 1 – IQC monitoring 
In the perspective of monitoring the stability of performance of IVD instruments, we 
discussed IQC for four analytes (calcium, sodium, inorganic phosphate, and albumin). We 
determined what type of information can be extracted from these stability studies. IQC data 
from Roche, which were evaluated daily, were visualized with Excel using a moving median 
grouped per 2, 5, 10, or 15 days. These data have proven to be ideal to focus on short-term 
(in)stability effects, however, they can also be used to address mid- to long-term effects. 
Daily IQC data also included the reagent container identification number of each 
measurement performed. With these data one can distinguish between analytical shifts 
which are caused by a new reagent container or by mathematical calibration (by plotting 
each measurement result in a scatterplot). Data provided by Bio-Rad only contained the 
monthly means of the QC materials which were measured daily. This type of data loses its 
ability for early recognition of measurement problems. Therefore, it can only be used to get a 
broad idea about the long-term performance of assays and/or IVD instruments. 
Chapter 2 – The Percentiler 
As a surplus to the established IQC in detecting analytical error, we discussed the Percentiler 
application. This freely available online web tool works with instrument-specific, daily 
outpatient medians. The latter are calculated and transmitted by participating laboratories 
from their middleware or LIS. The data are transmitted by e-mail, which is automatically read 
by our software and transferred into a MySQL database. In the pilot phase the project 
focused on 20 clinical chemistry analytes, FT4 and TSH, and on the instruments of five 
manufacturers (Abbott, Beckman, Ortho, Roche, and Siemens). Graphical and statistical 
interpretation of the data, allowed us to show that the Percentiler has the potential to 
visualize the analytical variation of measurement results from patient samples directly 
(instrument-specifically). It thereby provides real-time global evidence about mid- to long-
term variation of the instrument, calibrator, and reagent. In addition, it can create evidence 
about the reasons for the observed variation: own performance (e.g. recalibration or 
instability) or manufacturer performance (e.g. lot-to-lot-variation). This evidence is backed-up 
by information from other laboratories using the same assay. 
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Furthermore, we showed that the Percentiler is a good tool to demonstrate what 
stability can be achieved by current state-of-the-art performance. The stability limits, covering 
the grey shaded zone in the Percentiler graphs, are guided by the systematic error limits 
based on biological variation. However, we took the current capability of diagnostic 
manufacturers into account and expanded these when necessary. The Percentiler 
observations showed that many laboratories are able to achieve long-term stability within 
these desirable bias limits. Test variability, however, due to calibration and lot changes is still 
a significant problem for several laboratories and manufacturers, especially for certain 
enzymes (ALT, AST). The data further confirms that the ion selective electrode technique for 
chloride (and to a lesser extent for sodium) still has robustness issues. In several private 
laboratories, pre-analytical problems jeopardize the reliability of potassium and LDH testing. 
Finally, we proved that the Percentiler is useful for studying relative assay biases at 
median concentrations. This allows to assess the comparability of the different assays 
available on the market. Normally, the comparability status of the different assays can only 
be reliably assessed with an EQA study making use of commutable samples. However, by 
comparing the Percentiler peer group medians with the Master Comparison survey, we 
showed that the relative comparability between the peer groups was very similar in the 
Percentiler and Master Comparison data, for most analytes and peer groups. 
Chapter 3 – The Flagger 
Apart from the Percentiler, we discussed the Flagger application as an additional tool to 
monitor the (in)stability of assays. This tool makes use of the fact that the LIS alerts clinical 
biochemists about values which fall outside the reference interval, either lower or higher. The 
Flagger functionality is analogous to the Percentiler functionality. It is a freely available online 
web tool, which works with instrument-specific, daily outpatient hypo- and hyper-flagging 
rates. The latter are calculated and transmitted by laboratories from their middleware or LIS. 
The data are transmitted by e-mail, which is automatically read by software into a MySQL 
database. In the pilot phase the project focuses on the same analytes and peer groups as in 
the Percentiler. Participants can use the Flagger, just like the Percentiler, to monitor the 
stability of their instruments versus semi-arbitrarily chosen Flagger limits, which indicate what 
stability can be achieved at the lower and higher concentration ends. We also showed that 
combining the two online monitoring tools together has the additional potential of comparing 
the trends in patient medians with the trends in the hypo- and hyper flagging rate. Although a 
laboratory, thereby, still isn’t capable of translating the effect of limit violations on the clinical 
outcome, it can at least visualize the effect on the flagging rate. 
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Chapter 4 – The Master Comparison surveys 
The Master Comparison surveys make use of freshly frozen single donation serum samples 
from 20 apparently healthy donors. These samples are as commutable as possible and are 
therefore ideally suited to address comparability between both laboratories within a single 
peer group and across assays. In addition, by measuring several analytes with a reference 
measurement procedure these studies are also able to demonstrate the standardization 
status of the different assays. Previously performed Master Comparison studies assessed 
the comparability status of albumin, calcium, creatinine, glucose, HDL-cholesterol, LDL-
cholesterol, magnesium, phosphate, total protein, total cholesterol, triglycerides, and uric 
acid. In our 2014 study we focused our efforts on five common enzymes (ALP, ALT, AST, 
GGT and LDH) and three electrolytes (potassium, sodium and chloride) in eight different 
peer groups. 
Our 2014 Master Comparison survey showed that peer performance and assay 
comparability were generally good for all electrolytes. An exception was the negative bias of 
the Roche assays for chloride. For enzyme assays both manufacturers and laboratories still 
have a lot to do to accomplish trueness of measurement. Peer performance strongly 
depended on the enzyme measured. ALT assays were particularly problematic, possibly due 
to the nature of the samples (concentrations typically in the reference interval). AMTM/RMP-
corrected AMTM Sy/x values were similar to the peer estimates, indicating little influence of 
random sample-related effects. Comparability, or bias versus the RMP-corrected AMTM 
procedure, strongly depended on the enzyme measured. In general, the data show the need 
(i) to phase out the non-IFCC assay variants; (ii) to improve the quality, comparability, and 
standardization of the ALT assays; (iii) to improve the comparability of the GGT and LDH 
assays; (iv) to improve peer comparability at low concentration levels; (v) to aim for single-
manufacturer efforts for improvement of comparability for nearly all enzymes studied. 
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Chapter 5 – The Empower project 
To collect and communicate the combined information from the Master Comparison surveys, 
the Percentiler and the Flagger, the overarching Empower project was created. Its prrimary 
goal is to promote and improve the quality of global IVD testing by “bottom-up” cooperation of 
laboratories and IVD manufacturers. To accomplish these goals, the Empower project was 
founded on four pillars: (i) The Master Comparisons; (ii) virtual EQA 1: mid- to long-term 
monitoring of patient percentiles using the Percentiler and the Flagger; (iii) Virtual EQA 2: 
mid- to long-term monitoring based on IQC data; and (iv) conceptual and statistical education. 
Through the project we have been able to provide evidence on the intrinsic quality of assays 
and how this quality is sustained under field conditions (with data generated from real patient 
samples), to demonstrate how well assays and laboratories compare, and how stable they 
perform, and, in addition, to uncover all major bias components and sources. However, 
maybe most important is that the overarching Empower project functions as a 
communication and/or discussion platform of the Empower project team with both 
laboratories and IVD manufacturers.  
Chapter 6 – Alternative statistical tools 
The appropriate use of statistics is essential for correct data interpretation in the clinical 
laboratory. Several guidelines are available which aid clinical chemists for their local data 
processing and interpretation. These guidelines, however, have several limitations. The 
current C28 validation protocol for reference interval verification, for example, should be 
handled with caution. It tends to sacrifice power in order to avoid the error of falsely rejecting 
the reference interval. As an alternative we propose an optimized sampling protocol to avoid 
the chance of falsely accepting the existing reference interval. One possible approach could 
be to increase the sample size towards more statistical power. 
Also the current EP14 commutability assessment protocol should be handled with 
caution, since methods with lower accuracy are less likely to detect a non-commutable 
reference material. As an alternative we propose a t-testing approach which can be used for 
commutability assessment with consideration of a desirable non-commutability budget in 
relation to the sample size.  
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2. General conclusion 
Quality assurance in the clinical laboratory is essential to guarantee appropriate 
interpretation of clinical tests. In that regard, IQC and EQA have earned a well-established 
position. However, these tools don’t necessarily reflect the reality of patient testing due to 
non-commutability issues. We have, therefore, proven that the Empower project is a valid 
tool to circumvent that problem. When this project is integrated in the current QC 
environment, it can establish a bottom-up approach to quality assessment which facilitates 
collaboration between laboratories and IVD manufacturers. It has the potential to create 
reliable evidence about the intrinsic quality of assays and how this quality is sustained under 
field conditions. 
The Percentiler and Flagger have proven to be efficient tools for real-time monitoring 
of the mid- to long-term stability of assays, instruments, calibrators, and reagents. In addition, 
they create evidence about the reasons for the observed variation (lab performance or 
manufacturer performance), and translate the effect of analytical instability on the surrogate 
medical outcome. Although some issues, such as population variation and stratification 
differences, must still be taken into account, clinical laboratories can use these tools to 
directly relate analytical instabilities to their effect on the patient medians and on the hypo-
and hyper-flagging rates. Therefore, these tools can be applied as a stimulus for both 
laboratories and manufacturers to work towards improved assay stability, when needed.  
The Master Comparison surveys, which focus on the current standardization and 
comparability status of commonly used commercial assays, showed that even for “simple” 
clinical chemistry measurands such as enzymes and electrolytes, the standardization and/or 
harmonization status of certain assays is still a matter of concern and there is much room for 
improvement. 
 
From this perspective, we believe the Empower project is a new integrated tool for 
modern quality management which is of benefit to all stakeholders with interest in 
reliable laboratory data. 
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Samenvatting en 
algemene conclusie 
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1. Samenvatting 
Hoofdstuk 1 – IQC monitoring 
In het kader van stabiliteitsmonitoring van de prestatie van IVD instrumenten, hebben we 
IQC besproken voor vier analieten (calcium, natrium, anorganisch fosfaat, en albumine). We 
hebben bepaald welke informatie we kunnen extraheren op basis van deze stabiliteitsstudies. 
De IQC dataset van Roche, die dagelijks werd gemeten en geëvalueerd, werd gevisualiseerd 
met Excel aan de hand van een bewegende mediaan gegroepeerd per 2, 5, 10 of 15 dagen. 
Deze dataset was ideaal geschikt om korte-termijn (in)stabiliteitseffecten waar te nemen, 
maar de data was ook bruikbaar in het bestuderen van midden- tot lange-termijn effecten. De 
dagelijkse IQC dataset bevatte ook een identificatienummer van de container van de 
reagentia per meting. Met deze data kan men een onderscheid maken tussen de container- 
en kalibratie-effecten (door elk meetresultaat uit te zetten in een scatterplot). De IQC dataset 
van Bio-Rad rapporteerde enkel het maandelijks gemiddelde van de dagelijks gemeten QC 
materialen. Dit soort dataset verliest de mogelijkheid om analytische meetproblemen vroeg 
op te sporen en kan daarom enkel gebruikt worden om een idee te krijgen van de lange-
termijn prestaties van assay’s en/of IVD instrumenten. 
Hoofdstuk 2 – De Percentiler 
Bovenop de gevestigde IQC hebben we ook de Percentiler applicatie besproken om 
analytische fouten te detecteren. Deze gratis beschikbare online webtool werkt met 
dagelijkse instrument-specifieke medianen van ambulante patiënten. Die data wordt door 
een deelnemend labo berekend en verstuurd met hun middleware of LIS. De data wordt 
vervolgens verstuurd via e-mails, die automatisch ingelezen worden door onze software in 
een MySQL database. In de pilootfase van het project werd de focus gelegd op 20 analieten 
van de klinische chemie, FT4 en TSH en op de instrumenten van vijf fabrikanten (Abbott, 
Beckman, Ortho, Roche, en Siemens). Grafische en statistische interpretatie van de data 
toonde aan dat de Percentiler in staat is om de analytische variatie van meetresultaten van 
patiënten rechtstreeks te visualiseren (instrument-specifiek). Daardoor levert het wereldwijd 
bewijs over de midden- tot lange-termijn variatie van instrumenten, kalibratoren, en reagentia. 
Bovendien kan het bewijzen leveren over de reden van de geobserveerde variatie: kwaliteit 
van het labo (bv. herkalibraties of instabiliteit) of kwaliteit van de fabrikant (bv. variaties 
tussen verschillende loten). Dit bewijs wordt nog eens versterkt met informatie van labo’s die 
dezelfde assay’s gebruiken. 
 
  
251 
 
Daarnaast hebben we getoond dat de Percentiler een goeie tool is om te 
demonstreren welke stabiliteit bereikt kan worden met de huidige “state-of-the-art” prestaties. 
De stabiliteitslimieten, aangeduid met de grijze zone in de Percentiler grafieken zijn 
gebaseerd op de systemische fout limieten gesteund op het concept van biologische variatie. 
Maar, we hebben de huidige capaciteiten van de IVD toestellen in rekening gebracht en deze 
limieten verbreed wanneer dat nodig was. De Percentiler observaties toonden aan dat veel 
van de deelnemende labo’s in staat zijn om lange-termijn stabiliteit aan te houden binnen 
deze vooropgestelde limieten. Testvariabiliteit, als gevolg van kalibraties en lotwijzigingen, 
blijft helaas een significant probleem voor verschillende labo’s en fabrikanten. Zeker in het 
geval van bepaalde enzymen (ALT, AST). De data toont bovendien aan dat de ion-selectieve 
electrode techniek voor chloride (en in mindere mate voor natrium) nog steeds problemen 
heeft met de robuustheid. In sommige privélabo’s brengen preanalytiek problemen dan weer 
de betrouwbaarheid van kalium en LDH assay’s in gevaar. 
 Verder hebben we aangetoond dat de Percentiler kan gebruikt worden om de 
relatieve bias van de assay’s bij de mediaan concentratie te bestuderen. Dat maakt het 
mogelijk om de vergelijkbaarheid van de verschillende assay’s op de markt te beoordelen. 
Normaal gezien kan die vergelijkbaarheid van de assay’s enkel beoordeeld worden met een 
EQA studie die gebruik maakt van stalen die commutabel zijn. Maar, door de peer groep 
medianen van de Percentiler te vergelijken met de data van de Master Comparison studies, 
toonden we aan dat de relatieve vergelijkbaarheid tussen de peer groepen in de Percentiler 
sterk vergelijkbaar was met de Master Comparison data. 
Hoofdstuk 3 – De Flagger 
Naast de Percentiler, hebben we ook de Flagger besproken als extra tool om de stabiliteit 
van assay’s te monitoren. Deze tool maakt gebruik van het feit dat het LIS de klinisch bioloog 
alarmeert wanneer waarden buiten een referentie-interval vallen (zowel lager als hoger). De 
Flagger functioneert compleet analoog zoals de Percentiler. Het is een gratis beschikbare 
online webtool die werkt met dagelijks instrument-specifieke “hypo- en hyper-flagging rates”. 
Die data wordt door een labo berekend met hun middleware of LIS en wordt vervolgens 
verstuurd via e-mails, die automatisch ingelezen worden door onze software in een MySQL 
database. In de pilootfase werd de focus gelegd op dezelfde analieten en peer groepen als 
in de Percentiler. Deelnemers kunnen de Flagger dus op dezelfde manier gebruiken als de 
Percentiler om de stabiliteit van hun instrumenten te vergelijken met semi-arbitrair gekozen 
Flagger limieten, die aantonen welke stabiliteit kan bereikt worden bij de laagste en hoogste 
concentraties. Bovendien hebben we aangetoond dat, indien men de twee online monitoring 
tools combineert, men additioneel in staat is om de trends van de patiëntenmedianen te 
vergelijken met de trends van de “hypo- en hyper-flagging rates”. Alhoewel een labo dan nog 
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steeds niet in staat is om het effect van limietoverschrijdingen te vertalen in het klinische 
effect, kan het ten minste het effect op de “flagging rate” visualiseren. 
Hoofdstuk 4 – De Master Comparison studie 
Deze Master Comparison studies maken gebruik van vers ingevroren enkel-donatie 
serumstalen van 20 schijnbaar gezonde individuen. Deze stalen zijn zo commutabel als 
mogelijk en zijn daarom ideaal geschikt om de vergelijkbaarheid van labo’s binnen en tussen 
peer groepen te onderzoeken. Bovendien, doordat sommige analieten werden gemeten met 
een referentieprocedure, is het ook mogelijk om deze studies te gebruiken om de 
standaardisatiestatus van verschillende assay’s te demonstreren. Master Comparison 
studies, die voorafgaand aan dit doctoraal werk werden uitgevoerd, bestudeerden de 
vergelijkbaarheidsstatus van albumine, calcium, creatinine, glucose, HDL- en LDL-
cholesterol, magnesium, fosfaat, totaal-eiwit, totaal-cholesterol, triglycriden en urinezuur. In 
de recente studie uitgevoerd in 2014 legden we de focus op vijf enzymen (ALP, ALT, AST, 
GGT, en LDH) en drie elektrolyten (kalium, natrium en chloride) in acht verschillende peer 
groepen. 
 Onze 2014 master Comparison studie toonde aan dat peer prestaties en assay 
vergelijkbaarheid doorgaans goed zijn voor alle elektrolyten. Een uitzondering was de 
negatieve bias van de Roche assay’s voor chloride. In het geval van enzymen hebben zowel 
fabrikanten als labo’s nog veel te verwezenlijken met betrekking tot de “trueness” van hun 
metingen. De prestaties van de peer groepen waren sterk afhankelijk van het gemeten 
enzym. Vooral ALT assay’s waren problematisch, vermoedelijk door de aard van de stalen 
(concentraties binnen het referentie-interval). AMTM en RMP-gecorrigeerde AMTM Sy/x 
waarden waren vergelijkbaar aan de geschatte peer waarden, wat aanduidt dat er weinig 
invloed optrad van staal-gerelateerde effecten. De kwaliteit van de vergelijkbaarheid, of bias 
ten opzichte van de RMP-gecorrigeerde AMTM procedure, was sterk afhankelijk van het 
gemeten enzym. In het algemeen toonden de data nood aan (i) het verwijderen van niet-
IFCC assay varianten; (ii) het verbeteren van de kwaliteit, vergelijkbaarheid en 
standaardisatie van ALT assay’s; (iii) het verbeteren van de vergelijkbaarheid van de GGT 
en LDG assay’s; (iv) het verbeteren van de peer vergelijkbaarheid bij lage concentraties; (v) 
het streven van de fabrikanten om de vergelijkbaarheid van enzymen te verbeteren. 
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Hoofdstuk 5 – Het Empower project 
Om alle informatie van de Master Comparison studies en van de Percentiler en Flagger 
samen te bundelen en te verspreiden werd het Empower project gecreëerd. Het doel van dit 
project is om de vergelijkbaarheid en stabiliteit van labotesten te bestuderen en te verbeteren 
via bottom-up samenwerking tussen labo’s en IVD fabrikanten. Om deze doelen te vervullen, 
werd het project onderverdeeld in vier onderdelen: (i) de Master Comparisons; (ii) virtueel 
EQA 1: midden- tot lange-termijn monitoring van patiëntenpercentielen met behulp van de 
Percentiler en Flagger; (iii) Virtueel EQA 2: midden- tot lange-termijn monitoring gebaseerd 
op IQC data; en (iv) conceptuele en statistische educatie. Met dit project zijn we in staat om 
bewijs te leveren over de huidige intrinsieke kwaliteit van assay’s en of die kwaliteit stand 
houdt onder labocondities (met data gegenereerd van echte patiëntenstalen). Met dit project 
zijn we in staat te demonstreren hoe goed assay’s en labo’s vergelijken met elkaar, en hoe 
stabiel ze presteren, en zijn we instaat om alle voorname bias componenten op te sporen. 
Maar bovenal functioneert het Empower project als een communicatie-, en discussieplatform 
tussen het Empower project team en zowel de labo’s als de IVD fabrikanten. 
Hoofdstuk 6 – Alternatieve statistische tools 
Het gebruik van statistiek is essentieel voor correcte interpretatie van de data in een klinisch 
labo. Verschillende gebruiksaanwijzingen zijn beschikbaar die de klinisch bioloog helpen om 
hun lokale data te verwerken en interpreteren. Deze gebruiksaanwijzingen hebben helaas 
een aantal limieten. Het huidige C28-validatieprotocol om referentie-intervallen te 
interpreteren, bijvoorbeeld, moet voorzichtig gehanteerd worden. Dit protocol prefereert het 
opofferen van statistische power om te vermijden dat men het correcte referentie-interval 
verkeerdelijk verwerpt. Als alternatief stellen wij een geoptimaliseerd staalnameprotocol voor 
om te vermijden dat een verkeerd referentie-interval verkeerdelijk wordt aanvaard. Een 
mogelijke aanpak is onder andere het verhogen van het aantal stalen om meer power te 
krijgen. 
 Ook het huidige EP14 protocol om commutabiliteit te verifiëren moet voorzichtig 
gehanteerd worden. Methodes met een slechte accuraatheid hebben minder kans om een 
niet-commutabel referentiemateriaal te detecteren. Als alternatief stellen we een aanpak voor 
die gebruik maakt van een soort t-test. Deze aanpak verifieert de commutabiliteit rekening 
houdend met een zeker niet-commutabiliteitsbudget in relatie tot de grootte van de 
staalname.  
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2. Algemene conclusie 
Het garanderen van de kwaliteit in een klinisch labo is essentieel om correcte interpretatie 
van klinische tests te verzekeren. In dat opzicht hebben interne- en externe kwaliteitscontrole 
een belangrijke rol verworven in het klinisch labo. Helaas kunnen deze tools niet altijd de 
realiteit van de patiëntendata visualiseren omwille van commutabiliteitseffecten. Daarom, 
hebben we aangetoond dat het Empower project een geldig middel is om dat probleem te 
omzeilen. Wanneer dit project wordt geïntegreerd in huidige kwaliteitscontrole-omgevingen, 
dan kan het een “bottom-up” aanpak voor kwaliteitscontrole garanderen, die een 
samenwerking tussen labo’s en fabrikanten bevordert. Dit project heeft het potentieel om 
betrouwbaar bewijs te creëren over de intrinsieke kwaliteit van assay’s en hoe die kwaliteit 
wordt behouden in labocondities. 
 De Percentiler en Flagger zijn efficiënte middelen om op real-time basis de midden- 
tot lange-termijn stabiliteit van assay’s, instrumenten, kalibratoren en reagentia op te volgen. 
Bovendien creëren ze bewijs over de redenen van de geobserveerde variatie (prestaties van 
het labo of van de fabrikant) en vertalen ze het effect van analytische instabiliteit op 
surrogaat medische uitkomsten. Ondanks de aanwezigheid van enkele problemen, zoals 
hoge populatievariatie en verschillen in stratificatie, kunnen klinische labo’s deze tools 
gebruiken om het effect van analytische instabiliteit te observeren op patiëntenmedianen en 
“hypo- en hyper-flagging rates”. Daarom kunnen deze applicaties aangewend worden als 
stimulans voor zowel labo’s als fabrikanten om de stabiliteit van assay’s te verbeteren (indien 
nodig). 
 De Master Comparison studies, die focussen op de standaardisatie- en 
vergelijkbaarheidsstatus van commerciële assay’s, toonden dat er zelf voor eenvoudige 
klinische chemie analieten, zoals enzymes en elektrolyten nog veel ruimte voor verbetering 
is, met betrekking tot de standaardisatie- en/of harmonisatiestatus. 
 
Vanuit dit perspectief geloven we dat het Empower project een welkome nieuwe tool is 
voor integratie in het moderne kwaliteitssysteem ten voordele van alle 
belanghebbende partijen met interesse in betrouwbare laboratoriumdata. 
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